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Abstract 
The DNA damage activated checkpoint kinase ATM is mutated in ataxia telangiectasia, 
which is characterised by cancer predisposition and neural degeneration. After ionising 
radiation (IR) ATM signalling proceeds via interaction with Nijmegen breakage 
syndrome 1 (NBS1). Conversely, ATM INteractor (ATMIN) is required for ATM 
activation after hypotonic shock. Full ATM activation also requires concomitant 
chromatin modifications, including histone H4 acetylation at K16 (H4K16Ac) by Tip60. 
However, the molecular mechanisms underpinning ATM pathway choice and 
physiological stimuli for ATMIN dependent ATM signalling were unclear.  
 
The aims of my PhD studies were to (a) establish physiological roles for ATMIN 
dependent ATM signalling, (b) investigate the mechanisms and consequences of ATM 
co-factor choice, and (c) identify novel ATM regulatory proteins. 
 
I characterised ATMIN’s role in preventing DNA damage accumulation in the embryo. 
Moreover, ATMIN suppresses DNA damage at the telomere. Loss of ATMIN from 
telomerase deficient cells exacerbates telomere dysfunction. Conversely, ATMIN is 
dispensable for oncogene induced senescence after colonic KRasG12D expression. 
 
To investigate ATM pathway choice I generated nbs1∆/∆; atmin∆/∆ MEFs. These 
compound mutants exhibit reduced senescence and increased proliferation compared to 
nbs1∆/∆, despite increased endogenous DNA damage. A similar phenotype was observed 
in the intestine. Both nbs1∆/∆;atmin∆/∆ MEFs and intestinally-deleted nbs1∆G;atmin∆G 
mice were extremely radiosensitive. Furthermore, ATMIN deletion augments IR-
induced ATM substrate phosphorylation. Thus, competition between ATMIN and 
NBS1 for ATM interaction is fundamental to ATM signalling and disrupting this 
balance is deleterious to cells.  
 
An shRNA screen identified DMAP1 as a novel ATM regulator. DMAP1 deficient cells 
are radiosensitive, and exhibit impaired ATM signalling after both IR and hypotonic 
shock. DMAP1 interacts with Tip60, and is required for Tip60 acetylation of H4K16 
after DNA damage. Histone deacetylase inhibitors rescued ATM substrate 
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phosphorylation and H4K16Ac levels after IR in DMAP1 depleted cells. Thus DMAP1 
is a novel regulator of ATM function. 
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Chapter 1. Introduction 
1.1 DNA Damage And Disease 
1.1.1 The importance of DNA damage repair 
Cells continually experience a great variety of insults to their genome. Endogenous 
DNA damage includes replication errors, the spontaneous depurination of DNA bases 
and double strand breaks (DSBs). A DSB occurs when both strands of the DNA double 
helix are severed in close proximity, and arise from a range of situations including 
stalled replication forks or during B and T cell maturation. DNA damage can also be 
exogenously induced, for example cross-linked dimers induced by the UV component 
of sunlight or DSBs induced by ionising radiation (IR). Continued proliferation of cells 
with undetected and unrepaired DNA damage leads to increasing genomic instability. 
This is deleterious to cellular function, and dangerous for the organism as DNA damage 
underlies cancer development. It is therefore unsurprising that the cell has evolved 
exquisite, extensive networks for the detection, repair and resolution of DNA damage.  
 
At the hub of these networks sit three homologous phosphoinositide 3-kinase (PI3-K) 
related kinases - ataxia-telangiectasia mutated (ATM), ATM and Rad3-related protein 
(ATR) and the Catalytic Subunit of DNA-Dependent Protein Kinase (DNA-PKcs). The 
linchpins of the DNA damage response (DDR), each has specialised, complimentary 
and sometimes overlapping roles in maintaining genomic integrity. ATM and DNA-
PKcs principally detect double strand breaks, whereas ATR responds to single-strand 
DNA damage (Figure 1).  
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Figure 1: ATM, ATR and DNA-PKcs are activated by DNA damage 
ATR, together with its co-factor ATRIP, responds to single-strand DNA damage and 
phosphorylates Chk1, activating cell cycle checkpoints. ATM, together with its co-
factor NBS1, is activated by DNA double strand breaks and activates cell cycle 
checkpoints via Chk2. ATM also phosphorylates the DNA repair proteins 53BP1 and 
BRCA1, promoting repair by the HR pathway. Conversely, DNA-PKcs interacts with 
its co-factor Ku and phosphorylates Artemis, promoting repair by the NHEJ pathway. 
There is some cross talk between the pathways; for example ARTEMIS is an ATM 
substrate and ATM dependent HR repair proceeds via generation of single stranded 
DNA, activating ATR. 
HR, Homologous Recombination; NHEJ, Non-Homologous End Joining; DSBs  
 
 
It is crucial for organisms to maintain genomic integrity, as unrepaired or incorrectly 
repaired DNA lesions can contribute to cancer development. The majority of hereditary 
cancer syndromes involve mutation in DNA repair genes (Nagy et al., 2004), and 
genomic instability is a hallmark of tumour development (Hanahan and Weinberg, 
2011). The fundamental importance of DNA repair is highlighted by several systemic 
human disorders all caused by mutations in a single DNA repair gene. 
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1.1.2 Ataxia-telangiectasia 
The homozygous recessive disorder ataxia-telangiectasia (A-T) is caused by mutation in 
ATM. Patients are characterised by early onset progressive cerebellar ataxia, ocular 
telangiectasia, immunodeficiency, neurodegeneration, radiosensitivity, and cancer 
predisposition, especially to lymphomas. Although the first reported case of A-T was in 
1926 (Syllaba and Henner, 1926), and A-T was first described as a distinct disease in 
1957 (Boder and Sedgwick, 1957), it was not until 1995 the gene responsible, ATM, 
was identified by positional cloning (Savitsky et al., 1995).  
 
The atm gene occupies 160kB of genomic DNA and encodes a 13kB transcript from 
across 88 exons. To date, 430 different ATM mutations have been reported for A-T 
(Fokkema et al., 2011). Many of these are truncation or splicing mutations, which result 
in shorter, unstable ATM proteins. Some correlations have been drawn between the 
mutation site and phenotype severity (Guo et al., 2010b). Mouse models of A-T, with 
truncation mutations found in A-T patients, recapitulate many of the clinical features 
including radiosensitivity, sterility, growth retardation and T-cell lymphoma (Barlow et 
al., 1996; Xu et al., 1996; Elson et al., 1996). Although a very rare disorder, 
characterisation of the A-T phenotype and ATM protein function has been pivotal to 
our understanding of the cellular DNA damage response. 
 
1.1.3 Nijmegen Breakage Syndrome 
Nijmegen Breakage Syndrome (NBS) is caused by mutation in the ATM co-factor 
Nijmegen Breakage Syndrome 1 (NBS1). NBS has a similar clinical presentation to A-
T, including immunodeficiency and predisposition to cancer. However, in contrast to A-
T patients, NBS patients exhibit microcephaly. Like A-T, it is a rare autosomal 
recessive syndrome. Unlike A-T, the same mutation, nbs1657∆5, is present in 
approximately 90% of patients (Varon et al., 1998). Rather than a complete loss of the 
protein, this mutation occurs at a splice site and leads to the production of two truncated 
proteins (Maser et al., 2001). The N-terminal fragment, proximal to the mutation site, 
produces a 26kDa protein. The NBS1657∆5 mutation deletes five bases and introduces a 
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stop codon. Remarkably, an alternative, internal start codon is present approximately 30 
bases upstream of the deletion. After loss of the five bases, this start codon is in the 
same reading frame as the remainder of the NBS1 protein. Internal translation initiation 
from this methionine synthesises a 70kDa C-terminal NBS1 fragment in some cell types. 
Although this protein is present at much lower amounts than the wildtype protein, it is 
sufficient for viability (Maser et al., 2001). We know this as whilst the complete mouse 
knock-out for NBS1 is embryonically lethal (Zhu et al., 2001), a ‘humanised NBS 
mouse model’ containing the NBS1657∆5 mutation is viable (Difilippantonio et al., 2005). 
 
1.1.4 Ataxia-Telangiectasia Like Disorder 
Ataxia-Telangiectasia Like Disorder (A-TLD) shares many of the same clinical features 
as A-T, including cerebellar degeneration, radiosensitivity and chromosomal instability. 
A-TLD was only identified as a distinct disease in 1999, when four patients previously 
diagnosed with A-T were shown to have truncation mutations in the mre11 gene. 
Meiotic Recombination 11 (Mre11) encodes a component of the MRN complex (Mre11, 
Rad50, NBS1) that localises to DSBs. The atm locus is at 11q23 (Gatti et al., 1988), 
very close to mre11 at 11q21 (Petrini et al., 1995), which may explain why A-T and A-
TLD had not previously been identified as separate disorders. Although clinically very 
similar to A-T, A-TLD patients do not display immunodeficiency or cancer 
predisposition. Mice homozygous for the Mre11 truncation mutation observed in A-
TLD patients (mre11ATLD/ATLD) recapitulate the disorder, including increased genomic 
instability without malignancy (Theunissen et al., 2003). The difference between A-T 
and A-TLD symptoms suggests some distinct functions for ATM and Mre11.  
 
1.1.5 NBS-Like Disorder 
To date, a single patient with mutations in Rad50, the third component of the MRN 
complex, has been reported (Waltes et al., 2009). The maternally derived rad50 allele of 
this patient had a truncation mutation, whereas a mutated terminal ‘stop’ codon in the 
paternally derived allele gave rise to a longer Rad50 protein. However, very low 
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amounts of this protein were detected, suggesting the longer isoform is more unstable 
than wildtype Rad50. NBS-Like Disorder shares many of the same clinical features as 
NBS; including radiosensitivity, microcephaly, dwarfism and a ‘bird-like’ face. 
However, no immunodeficiency or cancer predisposition was observed. As this disorder 
has so far only been described in one individual, it is premature to conclude NBS-Like 
Disorder does not predispose to cancer development. Indeed, due to the combination of 
two distinct mutations in the patient’s two rad50 alleles it may be a unique case. 
 
1.1.6 Seckel Syndrome 
Seckel syndrome is characterised by dwarfism, mental retardation, microexencephaly 
with micrognathia, a narrow face and bird-like protrusion of the nose. All known 
patients have almost undetectable ATR protein levels and carry an ATRA2101G mutation, 
which results in impaired splicing and introduction of a premature stop codon . A recent 
mouse model, which introduced the human ATRA2101G mutation and surrounding exons, 
recapitulated Seckel syndrome. Mutants exhibit high levels of replicative stress, 
especially in tissues with high proliferation rates, including the intestine (Murga et al., 
2009). Murine models with a complete loss of the ATR locus are pre-gastrulation lethal 
(de Klein et al., 2000), so presumably the ‘leaky’ ATRA2101G splicing mutation allows 
enough ATR to be synthesised for viability, albeit with a severe clinical phenotype. 
 
1.2 ATM Orchestrates the DNA DSB Response 
1.2.1 ATM activation 
The DNA-damage activated checkpoint kinase ATM is a large 350kDa protein with 
several domains of interest (Figure 2). Towards ATM’s N-terminus lies the substrate 
binding domain (Khanna et al., 1998). The FAT (FATC, ATM, TRRAP) and FATC 
(FAT C-terminal) domains are conserved amongst, and indeed may be unique to, the 
PI3-K related kinase family (Bosotti et al., 2000). ATM’s protein kinase domain resides 
in the C-terminal half of the protein. 
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Figure 2: Overview of ATM protein domains 
ATM’s key domains of interest are depicted. The FAT and FATC domains are 
conserved amongst PI3-K related protein kinase family.  
 
 
ATM’s interaction with chromatin under basal conditions is dependent upon the 
chromatin architecture. Loss of the nucleosome binding protein High Mobility Group 
Nucleosomal binding 1 (HMGN1) results in global chromatin changes that increases the 
pool of chromatin bound ATM, and impedes ATM’s activation (Kim et al., 2009). In 
undamaged cells ATM is present as an unphosphorylated dimer. ATM’s FATC domain 
shields its kinase domain, preventing ATM autophosphorylation in undamaged cells 
(Bakkenist and Kastan, 2003).  
 
DNA damage promotes ATM autophosphorylation and monomerisation; and activated 
ATM localises to the DSB site (Bakkenist and Kastan, 2003). The activated ATM 
kinase has a wide range of substrates and our characterisation of all ATM’s substrates is 
far from complete. An IP-Mass Spec screen identified over 700 proteins phosphorylated 
upon consensus ATM and ATR phosphorylation sites (SQTQ) after DNA damage 
(Matsuoka et al., 2007). A positive control for this screen was the ATM co-factor and 
substrate NBS1.  
 
1.2.2 The MRN Complex is a DSB sensor 
The initial sensor of DSBs is believed to be the MRN complex. NBS1, Rad50 and 
Mre11 stably associate in a 2:2:2 ratio in vivo to form the MRN complex (Trujillo et al., 
1998); although in vitro purification studies suggest a range of stoichiometries are 
possible (van der Linden et al., 2009). In both human and murine cells depletion of any 
MRN protein reduces the levels of other complex members, suggesting reciprocal 
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stabilisation (Lamarche et al., 2010). Mre11 is at the heart of the complex, interacting 
with both Rad50 and NBS1. Neither direct interaction, nor binding motifs indicative of 
an interaction, have been observed between Rad50 and NBS1. Real-time imaging of 
laser-generated DSBs showed Mre11 and NBS1 localise to the break site within 
seconds of induction (Lukas et al., 2004), indicating the MRN complex is an initial 
sensor of DSBs. 
 
1.2.2.1 NBS1 is an essential DSB signalling scaffold 
NBS1 is a 95kDa protein containing a two BRCT and one Forkhead Associated (FHA) 
domain, an Mre11 interaction domain, and a C-terminal ATM interaction motif (Figure 
3). NBS1 has a nuclear localisation signal and localises the MRN complex to the 
nucleus, crucial for recruitment to DSBs. NBS1 mutants lacking the Mre11 interaction 
domain (nbs1tr645) are nuclear, but Mre112Rad502 is retained in the cytoplasm (Desai-
Mehta et al., 2001). Association of NBS1 with Mre11/Rad50 stimulates their nuclease 
and DNA binding activities, but NBS1 itself has no reported enzymatic activity - or 
indeed any putative enzymatic domains. Rather, NBS1’s BRCT domains bind serine-
phosphorylated Ser-X-Thr motifs, and the FHA domain binds threonine-phosphorylated 
Ser-X-Thr motifs (Lloyd et al., 2009; Williams et al., 2009) conferring NBS1 with the 
functions necessary to act as a key scaffolding and signalling protein. 
 
NBS1 is required for ATM activation and downstream substrate phosphorylation in 
response to DSBs. NBS1 is an ATM substrate - activated ATM phosphorylates NBS1 
after IR on consensus SQ motifs, including S278 and S343 (Gatei et al., 2000; Wu et al., 
2000; Lim et al., 2000).  However NBS1 is also upstream of ATM activation. The MRN 
complex is a key, early sensor of DSBs. Upon DSB induction NBS1 is rapidly recruited 
to the damage site where it remains stably bound to the chromatin. Immunofluorescence 
studies in irradiated A-T patient cells demonstrate ATM is not required for the 
localisation of Mre11 or NBS1 to DSBs (Mirzoeva and Petrini, 2001). Consequently, 
NBS1 can be considered to be both upstream and downstream of ATM activation. 
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Elucidation of which MRN complex functionalities are required for ATM activation is 
more intricate. Neocarzinostatin (NCS) treated NBS and A-TLD cells demonstrate 
markedly reduced pS1981-ATM (Uziel et al., 2003). Irradiation of NBS cells 
reconstituted with various NBS1 mutants indicates IR-induced pS1981-ATM 
phosphorylation is abolished in NBS1 deficient cells, but was recovered in a mutant 
lacking the ATM phosphorylation sites (S278A/S343A), but not by a mutant lacking the 
ATM binding domain (NBFR5) (Cerosaletti and Concannon, 2004). Thus, from these 
studies one would conclude NBS1-ATM interaction, but not ATM phosphorylation of 
NBS1, is required pS1981-ATM foci formation at DSBs. 
 
In summary, NBS1 is a key signalling scaffold effecting DNA repair, linking the DSB 
sensors Mre11 and Rad50 to a wide range of downstream repair and signalling proteins, 
and ensuring these interactions only occur at break sites. 
 
 
Figure 3: Schematic of domains present upon NBS1 
Overview of the protein domains present upon wildtype NBS1. The ATM 
phosphorylation sites, S278 and S434, are indicated by black circles.  
 
1.2.2.2 Mre11 facilitates DNA unwinding at DSBs 
Mre11 is a highly conserved 85kDa protein with a phosphoesterase domain, two C-
terminal DNA binding domains; and exhibits endo- and exonuclease activity against 
both single and double stranded DNA (Paull and Gellert, 1998; Paull and Gellert, 1999). 
Unwinding of DNA ends is essential for ATM activation (Lee and Paull, 2005). Mre11 
readily forms homodimers, which can use their DNA binding domains to bridge DSB 
termini (Williams et al., 2008). Mre11’s nuclease activity facilitates initial DSB 
resection. A mouse model for Mre11 with a mutated nuclease domain demonstrated 
whilst Mre11’s nuclease activity is an essential function for DSB repair, it is not 
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required for ATM activation (Buis et al., 2008). Thus Mre11 has functions in DNA 
damage repair distinct from ATM activation and the MRN complex.  
 
1.2.2.3 Rad50 synapses DSB termini 
Rad50 is a 150kDa protein with both structural and sequence homology to the 
Structural Maintenance of Chromosomes (SMC) family. Elucidation of the Rad50 
crystal structure revealed Rad50’s N-terminal Walker A, and C-terminal Walker B, 
motifs stably associate with one another forming a globular domain capable of binding 
DNA DSB termini (Hopfner et al., 2000). Further structural studies demonstrated 
Rad50 interacts with Mre11 through an interaction motif at the apex of its globular 
domain (Hopfner et al., 2001). The globular domains of two Rad50 molecules can 
interact. This binding is ATP dependent, with two ATP molecules binding at the 
interface. However, the ATP hydrolysis is too weak to support motor or helicase 
functions (Hopfner et al., 2000). Given ATP binding induces conformation changes 
enhancing Rad50’s affinity for dsDNA, perhaps ATP binding and hydrolysis cycles 
regulate the duration of MRN binding at DNA DSB termini.  
 
Between Rad50’s two Walker motifs are approximately 575 amino acids, which form a 
long coiled-coil domain terminating in a zinc hook (CXXC). The zinc-dependent 
dimerisation of two Rad50 molecules though the CXXC motifs enables Rad50/Mre11 
to span the two termini of a DNA DSB (de Jager et al., 2001; Hopfner et al., 2002). The 
coiled-coil domains confer Rad50 with the spatial and conformation flexibility required 
to span DNA DSBs of differing architecture. The tethering of DSBs is only observed in 
vitro at high Rad50/Mre11 concentrations, suggesting through Rad50 oligomerisation 
the summation of multiple weak interactions achieves robust and specific DNA DSB 
tethering (de Jager et al., 2001).  
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Figure 4: The MRN Complex Binds to DNA Double Strand Breaks 
Schematic of the MRN complex binding to a DNA DSB. The coiled-coil domains of 
Rad50 (yellow) dimerise through a zinc hook, and Rad50’s Walker A and Walker B 
domains bind the DNA DSB termini. Mre11 interacts with both NBS1 and Rad50.  
A = Walker A domain, B= Walker B domain.  
 
 
The current molecular model of DSB termini bridging by the MRN complex 
encompasses two distinct modes of binding. The two DNA binding domains of an 
Mre11 homodimer bridge DNA ends at short range. The long flexible coiled-coil arms 
of Rad50 permit longer-range binding, either to tether DNA DSB ends over a longer 
distance or facilitate the binding of a broken chromosome with its sister chromatid 
(Figure 4). The MRN complex is the key immediate early sensor of DSBs, and its 
recruitment and retention to the damage site is essential for downstream ATM 
signalling. Interestingly, the tethering of either NBS1, Mre11, Mediator of DNA-
damage Checkpoint 1 (MDC1) or ATM to chromatin was sufficient to elicit pH2AX 
foci formation (Soutoglou and Misteli, 2008), strongly suggesting the DNA damage 
response does not require DNA damage for signal transduction or amplification. 
 
1.2.3 ATM phosphorylates H2AX and MDC1 at the DSB 
Interaction between NBS1 and ATM facilitates ATM recruitment to the DSB, where 
ATM phosphorylates a wide range of DNA damage response proteins. Two crucial 
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ATM substrates are pT719-MDC1 (Kolas et al., 2007) and Serine-139 of histone variant 
H2AX, yielding pH2AX (γH2AX) (Rogakou et al., 1998). The H2A histone variant 
H2AX represents approximately 15% of all H2A in mammalian cells and is randomly 
incorporated into nucleosomes (Rogakou et al., 1998). H2AX is not an exclusive ATM 
target, the DNA damage kinases ATR and DNA-PKcs also phosphorylate S139-H2AX 
after replication stress and IR respectively (Ward and Chen, 2001; Stiff et al., 2004). 
Interestingly, analysis of H2AX-/- mutant mice revealed pH2AX is dispensable for the 
initial localisation of NBS1, Breast Cancer 1 (BRCA1) and p53 Binding Protein 1 
(53BP1) to DSBs, but is required for their maintenance at the damage site. The 
phosphorylation of S139-H2AX creates a docking site for downstream DDR 
components and is a key signalling event in mediating the assembly of DNA repair foci. 
 
Under basal conditions, tyrosine-142 of H2AX is constitutively phosphorylated by 
Williams-Beuren syndrome transcription factor (WSTF) (Xiao et al., 2009). After DNA 
damage, Tyr-142 is dephosphorylated by the phosphatases Eyes Absent Homolog 1 
(EYA1) (Cook et al., 2009) and EYA3 (Krishnan et al., 2009). The importance of Tyr-
142 dephosphorylation is demonstrated by the failure of WSTF deficient cells to 
maintain IR-induced pH2AX, pT719-MDC1 or pS1981-ATM foci (Xiao et al., 2009). 
Dephosphorylation of pY142-H2AX favours the recruitment of repair factors, including 
MDC1, over the recruitment of pro-apoptotic factors, such as JNK1, promoting DNA 
repair over cellular apoptosis (Cook et al., 2009). H2AX is therefore both an important 
binding platform for repair factors and a means to regulate the cellular outcome to DNA 
damage.  
 
MCD1 contains consensus SQ/TQ phosphorylation sites, and is phosphorylated by 
ATM in response to DNA damage (Matsuoka et al., 2007; Kolas et al., 2007; Mailand 
et al., 2007). Concomitant phosphorylation of Ser-139 and dephosphorylation of Tyr-
142 of H2AX creates a binding surface for MDC1 (Xiao et al., 2009). MDC1 serves as 
a key binding platform in DSB recognition, interacting with pH2AX through its C-
terminal BRCT repeats, ATM through its FHA domain and NBS1 though its SDTD 
motifs. MDC1 is constitutively phosphorylated upon its SDTD repeats by Caesin 
Kinase 2 (CK2), enabling NBS1 to interact with MDC1 and assisting pH2AX 
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‘spreading’. MDC1’s range of interactions with ATM, NBS1 and pH2AX confer 
specificity for DSBs to the assembly of DNA repair foci.  
 
Phosphorylation of H2AX spreads for up to several megabases either side of the DSB 
site in mammalian cells, although it is propagated less effectively on actively 
transcribed genes and heterochromatin (Iacovoni et al., 2010). Upon MDC1 binding to 
pH2AX, ATM is transiently anchored via NBS1, permitting ATM to phosphorylate 
adjacent H2AX motifs and achieve high density pH2AX spreading (Figure 5). 
Chromatin more distal from the DSB contains a lower density of pH2AX, and does not 
require MDC1. It is proposed a pool of soluble pS1981-ATM diffuses from the DSB 
site to phosphorylate more distal regions, allowing pH2AX spreading to bypass more 
compact heterochromatin (Savic et al., 2009) (Figure 5). As pH2AX does not propagate 
indefinitely, perhaps soluble ATM gradually looses its activity as it moves from the 
break site, capping the extent of pH2AX spreading. In yeast pH2AX also occurs, 
although it seems pH2AX spreading takes place over shorter distances of 50-100kB 
(Downs et al., 2000; Shroff et al., 2004).  
 
The phosphorylation of the key ATM substrates H2AX and MDC1 establishes a 
binding platform central to DSB signalling. It is important MDC1 is only recruited to 
damage sites, as its stable recruitment activates an ubiquitin signalling cascade which 
ultimately assembles DNA repair machinery. 
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Figure 5: pH2AX spreading is propagated by ATM, NBS1 and MDC1 
ATM is recruited to the DSB site by the MRN complex, and phosphorylates histone 
H2AX on Ser-139 in the region immediately surrounding the break. High density 
pH2AX spreading is achieved by MDC1 binding to pH2AX. MDC1 is constitutively 
phosphorylated by CK2, and NBS1 interacts with phosphorylated MCD1. This allows 
NBS1 to recruit ATM, which then phosphorylates the adjacent H2AX - and recruits 
MCD1, starting the cycle again. Unanchored ATM is prosed to phosphorylate 
lower density pH2AX. 
MRN, Mre11 Rad50 NBS1; CK2, Caesin Kinase 2;  
 
1.2.4 MDC1 phosphorylation activates a ubiquitination signalling cascade 
The phosphorylation of MDC1 by ATM creates a binding site for the RING-domain E3 
ubiquitin ligase RNF8, which binds MCD1 through an N-terminal FHA domain (Figure 
6). The ubiquitin signalling cascade at a DSB can amplify the DNA damage signal to a 
sufficient magnitude to recruit and retain repair proteins. Once recruited, RNF8 
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ubiquitinates H2A and H2AX with K63-linked ubiquitin chains (Mailand et al., 2007) 
(Huen et al., 2007). This in turn recruits a second RING-domain E3 ubiquitin ligase, 
RNF168 (Doil et al., 2009; Stewart et al., 2009). RNF168 contains two Ubiquitin 
Interacting Motifs (MIU) and binds ubiquitinated H2A, amplifying K63 ubiquitin 
chains on the chromatin around the damage site (Doil et al., 2009; Stewart et al., 2009). 
Although not yet demonstrated, it is feasible that RNF168 has a distinct spectrum of 
substrates from RNF8. Nevertheless, it is evident that the key function of RNF168 is to 
increase the magnitude of K63-linked ubiquitinated chromatin chains initiated by RNF8 
to sufficiently high concentrations for the retention of repair factors, including 53BP1 
and BRCA1, at the damage site (Figure 6). 
 
The specificity of RNF8 and RNF168 for DNA damage sites is not solely attained by 
MDC1. Both RNF8 and RNF168 cooperate with the same E2, UBC13. Interaction 
between UB13 and RNF8 is mediated by HERC2 in a DNA damage dependent manner. 
After DNA damage HERC2 is phosphorylated upon the consensus SQ/TQ site T4827, 
enabling HERC2 to bind to RNF8’s FHA domain (Bekker-Jensen et al., 2010). 
Moreover, HERC2 is also able to bind RNF168 although the full significance of this is 
unknown. Knock-down of HERC2, RNF168 or RNF8 abrogates the K63-ubiqutin 
dependent retention of the repair proteins 53BP1 and BRCA1 at damage sites (Bekker-
Jensen et al., 2010).  
 
A recent report demonstrated DNA damage dependent SUMOylation of RNF168 and 
HERC2 by PIAS4 promotes their interaction with RNF8 (Rendtlew Danielsen et al., 
2012). This offers the exciting possibility that SUMOylation may prove to be as crucial 
to DNA damage signalling as ubiquitination, phosphorylation and acetylation. 
Nonetheless, it is clear HERC2’s ability to promote RNF8’s interaction with UBC13 in 
a DNA damage dependent manner provides a critical regulatory loop in paring DNA 
damage detection and repair factor recruitment. 
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Figure 6: The Ubiquitin Signalling Cascades Amplifies The DNA Damage Response 
The phosphorylation of MDC1 by ATM creates a binding site for the Ubiquitin Ligase 
RNF8. HERC2 dependent histone H2A and H2AX ubiquitination by RNF8 recruits 
RNF168, which amplifies the ubiquitin chains to a concentration able to recruit and 
retain the DNA repair factors 53BP1 and BRCA1. 
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An exciting new and expanding research area is negative regulators of ubiquitination-
dependent DNA damage signalling. The deubiquitinase OTUB1 inhibits RNF168 
dependent ubiquitination. In a novel mechanism, OTUB1 binds and inhibits the E2 
ubiquitin ligase UBC13, preventing RNF168 activity (Nakada et al., 2010). Although 
little is known about the regulation of OTUB1, the observation that OTUB1 depletion 
increases HR-mediated DNA DSB break repair in cells treated with ATM inhibitor 
strongly suggests a physiological relevance for OTUB1 (Nakada et al., 2010).  
 
1.2.5 ATM activates cell cycle checkpoints after DNA damage 
Cell cycle arrest of damaged cells is critical as replication of damaged DNA and 
segregation of damaged chromosomes prompts escalating genomic instability. A crucial 
outcome of ATM activation is cell cycle-checkpoint activation. A-T patients exhibit 
radioresistant DNA synthesis (Houldsworth and Lavin, 1980; Painter and Young, 1980), 
and fail to activate the G1/S (Kastan et al., 1992) and G2/M (Beamish and Lavin, 1994) 
checkpoints after DNA damage. ATM phosphorylates a plethora of proteins to 
orchestrate cell cycle arrest, including substrates that remain bound to the damage site 
and those that freely diffuse in the nucleus (Figure 7). 
 
1.2.5.1 An ATM substrate network activates cell cycle checkpoints 
ATM signalling should be viewed as a network rather than discrete linear pathways; 
multiple activated substrates act in concert towards a common signalling outcome. For 
example, ATM controls S phase checkpoint activation by several complementary 
mechanisms. Firstly, the direct phosphorylation of Ser-957 on Structural Maintenance 
of Chromosome protein 1 (SMC1) is critical for S-phase checkpoint activation 
(Kitagawa et al., 2004). Secondly, phosphorylation of the phosphatase CDC25A by the 
ATM substrate Cdk2 targets CDC25A for ubiquitin mediated degradation (Falck et al., 
2001). This leads to increased Thr-14 and Tyr-15 phosphorylation upon the CDC25A 
target Cdk2. These phosphorylations inhibit Cdk2’s kinase activity and promote an S-
phase arrest (Falck et al., 2001). Thirdly, ATM phosphorylates FANCD2 upon Ser-222 
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promoting activation of the S-phase checkpoint. Chk2 The-14 and Tyr-15 
phosphorylation levels are normal in fancd2-/- cells suggesting FANCD2 signals to the 
checkpoint machinery in a Cdk2 and CDC25A independent mechanism (Taniguchi et 
al., 2002). ATM therefore activates a signalling network to effect cell cycle checkpoint 
activation, not just a single substrate.  
 
 
 
 
Figure 7: A network of ATM signalling activates cell cycle checkpoints and DNA repair 
ATM activation in response to DNA DSBs controls a range of processes, including 
DNA repair and cell cycle checkpoint activation. Some ATM substrates, such as H2AX, 
NBS1, MDC1 and 53BP1 form part of the ‘DNA Repair Foci’ and remain stably bound 
and the DNA damage site. Others, including p53, Chk2, CDC25C and CDC25A freely 
diffuse through the nucleus, and bring about cell cycle checkpoint activation.  
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1.2.5.2 ATM and p53 
The ‘guardian of the genome’, p53, is a key effector of G1/S checkpoint activation. p53 
deficient cells fail to activate the G1/S checkpoint after irradiation. ATM 
phosphorylates p53 upon Ser-15, although this event is not sufficient to stabilise and 
activate p53 (Banin et al., 1998; Canman et al., 1998). Mice with the equivalent ATM 
phosphorylation site mutated, p53S18A/S18A, exhibit a modest reduction in apoptosis after 
DNA damage, but have normal DNA damage checkpoint activation and a modest 
increase in tumourigenesis in old mice (Sluss et al., 2004). ATM activates p53 through 
a wider range of indirect mechanisms than just direct phosphorylation. For example, 
ATM phosphorylates Ser395 of MDM2, an E3 ligase that targets p53 for ubiquitin 
mediated degradation under basal conditions (Maya et al., 2001). Phosphorylation of 
MDM2 alters its oligomerisation and reduces the processivity of MDM2’s ligase 
activity, impairing MDM2’s ability to target p53 for degradation and hence increasing 
p53 protein levels. Moreover, pS395-MDM2 interacts with p53 mRNA in the nucleolus. 
This interaction promotes MDM2 sumolaytion, and sumolyated MDM2 stimulates the 
translation of p53 mRNA (Gajjar et al., 2012). 
 
In addition to p53’s important role in ATM signalling, p53 has a wider range of tumour 
suppressive activities. The Arf pathway activates p53 in response to hyperproliferation, 
and is thought to largely function independently of DNA damage signalling. Arf 
promotes p53 stabilisation by reducing MDM2’s affinity for p53. p53 also has a broad 
range of transcriptional targets, including the pro-apoptotic genes PUMA and NOXA; 
the anti-oxidant protein TIGAR, and the cell-cycle inhibitor p21. Given the range of 
p53’s tumour suppressive targets it is unsurprising p53-/- mice succumb to a wide range 
of cancers, including lymphomas, carcinomas and sarcomas (Donehower et al., 1992). 
The compound atm-/-; p53-/- mutant developed lymphoma at an average age of two 
months, earlier than either of the single mutants, suggesting synergy between p53 and 
ATM mutations (Westphal et al., 1997; Xu et al., 1998). 
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1.2.6 Acetylation and the DNA damage response 
Acetylation plays a crucial role in the DDR, both as a signalling moiety and by 
allosterically promoting the chromatin changes required for DNA repair. The histone 
acetyltransferase Tip60 and PI3-K-related protein TRRAP, both NuA4 complex 
members, are rapidly recruited to the break site (Murr et al., 2006). The yeast Tip60 
homologue, Esa1, was shown to acetylate histone H4 and is required for efficient DNA 
repair (Bird et al., 2002). In mammalian cells, Tip60 loss is embryonically lethal and 
accelerated tumour onset in Eµ-Myc+;  tip60+/- mice demonstrated Tip60 is a 
haploinsufficient tumour suppressor (Gorrini et al., 2007). Indeed, multiple studies have 
demonstrated Tip60 deficient cells have defects in HR and DNA damage signalling. 
Specifically, defects in Rad51 foci formation after IR (Murr et al., 2006), reduced ATM 
substrate phosphorylation upon oncogenic Myc expression (Gorrini et al., 2007) and 
reduced IR-induced apoptosis (Ikura et al., 2000) have been reported in cells with 
compromised Tip60 function.  
 
Multiple proteins associated with the NuA4 complex, including Tip60 and DNA 
Methyltransferase Associated Protein 1 (DMAP1), were recently identified in a genome 
wide shRNA screen for positive regulators of HR (Adamson et al., 2012). DMAP1 was 
originally characterised as an interaction partner of DNA Methyltransferase 1 (DNMT1) 
(Rountree et al., 2000) and subsequently shown to be part of the NuA4 complex (Cai et 
al., 2003), (Doyon et al., 2004). Knock-down of dmap1 in MEFs leads to increased 
levels of DNA damage (Negishi et al., 2009), but the mechanistic role of DMAP1 in 
DNA damage signalling and repair is largely unknown.  
 
Tip60, together with the histone acetyltransferase MOF, acetylates histone H4 tails 
upon K4, K8, K12 and K16. Histone H4 acetylation, in particular of H4K16, is 
increased after DNA damage (Li et al., 2010). Loss of H4K16 acetylation has been 
associated with a wide range of cancers (Fraga et al., 2005). Acetylation of H4K16 
modulates both higher order chromatin structure and interaction with non-histone 
proteins (Shogren-Knaak et al., 2006). The impaired pH2AX and MDC1 foci formation 
in MOF deficient cells is largely rescued by pre-treatment with the histone deacetylase 
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inhibitor TSA (Sharma et al., 2010). This suggests histone acetylation is required for 
chromatin to adopt a state ‘permissive’ for DNA repair rather than as a specific post-
damage signalling event. It is noteworthy that Histone Deacetylase 1 (HDAC1) and 
Histone Deacetylase 2 (HDAC2) are recruited to DSBs and mediate hypoacetylation of 
histone H3K56, promoting NHEJ repair (Miller et al., 2010). Thus, histone acetylation 
in DNA damage signalling is subtler that simply a crude summation of total acetylation; 
rather the dynamic acetylation status of specific histone residues is crucial.  
 
A range of histone modifications, including phosphorylation, ubiquitination and 
methylation, have been implicated in Tip60 recruitment to DSBs. The NuA4 complex 
contains components capable of binding ubiquitinated and phosphorylated chromatin. 
Arp4 binds phosphorylated Ser129 of yeast H2A (the orthologue of human pS139-
H2AX) and is essential for NuA4 recruitment to DSBs (Downs et al., 2004). MRG15, 
present in both MOF and Tip60 complexes, binds ubiquitinated H2B facilitating MOF 
and Tip60 recruitment to the damage site (Wu et al., 2011). Cells doubly deficient for 
RNF8 and the closely related E3 ubiquitin ligase Chfr, which ubiquitinate histone H2B, 
exhibit reduced H4K16Ac and impaired ATM activation. Compound mutant Chfr-/-
Rnf8-/- mice develop lymphoma, illustrating the importance of histone modifications in 
DNA damage signalling (Wu et al., 2011).  
 
Tip60’s chromodomain binds tri-methylated histone 3 K9 (H3K9me3). It is postulated 
Tip60 recruitment to DSBs requires dissociation of heterochromatin-binding protein 1 
(HP1) to expose the constitutive H3K9me3 (Sun et al., 2009). These results are in 
agreement with the finding HP1-β is phosphorylated by casein kinase 2 (CK2) upon 
Thr-51 after DNA damage, prompting is dissociation from chromatin and exposing the 
H3K9me3 mark (Ayoub et al., 2008). While these are intriguing results, the signal for 
CK2 localisation - which ensures Tip60 is specifically localised to damage sites -
remains unclear. Neither CK2 nor HP1- β appear to be ATM, ATR or DNA-PKcs 
targets (Matsuoka et al., 2007). Nevertheless, the ability of NuA4 complex components 
to recognise phosphorylated, ubiquitinated or methylated histones underscores the 
extensive crosstalk between histone modifications in ATM signalling networks.  
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A direct role for acetylation in ATM activation is proposed by several recent papers 
from the Price group. It is suggested the majority of ATM molecules in an undamaged 
cell are constitutively associated with Tip60. Upon DNA damage ATM is acetylated by 
Tip60 on Lys-3016. ATM’s kinase activity is dispensable for ATM acetylation, placing 
acetylation as a very early event of ATM activation (Sun et al., 2007). Indeed, ATM 
mutants with mutations in the FATC domain are unable to bind Tip60 and demonstrate 
defective in vitro kinase activity (Sun et al., 2005). It is postulated by the authors that 
ATM is only acetylated, and therefore activated, at the DNA damage site. However, 
earlier studies have demonstrated purified ATM is catalytically active in vitro, 
suggesting either ATM is constitutively acetylated or that ATM acetylation may not be 
crucial to its activity (Lee and Paull, 2005).  
 
1.2.7 The repair of DNA DSBs 
Cells have two main mechanisms to repair DSBs; the largely error-free homologous 
recombination (HR) and the error prone Non-Homologous End Joining (NHEJ) 
pathways (Figure 8). NHEJ enables the ligation of two DNA ends regardless of 
sequence, whereas HR uses the broken DNA’s sister chromatid as a template to join 
two homologous broken ends. Thus HR is only feasible in S and G2 phase cells, and 
predominates during these cell cycle phases. Although NHEJ cannot discern whether 
two broken ends belong together, it is essential for the repair of deleterious breaks when 
a template chromatid is unavailable. 
 
1.2.7.1 Non homologous end joining 
The core NHEJ machinery includes the Ku heterodimer (Ku70/Ku80), recruited to the 
damage site within seconds of DSB induction. Ku has a toroidal structure and the 
central, open ring is loaded onto the DNA ends (Walker et al., 2001). Furthermore, Ku 
has 5’-deoxyribose-5-phosphatase (5’-dRP) lyase activity and can remove abasic sites 
near DSBs, helping to ‘clean-up’ DNA ends without extensive resection, which would 
favour HR over NHEJ. (Roberts et al., 2010). Ku recruits DNA-PKcs to the DSB site, 
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facilitating the interaction between DNA-PKcs and the DNA ends. A series of 
phosphorylation reactions catalysed by DNA-PKcs stabilise the DNA end, preventing 
resection. DNA-PKcs autophosphorylates upon a PQR cluster, inhibiting end resection; 
and upon an ABCDE motif, recruiting the nuclease and ATM substrate ARTEMIS. 
ATM also phosphorylates the DNA ligase XRCC4/LIG4 and the stimulatory factor 
XLF, which together ligate the broken DNA ends. ATM is estimated to be required for 
at least 10% of NHEJ mediated DSB repair; but the core NHEJ machinery is not 
required for ATM activation and recruitment. It is postulated ATM mediated cell cycle 
arrest is required to allow sufficient time for the NHEJ pathway to repair 
heterochromatic DNA breaks (Jeggo and Lobrich, 2005).  
 
A variation on classical NHEJ is microhomology-mediated end-joining (MMEJ). The 
key distinction of MMEJ is the resection of approximately 4-6 nucleotides from the 
DNA termini to create short, complementary ends prior to ligation. MMEJ mediated 
DSB repair always results in the loss of some nucleotides, and it remains unclear to 
what extent this pathway is employed in cells with intact NHEJ components (McVey 
and Lee, 2008). 
 
1.2.7.2 Homologous recombination 
Entry into either the NHEJ or HR repair pathways is largely regulated at the stage of 
extensive DNA resection; required for HR but inhibitory to NHEJ repair. Although 
Mre11 is involved in the initial resection events at a DSB, it lacks the 5’-3’ exonuclease 
activity required to generate the HR-promoting long 3’ssDNA overhangs. It is possible 
unidentified co-factors associate with Mre11 and switch its polarity, but Mre11’s 
nuclease activity is likely to be limited to initial DSB resection and thus Mre11 
facilitates both HR and NHEJ repair pathways (Milman et al., 2009; Zhuang et al., 
2009).  
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Figure 8: The Repair of DNA DBSs by HR or NHEJ 
The choice of DNA DSBs repair pathway is regulated by the cell cycle; during G2/S 
HR predominates, and during G1 NHEJ is employed. Both pathways involve DSB 
detection and finish with DNA ligation, but HR also involves resection to form single 
stranded DNA, and homology search for a sister chromatid to use as a template for DSB 
repair.  
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End resection to form long 3’ssDNA overhangs is regulated in a cell-cycle dependent 
manner. During S and G2 the mammalian cell cycle dependent kinase (Cdk2) 
phosphorylates CtIP upon S374 (Huertas and Jackson, 2009). Phosphorylated CtIP 
interacts with BRCA1’s C-terminal BRCT domain and the MRN complex (Yu and 
Chen, 2004). Thus, CtIP is only recruited to DNA damage sites when Cdk2 is active, 
which is when a sister chromatid would be available for HR. Upon BRCA1 binding 
CtIP is ubiquitinated, promoting its end-resection function (Sartori et al., 2007). 
Additional nucleases and helicases, such as Mre1, EXO1 and BLM also contribute to 
resection. ATM phosphorylates CtIP upon S664 and S745. Although the relevance of 
these phosphorylations for HR is unclear, they are known to upregulate transcription of 
the cell cycle inhibitor genes p21 and Gadd45 (Li et al., 2000b; Wu-Baer and Baer, 
2001). ATM’s role as a master regulator of the DNA damage response becomes evident 
when we consider it phosphorylates proteins at every level of the response - from 
detection to repair. 
 
Resection of the DNA ends at the break site yields a single stranded DNA overhang of 
100-200 nucleotides. The single-strand DNA is rapidly coated and stabilised by the 
single-strand DNA binding protein Replication Protein A (RPA). Rad51 filaments can 
then form upon the RPA-ssDNA complex, which in turn recruits Breast Cancer 2 
(BRCA2). These events are also regulated by cell cycle dependent phosphorylation. 
Binding between BRCA2 and Rad51 is dependent upon phosphorylation of BRCA2 
upon Ser-2319 by Cdk2. Phosphorylation upon Thr-309 of Rad51 by Chk1 is necessary 
for Rad51 recruitment to damage sites (Esashi et al., 2005; Sorensen et al., 2005). The 
formation of stable RAD51 filaments prompts ssDNA a homology search and strand 
invasion into homologous sequences. Finally, a range of DNA polymerases, ligases and 
resolvases promote the resolution of the crossover, yielding two repaired, intact DNA 
molecules (Sung and Klein, 2006). 
 
1.2.7.3 ATM is required for repair of heterochromatin associated DSBs 
ATM is required for the repair of approximately 10-25% of all DSBs (Deckbar et al., 
2007; Riballo et al., 2004). Although the cell has some redundancy in its DSB repair 
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pathways, through DNA-PKcs dependent NHEJ repair, there is a subset of breaks 
critically dependent upon ATM for repair. These DBSs are not necessarily those of 
increasing complexity, but rather heterochromatin associated damage (Goodarzi et al., 
2008). ATM’s role at heterochromatin associated breaks was revealed by the 
observation heterochromatic breaks in KRAB-Associated Protein 1 (KAP1) deficient 
cells do not require ATM for repair. ATM phosphorylates KAP1 upon Ser824, reducing 
KAP1’s affinity for heterochromatic chromatin and prompting chromatin relaxation 
(Goodarzi et al., 2008). A MCD1, RNF8, RNF168 and 53BP1 dependent signalling 
cascade promotes pS824-KAP1 localisation into repair foci at late repairing DSBs 
(Noon et al., 2010). 
 
Although ATM phosphorylates pS824-KAP1 to a wildtype extent in 53bp1-/- cells, 
pS824-KAP1 does not localise into foci at late-repairing breaks. 53BP1 is required to 
amplify the Mre11-NBS1 concentration at late repairing DSBs, thus increasing local 
ATM concentration. This achieves sufficient KAP1 phosphorylation at these breaks to 
promote the alteration of chromatin to a state permissive for DNA repair (Noon et al., 
2010). The key NHEJ protein Artemis is dispensable for p S824-KAP1 and 53BP1 foci 
formation at late repairing breaks (Woodbine et al., 2011), strongly suggesting that the 
NHEJ pathway cannot compensate for ATM function at heterochromatic DSBs.  
 
1.2.8 ATM and non-canonical stimuli 
1.2.8.1 ATM is activated by oxidative stress 
A subset of A-T symptoms, including cerebellar degeneration and ataxia, cannot readily 
be attributed to ATM’s DSB signalling role. In cerebellar neurons ATM is equally 
located in the nucleus and cytoplasm, suggesting a non-DSB function for ATM (Barlow 
et al., 2000; Boehrs et al., 2007; Li et al., 2009). Moreover, it is well established A-T 
cells exhibit increased sensitivity to reactive oxygen species (ROS) (Yi et al., 1990). In 
parallel to this, the brains of atm-/- mutant mice display elevated levels of oxidative 
stress (Kamsler et al., 2001). Intriguingly, the free radical scavenger N-acetyl cysteine 
(NAC) rescues the haematopoietic stem cell (HSC) defect of atm-/- mice (Ito et al., 
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2004). Although in that study an effect on tumour-free survival was not commented on, 
a subsequent paper reported feeding atm-/- mice NAC delays thymoma onset (Reliene 
and Schiestl, 2006).  Despite the mounting evidence for ATM’s involvement in 
oxidative stress, it was only in 2010 that the Paull lab elucidated a direct role, and 
defined molecular mechanism, for ATM in the oxidative stress response (Guo et al., 
2010b). 
 
In response to H202 induced oxidative stress, ATM autophosphorylates upon Ser-1981 
and phosphorylates a subset of its known substrates, including pS15-p53 and pT68- 
Chk2, but S139-H2AX phosphorylation is not observed (Guo et al., 2010b). ATM’s 
kinase activity in response to oxidative stress is independent of interaction with the 
MRN complex. Indeed, it appears oxidative stress induced ATM activation slightly 
inhibits ATM’s association with MRN (Guo et al., 2010a). This is explained by the 
finding ATM’s active conformation after H202 treatment is different from the 
phosphorylated monomer it adopts after DSB induction. Upon oxidative stress, ATM 
forms a cysteine-linked dimer, held together by an intermolecular cysteine bridge upon 
C2991. Mass spectrophotometry studies suggest other cysteine residues are also 
oxidised, but point mutation studies suggest they are dispensable for dimer formation. A 
subset of A-T patients carry a R3047X truncating mutation. As their symptoms differ 
from classical A-T, including less severe radiosensitivity and no immunodeficiency, 
patients with this mutation are often referred to as alterative-A-T. Zuo and colleagues 
demonstrated cells carrying an R3047X mutation have largely normal pS1981-ATM 
autophosphorylation after the DSB inducing agent camptothecin, but an impaired 
response to H202 treatment (Guo et al., 2010b). It is postulated the region of ATM 
deleted in the R3047X truncation is a peroxisome targeting signal (Watters et al., 1999). 
It is not shown whether R3047X patients retain the ability to form cysteine linked 
dimers (Guo et al., 2010b), but as these patients presumably retain an intact Cys-2991, 
there must be additional molecular steps beyond cysteine dimer formation required for 
ATM activation by oxidative stress. 
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1.2.8.2 Non-canonical ATM stimuli alter the chromatin structure 
In addition to its roles in DSB and oxidative stress signalling, ATM is activated by 
treatments that alter chromatin structure, including hypotonic shock and chloroquine 
(Bakkenist and Kastan, 2003; Kanu and Behrens, 2007). Interestingly, pH2AX foci 
formation is not observed under these conditions. Although ATM unequivocally plays 
an essential role on DSB signalling, it is evident ATM has important cellular functions 
beyond DSB signalling and repair. 
 
1.2.9 ATM pSer-1981 phosphorylation 
In undamaged cells, ATM is an unphosphorylated monomer. Upon DNA damage 
induction, such as IR-induced DSBs, ATM undergoes intermolecular phosphorylation 
upon Ser1981 (human) or Ser1987 (mouse) and dissociates into an active, 
phosphorylated monomer (Bakkenist and Kastan, 2003). Whilst pSer-1981 is a widely 
accepted mark of active ATM, and indeed pre-treatment with a small molecule ATM 
inhibitor abolishes pSer-1981 and ATM’s kinase activity, pSer-1981 does not appear to 
be necessary for ATM activation and its function remains a controversial debate.  
 
To address the importance of ATM phosphorylation in vivo, atmS1987A mice were 
generated by reconstitution of atm-/- mice with an atm allele harbouring a Serine to 
Alanine (S1987A) mutation. This revealed S1987 phosphorylation is dispensable for 
functional ATM responses at both the cellular and organismal level (Pellegrini et al., 
2006). It was postulated other serine residues could compensate for S1987A. However, 
generation of a mouse model revealed mutation of multiple serine residues 
phosphorylated upon ATM (S367, S1899, S1987) did not impair ATM activation or 
signalling after IR (Daniel et al., 2008). Analogously, a recombinant, in vitro study 
confirmed S1981A mutation inhibits neither ATM kinase activity nor ATM dimer 
dissociation (Lee and Paull, 2005). Although pS1987 correlates with active ATM, from 
these studies one would conclude it is neither causative nor required for ATM activation.  
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ATM autophosphorylation appears to be modulated by chromatin proximity. An in vitro 
study by You and colleagues elegantly demonstrated that when non-DNA bound, 
phosphorylated pS1981-ATM was removed from DNA damage containing Xenopus 
extracts and incubated in DNA-damage free extracts ATM could phosphorylate a 
recombinant Thr-68 containing Chk2 substrate, but not promote the 
autophosphorylation of inactive ATM in the extract (You et al., 2007). This suggests 
ATM autophosphorylation occurs in the vicinity of DNA breaks. However, their data 
does not exclude a model in which other factors, modified by a break, interact with 
ATM in the nucleolus to aid ATM activation. In vitro pull-down studies of ATM in 
Xenopus egg extracts containing DNA fragments suggested some of the ATM 
molecules localised to the putative break site were not phosphorylated (You et al., 
2005). These reports suggest a model whereby pS1981-ATM phosphorylation is not 
required for ATM recruitment to the DSB, but that ATM autophosphorylation can only 
occur in the DSB vicinity.  
 
A conflicting study demonstrated that only wildtype ATM, and not kinase dead or 
pS1981A mutants, were associated with DSBs induced by I-PpoI endonuclease 
(Berkovich et al., 2007). However, possible reconciliation between these reports is the 
difference in time after damage induction. Whereas You and colleagues assessed ATM 
5-15 minutes after DNA damage, the endonuclease system employed by Berkovich and 
colleagues has DSB induction up to 12-15 hours before analysis of ATM recruitment. 
These two studies raise the intriguing possibility pS1981-ATM phosphorylation is 
required for ATM retention at DSBs, rather than recruitment, and mutants that cannot 
be activated subsequently dissociate from the surrounding chromatin. However, 
enhanced atmS1987A retention at sites of DNA damage was observed in atmS1987A animals, 
suggesting this is not the case (Pellegrini et al., 2006). Although ATM could be 
differentially regulated in murine and human cells, it seems likely that while pS1897-
ATM (or pS1981) correlates with activated ATM it is not necessary for ATM activation.  
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1.3 ATM Has Two Co-factors - NBS1 and ATMIN 
1.3.1 Murine models for NBS1 function 
A range of mouse models have contributed to our understanding of NBS1 function. The 
first NBS1 model was the complete ablation of NBS1, by deletion of a 2kb region 
encompassing the promoter, exon 1 and intron 1 (Zhu et al., 2001). This approach was 
taken as the nature of the NBS1 mutation in NBS patients was unknown at the time. 
Although heterozygous nbs1+/- mice were viable, no nbs1-/- offspring were obtained. 
Loss of nbs1 resulted in very early embryonic lethality at approximately E3.5. Even by 
this early stage the mutant blastocysts were very poorly developed. Unlike other DNA 
damage proteins, including BRCA1 (Xu et al., 2001), the embryonic lethality of nbs1 
deletion is not overcome by co-deletion of p53 (Yang et al., 2006).  
 
 
Figure 9: Overview of domains present upon NBS1, NBS1p26 and NBS1p70 
Wildtype NBS1 (top) contains FHA and BRCT domains towards its N-terminus, and 
Mre11 and ATM interaction domains towards the C-terminus. The ATM 
phosphorylation sites, S278 and S434, are indicated with black circles. The domains 
present on the NBS1p26 (middle) and NBS1p70 (bottom) truncations produced by 
nbs1657∆ mutation are indicated  
 
 
As nbs1 loss is embryonically lethal, a revised approach was to recapitulate the 
mutations observed in NBS patients. Approximately 95% of NBS patients exhibit a five 
base pair truncation mutation, nbs1657∆5, producing a 70kDa protein (Maser et al., 2001) 
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(Figure 9). Williams and colleagues deleted exons 4 and 5, encompassing the BRCT 
domain, to generate an 80kDa N-terminal truncated NBS1 protein (Williams et al., 
2002). Mice homozygous for the mutation, nbs1∆BRCT, are viable and thus the BRCT 
domain of NBS1 is not required for viability. nbs1∆BRCT MEFs are radiosensitive, but no 
cancer predisposition was observed in nbs1∆BRCT mice, in contrast to the lymphoma 
predisposition of NBS patients. Moreover, nbs1∆BRCT mice do not exhibit growth 
retardation, female sterility, immunodeficiency or spontaneous chromosomal instability 
(Williams et al., 2002). Although a reasonable approximation of NBS, the mutation 
introduced by Williams and colleagues differs from the common NBS mutation 
nbs1657∆5 in two key ways. Firstly, the truncated NBS1 protein in the nbs1∆BRCT model is 
10kDa larger than the 70kDa protein produced in NBS cells. Secondly, internal 
translation initiation yields synthesis of a N-terminal, 26kDa NBS1 protein in nbs1657∆5, 
but not nbs1∆BRCT, cells. A second model for NBS was the deletion of exon 2 and 3 to 
introduce a frameshift mutation (Kang et al., 2002). The subsequent nbs1m/m mice were 
viable, and produced a 75kDa N-terminal truncated NBS1. Again, this model did not 
fully recapitulate the NBS phenotype. Although cells were radiosensitive and displayed 
genomic instability; in contrast to NBS patients spermatogenesis was normal in nbs1m/m 
mice (Kang et al., 2002).  
 
A far closer model for NBS is the ‘humanised NBS1 mouse’ generated by 
Difilippantonio and colleagues (Difilippantonio et al., 2005). The human nbs1 locus, 
including the nbs1657∆5 mutation and regulatory elements, was used to generate nbs1657∆5, 
which were crossed to nbs1+/- mice, yielding mNbs1-/-; hNbs1657∆5. These mice 
recapitulated NBS, including cancer predisposition, immunodeficiency and cell cycle 
checkpoint defects. Cells derived from mNbs1-/-; hNbs1657∆ animals exhibited 
diminished, but not abolished, pS1987-ATM foci formation after IR. Difilippantonio 
and colleagues also reconstituted nbs1-/- mice with various other NBS1 mutants. 
Interestingly, nbs1tr645, lacking the Mre11 binding domain did not rescue the embryonic 
lethality of nbs1-/- mice (Difilippantonio et al., 2005). However, nbs1H45A mice mutants 
with a point-mutant in the FHA domain were viable. This suggests the loss of the 
Mre11-NBS1 interaction may be cause of the nbs1-/- lethal phenotype. However, FHA 
domain function cannot be solely attributed to Mre11 binding. Other proteins, including 
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CtIP, interact with NBS1 upon its FHA domain (Williams et al., 2009; Lloyd et al., 
2009). Given mdc1-/- mice show a milder phenotype than the nbs1-/- lethal phenotype it 
seems likely the cell-lethality of nbs1 deletion is not solely due to impaired Mre11 
function.  
 
Upon conditional nbs1 deletion MEFs undergo premature proliferation arrest, exhibit 
markedly reduced Rad50 and Mre11 recruitment to DNA DSBs, and increased genomic 
instability (Yang et al., 2006). Interestingly, nbs1 deletion from immortalised nbs1f/f 
MEFs did not lead to proliferation arrest, suggesting immortalisation enables unknown 
factors to compensate for NBS1’s essential role in cell viability (Yang et al., 2006).  
 
The nbs1 conditional model (nbs1f/f) enables tissue-specific nbs1 deletion, overcoming 
the embryonic lethality of nbs1-/- mice and enabling elucidation of NBS1 function in 
adult mice. T-cell specific nbs1 ablation, using Lck-Cre, leads to lymphopenia, reduced 
proliferation and aberrant V(D)J recombination (Saidi et al., 2010). Similarly, Central 
Nervous System (CNS)-specific deletion of nbs1 results in cerebellar loss, proliferation 
arrest and apoptosis; a more severe phenotype than the atm-/- mutant (Frappart et al., 
2005). This suggests NBS1 has ATM independent functions. Intriguingly, co-deletion 
of atm exacerbates the phenotype, with drastically reduced survival (Dar et al., 2011), 
suggesting ATM has NBS1 independent functions. 
 
1.3.2 ATMIN defines an NBS1-independent ATM signalling pathway 
NBS1 is dispensable for ATM activation in response to osmotic stress (Figure 5c of 
Difilippantonio et al., 2005). This observation demonstrated not all ATM signalling is 
NBS1 dependent. Indeed, the discrepancy between the nbs1657∆5 and atm-/- mouse 
phenotypes suggests NBS1-independent functions for ATM. The mechanism of NBS1-
independent ATM activation was unclear, and the existence of other ATM co-factors 
was unknown. NBS1 interacts with ATM through a conserved PI3-K interaction motif 
at its C-terminus, a motif that is shared with several other PI3-K interacting proteins 
including ATR interacting protein (ATRIP) and Ku80 (Falck et al., 2005). This motif 
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was also shown to be present on the novel protein ATM-INteractor (ATMIN) (Kanu 
and Behrens, 2007).  
 
 
Figure 10: The novel protein ATMIN contains an ATM interaction motif 
ATMIN contains four zinc fingers at its N-terminus, an extreme C-termial ATM 
interaction motif, and a PEST domain. Fourteen consensus ATM phosphorylation sites 
(SQTQ) are also present, although phosphorylation of ATMIN by ATM has not been 
observed. 
 
ATMIN is a novel 823 amino acid protein located at 16q23 with a predicted molecular 
weight of 88.3kDa. The Behrens group were the first to identify and characterise full-
length ATMIN. Previously, Heierhorst and colleagues had named ATM substrate Chk2-
interacting Zn2+-finger protein (ASCIZ) as a protein recruited into DNA damage foci 
induced by DNA methylating agents (McNees et al., 2005). ASCIZ is in fact ATMIN, 
but the group had not identified ATMIN’s first two exons and characterised a truncated 
form of ATMIN lacking the first two zinc fingers. ATMIN has several domains of 
particular interest, including four zinc-fingers near the N-terminus, a PEST domain, 
several SQ consensus ATM phosphorylation motifs and a C-terminal ATM interaction 
motif. It is notable that despite extensive effort, and mutation of each of the SQ motifs, 
no phosphorylation of ATMIN by ATM has been observed (Dr Janet Cronshaw, data 
not shown). 
 
The ATM interaction motif present upon ATMIN strongly suggests ATMIN and ATM 
interact, and indeed ATMIN co-immunoprecipitates with ATM but not the related 
kinase ATR. Immunofluorescence (IF) analysis demonstrated ATMIN co-localised with 
ATM after chloroquine and hypotonic shock treatment. Furthermore, ATMIN deficient 
MEFs (atmin∆/∆) have normal ATM activation and substrate phosphorylation after IR, 
but not after hypotonic shock or replicative stress (Kanu and Behrens, 2008) .Thus, 
ATMIN defines an NBS1-indpedent ATM signalling pathway (Figure 11). 
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Figure 11: ATMIN defines an NBS1 independent ATM signalling pathway 
In response to double strand break causing agents, such as IR, ATM associates with 
NBS1. However, in response to agents that cause changes in chromatin structure, such 
as osmotic shock, ATM interacts with its co-factor ATMIN. ATMIN is dispensable for 
ATM signalling after IR, and NBS1 is not required for ATM signalling after osmotic 
shock. 
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With the identification and characterisation of ATMIN, the long-standing assumption 
that ATM’s only co-factor was NBS1 was challenged. However, the physiological 
relevance of ATMIN’s role in ATM signalling was still unclear. Whilst the initial report 
of ATMIN by Kanu and Behrens clearly demonstrated a role for ATMIN in ATM 
activation by hypotonic shock and chloroquine, the consequences of a defective 
response pathway to these stimuli was unclear. To address this, a murine model for 
atmin loss was generated.  
 
1.3.3 ATMIN contributes to ATM signalling in the CNS 
The loss of ATMIN is embryonically lethal at approximately E16.5. Mutant embryos 
are characterised by exencephaly, are smaller than littermates and display organs 
defects, including severely impaired lung development and severe heart malformation.  
 
 Conversely, specific deletion of ATMIN in the neuronal system (atmin∆N/∆N) leads to 
viable mice, albeit with a reduced lifespan (Kanu et al., 2010). Interestingly, the 
atmin∆N/∆N phenotype partially recapitulates the atm-/- mouse model, exhibiting mild 
neurodegeneration, and growth defects - atmin∆N/∆N mice are significantly smaller than 
littermate controls at birth and remain so throughout their lifespan. Moreover, ATMIN 
deficiency reduced the number of tyrosine positive, dopaminergic neurons, 
recapitulating the atm-/- phenotype. Additionally, atmin∆N/∆N mutants displayed 
increased levels of DNA damage in the ageing brain but reduced ATM activation. This 
demonstrates ATMIN dependent ATM signalling is physiologically relevant (Kanu et 
al., 2010). 
 
1.3.4 ATMIN protects against B cell lymphoma 
ATMIN is a tumour suppressor; B cell specific ATMIN deletion (atmin∆B/∆B) results in 
B cell lymphoma with approximately 60% penetrance and a mean onset at 6 months 
(Loizou et al., 2011; see 1.5.2). As expected, the B cells from atmin∆B/∆B exhibit 
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severely impaired ATM signalling in response to hypotonic shock, but no reduction in 
IR-induced ATM signalling. SKY analysis revealed increased chromosomal 
translocation, including between the Myc and IgH loci (Loizou et al., 2011). Thus, it is 
clear that the non-canonical, ATMIN-dependent ATM signalling pathway has a 
physiological role in DNA damage repair and suppressing genomic instability and 
cancer development.  
 
1.3.5 ATMIN is a transcriptional regulator 
An intriguing twist in the ATMIN story has been the discovery that its four zinc fingers 
have DNA binding ability, and ATMIN is a transcriptional regulator (N. Kanu, 
manuscript in preparation). ATMIN is therefore a highly unusual protein in exhibiting 
both DNA damage response and transcriptional activity. A recent report characterised 
ATMIN as an activator of L8 Dynein light chain (DYNLL1) transcription (Jurado et al., 
2012). Moreover, it has been shown that DYNLL1 is capable of binding ATMIN, and 
overexpression of Cherry-DYNLL1 impairs recruitment of ATMIN into foci in 
response to DNA methylating agents (Rapali et al., 2011). Although these are intriguing 
results, these in vitro studies did not address the relevance of the interaction for cell 
viability or DNA signalling, and it is unclear if the DYNLL1-ATMIN interaction is 
DNA damage dependent. Furthermore, in stark contrast to Rapali and colleagues, 
Jurado and colleagues do not see any impairment in ATMIN foci formation in Flag-
DYNLL1 overexpressing cells upon MMS treatment. This may therefore be an artefact 
of protein overexpression or the tag, and not relevant at physiological ATMIN and 
DYNLL1 protein expression levels. More work is needed to establish if ATMIN’s 
transcriptional activity is regulated by DNA damage. 
 
In summary, it is clear the ATMIN dependent, non-canonical arm of ATM signalling 
has an important function in DNA damage signalling and cancer protection.   
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1.4 ATM and Oncogene-Induced-Senescence 
1.4.1 Senescence is a permanent state of cell cycle arrest 
Senescence was first characterised by Hayflick, who proposed non-immortalised human 
cells cultured in vitro undergo a finite number of cell divisions (Hayflick and Moorhead, 
1961). When a cell exhausts its ‘replicative potential’ it does not enter apoptosis, but 
enters a long-term, stable cell cycle arrest. In vitro, senescent cells have a characteristic 
large flattened morphology. Definitive markers for senescence remain controversial, but 
p53, p21, Dec1, p16 and p19 are commonly upregulated in senescent cells. These 
markers can also be upregulated in non-senescent cells so concomitant upregulation of 
several markers is usually required to score a cell as senescent. One of the most widely 
accepted assays for senescence, despite a poor understanding of the molecular 
mechanism, is β-galactosidase activity at pH6.0 (Collado and Serrano, 2006). 
Senescence can be triggered by one of several oncogenic stimuli, including telomere 
shortening, DNA damage, epigenetic derepression of the INK4a/ARF locus and 
oncogenic stress  
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Figure 12: Multiple cellular stress signals induce senescence 
Many cellular stresses activate p53 and induce senescence. There is crosstalk between 
senescence pathways; for example telomere dysfunction and high levels of oncogene 
expression promote DNA damage and can activate the ATM dependent DNA damage 
signalling cascade.  
 
The tumour suppressors p53, Ink4a (p16) and Arf (p19) are key inducers of senescence. 
The Ink4a/Arf locus encodes both Ink4a and Arf (Gil and Peters, 2006). Although these 
two proteins share exons, their different reading frames preclude any sequence 
homology. Ink4a inhibits CDK4 and CDK6 promoting a G1 cell cycle arrest. Arf 
positively regulates p53 stability by inactivating the E3 ligase MDM2, which targets 
p53 for ubiquitin mediated degradation. p53 is activated by a range of stimuli, including 
ATM-dependent DNA damage signalling. Use of mouse models with inducible p53 
expression revealed switching on p53 expression in sarcomas and liver carcinomas 
prompted tumour regression by senescence, involving immune cell mediated clearance 
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of tumour cells (Ventura et al., 2007; Xue et al., 2007). However, the regression of 
lymphomas following p53 expression involved widespread apoptosis rather than 
senescence. Thus whilst p53 is a key mediator of senescence, its activation can also lead 
to a variety of other outcomes. 
 
1.4.2 Senescence is a tumour suppressive mechanism 
Exciting recent advances have been made in understanding the physiological role of 
senescence as a stress response in ageing and cancer protection. Senescent cells can be 
long-lived and reside in the organism for many years, for example senescent 
melanocytes in moles or naevi (Michaloglou et al., 2005). Conversely, senescent cells 
can also be short-lived, for example phagocytes rapidly remove senescent tumour liver 
cells (Xue et al., 2007).  
 
Senescence is a tumour suppressive mechanism stably blocking pre-cancerous cells in a 
non-proliferative state, which needs to be overcome for progression to malignancy. It 
was first shown by Serrano and colleagues that high levels of oncogenic HRasV12 
expression caused in vitro cultured cells to enter senescence (Serrano et al., 1997). 
Senescence as a tumour suppressive mechanism has subsequently been firmly 
established for a range of oncogenic stimuli and cancer types. Three seminal reports 
first established for a range of cancers the presence of senescent cells in pre-malignant 
lesions, and their absence in malignant tumours. Namely; in KRasG12D induced lung 
tumourigenesis (Collado et al., 2005); p53- dependent senescence in the early stages of 
a pten-/- prostate cancer model (Chen et al., 2005); and Su39/h1- and p53-dependent 
senescence in a Eµ-N-Ras lymphoma model (Braig et al., 2005). It was subsequently 
shown using a transgenic mouse model of doxycycline-inducible, titratable Ras 
expression that whilst low levels of Ras expression induced hyperplasia, high levels of 
Ras expression prompted Ink4a/Arf dependent senescence (Sarkisian et al., 2007). 
Together, these observations underpin the ‘Oncogene Induced Senescence’  (OIS) 
model - high levels of oncogenic signalling are recognised as a stress signal by the cell, 
prompting entry into senescence.  
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A pivotal role for DNA damage has since been incorporated into the OIS model. 
Aberrant oncogene expression causes DNA damage, for example through replication 
stress, in pre-malignant cells. The activated DNA damage response can signal for a cell 
to enter a senescence programme and acts as a barrier to tumuorigenic progression 
(Bartkova et al., 2005). Breaching this tumour suppressive barrier allows cells to 
overcome senescence and progress towards cancer. There is now much experimental 
evidence for OIS. Early studies used immunohistochemical staining of lung, bladder 
and colon cancers to demonstrate an activated DNA damage response in pre-malignant 
lesions, and demonstrated the presence of DNA damage by showing allelic imbalance 
(Bartkova et al., 2005; Gorgoulis et al., 2005). A causal link between the DNA damage 
response and OIS was established by the observation ablation of individual DNA 
damage components, such as ATM, Chk2, or p53, abrogated senescence entry and 
enhanced tumourigenesis in several mouse engraftment studies (Bartkova et al., 2006; 
Di Micco et al., 2006).  
 
Although an important role for DNA damage signalling in OIS is well established, it 
does not appear to be absolutely required for senescence induction. For example, loss of 
the E3 ligase Skp2 in a pten+/- background resulted in p53 and Arf independent 
senescence and delayed tumour onset, without any observable DDR activation (Lin et 
al., 2010). Moreover, there is some discrepancy between the precise role ATM plays in 
OIS - whether it is limited to maintaining genomic stability or extends to activating 
senescence pathways. Bartkova and colleagues showed overexpression of mos, cdc6 or 
cyclin E promotes senescence in wildtype cells, but this does not occur in cells lacking 
functional ATM, achieved either by siATM treatment or ATM inhibitor (Bartkova et al., 
2006). This suggests ATM is part of the inducible OIS barrier. Conversely, Efeyan and 
colleagues used atm-/- mice in a K-RasG12D model for lung adenomas, and did not 
observe appreciable induction of pH2AX in senescent murine lung tumours (Efeyan et 
al., 2009). However, as atm-/- mice succumb to T-cell lymphomas at an early age, and 
K-RasG12D driven lung tumours have an average onset of approximately one year, they 
were not able to study the effect of ATM loss on K-RasG12D driven lung adenoma. They 
did observed an increase in tumour grade in the lung tumours five month old of atm-/-; 
K-RasG12D compared to atm+/+; K-RasG12D. This suggests that although ATM may not 
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be a critical activator of p53 -mediated OIS, ATM still has a protective function in K-
RasG12D driven lung adenomas.  
 
1.4.3 Senescence and colonic serrated hyperplasia 
The critical function of OIS as a tumour suppressive mechanism was recently illustrated 
in a model for Alternative Colorectal Tumourigenesis. This alternative ‘serrated’ colon 
cancer subtype accounts for approximately 17.5% of all proximal colonic cancers and is 
not thought to have APC mutations (Makinen, 2007). Although a morphologically 
heterogeneous group, all exhibit a serrated infolding of the neoplastic epithelium, 
immune cell infiltration and poor differentiation. KRas and BRAF are common 
activating mutations (Noffsinger, 2009). Bennecke and colleagues used intestine 
specific K-RasG12D expression as a model for serrated colonic cancers (Bennecke et al., 
2010). The colons of mice expressing oncogenic KRasG12D exhibit serrated hyperplasia, 
senescence and p16INK4a upregulation. However, the serrated hyperplasia did not 
progress to adenoma unless the senescence regulator Ink4a/Arf was also lost. The 
colons of KRasG12D+ ;Ink4aArf-/- animals were characterised by invasive, metastasising 
carcinoma, which both molecularly and morphologically resembles human serrated 
tumours. Thus, the authors demonstrate the critical important of OIS in alternative 
colorectal tumours as a barrier to tumour progression (Bennecke et al., 2010). 
 
1.5 ATM and B cell Maturation 
1.5.1 B cell maturation requires DNA damage 
In addition to ATM’s role in orchestrating the cellular response to spontaneous and 
exogenously induced DSBs, ATM functions in the repair of programmed DSBs. 
Examples of programmed DBSs repaired by ATM include those induced during meiotic 
recombination, T and B cell maturation (Barlow et al., 1998; Xu et al., 1996). At least 
three different stages of B cell maturation are dependent upon DNA damage - V(D)J 
recombination, somatic hypermutation (SHM) and class switch recombination (CSR).  
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The antigen-independent somatic recombination of Variable, Diversity and Joining 
segments is essential for generation of antibody diversity. V(D)J recombination requires 
DNA DSB induction by the sequence specific Recombination Activating Gene 1 
(RAG1)-2 endonuclease complex. These breaks are dependent upon the NHEJ pathway 
for repair; mice deficient in the NHEJ components DNA-PKcs, Ku or Ligase IV exhibit 
severe immunodeficiency and a block in B (and T) cell development (Bassing et al., 
2002). Although not absolutely required for V(D)J recombination break repair, ATM 
localises to the DSB ends and facilitates repair by maintaining the DNA ends in repair 
complexes (Bredemeyer et al., 2006). Peripheral B cells undergo secondary V(D)J 
recombination, and DSBs in this process are repaired with reduced efficiency in atm-/- 
mice (Loizou et al., 2011). 
 
Somatic hypermutation generates higher affinity antibodies by the induction of point 
mutations in the variable exons of IgH and IgL genes. Activation-induced cytidine 
deaminase (AID) catalyses the deamination of DNA bases in a transcription dependent 
mechanism introducing mutation, and hence variability, into V-region exons (Petersen-
Mahrt et al., 2002). Although some initial studies suggested repair of the deaminated 
bases could proceed via DSB generation and repair, a plethora of more recent studies 
strongly suggests SHM predominantly occurs independently of the DSB repair 
machinery. No SHM defect is observed in dna-pk-/-, ku80-/-, ku70-/-, H2AX-/-, 53bp1-/- or 
atm-/- mutant mice. On the contrary, the loss of the Base Excision Repair (BER) protein 
uracil-DNA glycosylase (UNG) or the MMR proteins mutS homologue 2 (MSH2), 
exonuclease I (Exo1) and mutL homologue 1 (MLH1) all lead to an impairment in 
SHM (Chaudhuri and Alt, 2004). Therefore whilst SHM harnesses the DNA damage 
machinery, it does not depend upon programmed induction and repair of DNA DSBs or 
ATM function.  
 
Thirdly, AID is also involved in CSR which somatically recombines the constant 
regions of IgH for IgG, IgA, IgM or IgE (Figure 13). This allows specialised of a 
variable, antigen binding region for a range of functions (Chaudhuri and Alt, 2004). For 
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example, IgA is secreted in saliva and breast-milk, whereas IgM is expressed on the 
surface of mature B cells.  
 
Figure 13: Class Switch Recombination of immunoglobin heavy chains 
Transcription of switch regions generates single strand DNA substrates for the single-
strand cytidine deaminase AID. The deoxyuridine bases created by AID are removed by 
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UNG1 to leave abasic sites. The endonuclease APE1 cleaves the phosphodiester 
backbone at abasic sites, introducing a nick into the DNA strand. The close proximity of 
nicks on both strands can generate a DSB. The DSB termini are synapsed by ATM and 
53BP1, and the ligation of two S regions by the NHEJ pathway completes CSR.  
AID, activation-induced cytidine deaminase; UNG, uracil-DNA glycosylase; APE1 
apurinic/apyrimidinic endonuclease 1. 
 
1.5.2 ATM is required for efficient class switch recombination 
The important role of ATM in CSR is illustrated by the observation atm-/- B cells have a 
70-80% reduction in CSR efficiency (Lumsden et al., 2004). Moreover, atm-/- B cells 
exhibit genomic instability, including on chromosome 12 which harbours the IgH locus 
(Callen et al., 2007). These defects manifest as a mild impairment in progression from 
the pro-B to pro-B stages of B cell development, but it should be noted that atm-/- mice 
have normal numbers of mature, re-circulating B cells (Xu et al., 1996).  
 
The B cell specific deletion of nbs1 (nbs1∆B/∆B) leads to approximately a 50% reduction 
in CSR efficiency (Reina-San-Martin et al., 2005), compared to the atm-/- reduction of 
70-80%. Moreover nbs1∆B/∆B do not develop B cell lymphoma, and the humanised 
NBS1 mouse model (nbs1657∆5) only develops B cell lymphoma upon co-deletion of p53 
(Difilippantonio et al., 2005). Although atm-/- mice do not commonly develop B cell 
lymphoma, this could be because they succumb at a young age to T-cell lymphoma and 
therefore they do not live along enough for B cell lymphoma to develop. In a mouse 
knock-in model for a nine base-pair truncation mutation commonly found in A-T 
patients, which produces near-full length but kinase-inactive ATM (atm7636del9), some 
mice developed B cell lymphoma (Spring et al., 2001). The reduced penetrance of T-
cell lymphoma in atm7636del9 mice presumably permitted the necessary time for the 
genomic instability resulting from ATM truncation to gain the additional mutation hits 
required for B cell lymphoma to develop. Given the firmly established importance of 
the ATM co-factor NBS1 for ATM function in DSB repair, a long-standing conundrum 
is the discrepancy between the phenotypes of atm and nbs1 deficient B cells. 
 
In contrast to nbs1∆B/∆B mice, B cell specific deletion of ATMIN (atmin∆B/∆B) leads to B 
cell lymphoma with approximately 60% penetrance and a mean onset age of six months 
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(Loizou et al., 2011). Analysis of the tumours from these mice revealed genomic 
instability in the B cells, including on chromosome 12, which contains the IgH locus. 
Loss of ATMIN also re-capitulates the reduction in the pre-B population, and normal 
numbers of re-circulating B cells, observed in the atm-/- mutant (Loizou et al., 2011). 
Akin to ATM loss, atmin∆B/∆B mice do not demonstrate an impairment in somatic 
hypermutation, but have a reduced efficiency in repair of the DBSs induced in 
peripheral B cells undergoing secondary V(D)J recombination. They have 
approximately a 50% reduction in CSR efficiency, and reduced co-localisation of 
pS1987-ATM to pH2AX sites in cells undergoing CSR (Loizou et al., 2011). ATMIN 
deficient chicken DT40 B lymphocytes exhibit increased rates of Ig gene conversion. 
Neither hypermutation nor DSB repair efficiency was affected, indicating ATMIN does 
not directly control the formation of abasic sites or HR (Oka et al., 2008). Taken 
together with observations of the nbs1∆B/∆B mutant, this suggests both canonical NBS1-
dependent and non-canonical ATMIN-dependent ATM signalling is required for 
efficient CSR and maintenance of genomic stability in B cells.  
 
1.6 Telomeres and the DNA Damage Response 
The terminal ends of eukaryotic chromosomes pose three distinct problems to the cell. 
Firstly, naked chromosome ends resemble a double strand break. Left unprotected, they 
are recognised as HR or NHEJ substrates and deleterious chromosome fusion occurs 
(Figure 14). Secondly, DNA replication during S phase is unable to copy the terminal 
ends of a chromosome by lagging-strand synthesis, so with each round of replication 
terminal nucleotides are lost. Unless these are filled in, genetic information will be 
eroded with each successive cell division. Thirdly, the terminal ends of chromosomes 
are fragile sites, and as such are susceptible to replication stress. Given these facets, it is 
unsurprising that the eukaryotic cell has evolved highly conserved solutions to the 
‘chromosome end problem’.
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Figure 14: Telomere dysfunction can lead to genomic instability  
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Telomere dysfunction, arising either from critically short telomeres or loss of the 
shelterin complex, activates and recruits ATM. The NHEJ pathway can recruit DNA 
Ligase IV to join the ends of two different chromosomes, shown here in blue and green. 
Chromatid breakage can occur during mitosis and the unequal distribution of genetic 
material leads to chromosome translocations. The fusion-breakage-fusion cycle can 
continue though the subsequent cell divisions, leading to increasing genomic instability.   
 
1.6.1 The end-protection problem 
In human cells chromosome ends comprise of 9-15kB of the telomeric repeat TTAGGG. 
In mice these repeats - the telomeres - can extend as long as 100kB. Regardless of 
telomeres length, the distal end of an undamaged telomere is distinguished by the ‘G-
tail’, a single stranded 3’ overhang of 50-300 bases. Its name arises as it is presumed to 
arise by post-replicative 5’-3’ exonuclease resection of the C-rich strand, leaving the G-
rich ‘TTAGGG’ repeats of the 3’ strand (Makarov et al., 1997). However, the extensive 
single-strand overhang, if not camouflaged in some way, is a substrate for HR. The 
highly repetitive sequence enables the G-tail to invade into the double-strand TTAGGG 
repeats and complementary base pair with bind the 3’-5’ strand, forming the Telomeric 
Loop, or T-loop (Griffith et al., 1999)(Figure 15). This protective structure sequesters 
the single strand overhang so that the telomere no longer resembles a double strand 
break, and is therefore not recognised by ATM and the cellular DNA damage 
machinery. 
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Figure 15: The Structure of Telomeres and the Shelterin Complex 
Schematic representation of the T-loop and D-loop conformations adopted by telomeric 
DNA. The interactions of shelterin complex, consisting of TRF1, TRF2, POT1, TIN2 
and TPP1, with each other and with the telomeric DNA are depicted. The inhibition of 
ATM and ATR by TRF2 and POT1 respectively is indicated.  
 
As well as the T-loop, end-protection is also conferred by six proteins collectively 
termed the ‘Shelterin Complex’, which constitutively bind the telomere (Figure 15). 
Telomeric Repeat-Binding Factor 1 (TRF1) was identified based on its ability to bind 
TTAGGG repeats (Chong et al., 1995), and Telomeric Repeat Binding-Factor 2 (TRF2) 
as a TRF1 paralogue (Broccoli et al., 1997; Bilaud et al., 1997). Both contain 
SANT/Myb domains with very high specificity for the double-stranded TTAGGG 
telomeric repeats (Bianchi et al., 1999; Hanaoka et al., 2005). In complement to this, 
Protector of Telomeres 1 (POT1) binds the single stranded telomeric repeats of the G-
tail overhang (Baumann and Cech, 2001). POT1-and TIN2-interacting protein (TPP1) 
was discovered as a POT1 interacting protein by IP-Mass Spectrometry (Liu et al., 
2004). TRF1-Interacting Nuclear protein 2 (TIN2) and Repressor and Activator Protein 
1 (RAP1) were first identified in yeast-two-hybrid screens for TRF1 and TRF2, 
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respectively (Kim et al., 1999; Li et al., 2000a). Neither TIN2 nor TPP1 directly bind 
DNA. TIN2 bridges TRF1 and TRF2, and TTP1 bridges POT1 and TIN2. 
 
The affinity of some shelterin components for telomeric repeats, and others for bridging 
shelterin proteins, confers the shelterin complex with an exquisite selectivity for 
telomeres. It is critically important shelterin only localises to the telomere, as its binding 
to double strand breaks would inhibit DNA repair. Several independent mass 
spectrometry studies for shelterin interacting proteins have yielded no new members of 
the shelterin complex, suggesting these six factors may represent a complete picture of 
the shelterin complex (O'Connor et al., 2004), (Liu et al., 2004), (Ye et al., 2004). Of 
course, many other proteins have been identified as interacting with shelterin or the 
telomere, but none that are considered part of the core protective complex (Dejardin and 
Kingston, 2009).  
 
Shelterin protects telomeres in part by shaping telomere structure. Firstly, shelterin aids 
T-loop formation, by harnessing TRF1 and TRF2’s DNA remodelling activities 
(Griffith et al., 1998; Stansel et al., 2001). Secondly, POT1 is required for control of 
telomere termini. POT1 loss leads to shorter 3’ overhangs and a loss of sequence 
specificity at the 5’end (Hockemeyer et al., 2005). Thirdly, shelterin is proposed to be a 
negative regulator of the enzyme telomerase, and therefore negatively regulates 
telomere length. POT1’s single-strand DNA binding domain is required for telomerase 
inhibition, supporting a model whereby shelterin binding blocks telomerase from 
accessing the telomere (Loayza and De Lange, 2003). It is thought the binding of 
shelterin to telomeres is roughly proportional to telomere length. Thus shorter telomeres 
have fewer shelterin complexes bound, stochastically reducing inhibition of telomerase 
binding and increasing the propensity for telomere extension.  
 
1.6.2 The end-replication problem 
The solution to the ‘end-replication problem’, telomerase, was first identified by Carol 
Greider and Elizabeth Blackburn in tetrahymena thermophile (Greider and Blackburn, 
1985, 1987, 1989). A unique reverse transcriptase, telomerase synthesises telomeres. 
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Telomerase comprises of a protein catalytic component, Tert, and an integral RNA 
subunit, Terc. Telomerase is a highly processive enzyme capable of adding hundreds of 
nucleotides to one DNA primer. The RNA Terc component recognises and binds the 
telomeric repeats and serves as a template for the reverse transcriptase domain of Tert. 
Loss of either component abolishes the enzyme’s activity. Although in vitro 
reconstitution of these two subunits is sufficient for telomerase activity (Weinrich et al., 
1997), several other proteins associate with the core enzyme, together termed the 
holoenzyme. Dyskerin binds Tert, and is believed to function as a crucial scaffold 
protein (Mitchell et al., 1999a). Patients with mutations in dyskerin suffer from 
dyskeratosis congenital and exhibit shorter telomeres and lower levels of Tert protein 
(Mitchell et al., 1999b). The ATPases pontin and reptin interact with Tert and dyskerin, 
particularly in S-phase, and their ablation impairs telomerase assembly (Venteicher et 
al., 2008). It is likely our picture of all proteins associated with Terc and Tert is far from 
complete.  
 
In humans telomerase is normally only active in stem and progenitor cells - and is also 
commonly re-activated in cancer cells (Meyerson et al., 1997; Wright et al., 1996). A 
second, telomerase-independent, mechanism for telomere maintenance is Alternative 
Lengthening of Telomeres (ALT). This mechanism is observed principally in cancer 
cells and allows cells to maintain telomere length, and hence overcome the proliferation 
arrest induced by critically short telomeres, without reactivating telomerase expression. 
Although some mechanistic details are still to be elucidated, ALT does depend on 
homologous recombination. It is thought the recombination template for ALT may be 
either sister chromatids or C-circles - partially single stranded, circular C-rich 
extrachromosomal DNA comprising of telomeric repeats (Henson et al., 2009). 
Regardless of the precise molecular mechanism, it is clear ALT requires a range of 
DNA damage proteins, including Mre11, NBS1, Rad50 and FANCD2 (Jiang et al., 
2005), (Fan et al., 2009). Experimental support that this mechanism only occurs in 
transformed cells is the observation fusion of an ATL cell with a non-transformed cells 
inhibits ATL activity, indicating ‘normal’ cells must have a molecular mechanism to 
suppress ATL (Perrem et al., 1999). Although many open questions remain, the 
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existence of a second mechanism for telomere lengthening in cancer cells underscores 
the fundamental importance of maintaining telomere length to every proliferative cell. 
 
Several murine models for telomere dysfunction have been generated, including the terc 
and tert null strains. Terc deficient mice, terc-/-, are characterised by premature ageing, 
shorter telomeres and genomic instability. However, as mice telomeres are up to 100kB 
long it takes several generations of null mice to produce mice with sufficiently short 
telomeres to manifest a strong phenotype. First generation terc-/- offspring are largely 
normal, whereas the phenotype becomes increasingly severe from the third generation 
onwards (Rudolph et al., 1999). Akin to this, mice lacking the reverse transcriptase 
component of telomerase, mTert-/-, also display increasing genomic instability and 
shorter telomere length as homozygous null generation number increases (Erdmann et 
al., 2004). 
 
Whilst it is evident from these studies in telomere deficient mice that critically short 
telomeres can induce proliferation arrest and senescence, it is unclear what length of 
telomeric repeats is considered ‘critically short’ by the cell. In yeast, a cell containing a 
telomere bereft of all telomeric repeats can still undergo several divisions before 
entering proliferation arrest (Abdallah et al., 2009). Thus in yeast telomere length is not 
a simple, immediate determinant of proliferative potential. The situation in mammals is 
increasingly complex. Primary cells cultured at atmospheric oxygen conditions, such as 
MEFs, tend to enter senescence within 6-10 population doublings; at which time their 
telomeres are still substantial in length. Thus telomeric length cannot be the sole 
determinant of replicative potential. TRF2 overexpression in human fibroblasts reduced 
average telomere length at senescence onset from 7 to 4kB and repressed chromosome 
fusions (Karlseder et al., 2002), suggesting the protected status of telomeres, and not 
just telomere length, affects senescence onset. A range of damage signals - such as short 
telomere length, DNA damage accumulation, oxidative stress and protein damage - 
contribute to activation of the senescence programme. The shorter the telomere the 
greater the damage signal, and so fewer additional stress signals are required from other 
components to exceed the ‘critical’ damage level and enter senescence. This model 
suggests a precise telomere length cannot be defined as ‘critically short’, but rather 
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telomere length as an indicator of proliferative potential must be viewed in the context 
of other cellular damage signalling. 
 
1.6.3 Telomere dysfunction and the DNA damage response 
Unprotected, damaged or critically short telomeres are recognised by the cellular DNA 
damage machinery. Acute deletion of trf2 from p53-/- MEFs demonstrated the NHEJ 
pathway processes unprotected telomeres and widespread interchromosomal fusion 
ensues (Celli and de Lange, 2005). Interestingly, the concomitant deletion of DNA 
Ligase IV, which ablates the processing necessary for NHEJ, does not inhibit ATM 
activation and signalling at these deprotected telomeres - pS1987-ATM, 53BP1 and 
pH2AX foci all still form (Celli and de Lange, 2005). Therefore no overt processing of 
damaged telomeres is required for ATM signalling. Moreover, the molecular role of 
individual DNA damage components is starting to become clear. For example, 53BP1 
binding to deprotected telomeres in trf2-/- MEFs increased chromatin motility and was 
required for efficient NHEJ (Dimitrova et al., 2008). The 53BP1- and ATM- dependent 
increase in telomere mobility presumably facilitates NHEJ between distant sites. 
 
The 3’ overhang sequestration in T-loops and masking of the telomeric repeats by 
shelterin binding are only part of the reason telomeres are not recognised by the DNA 
damage machinery. Experiments in combinations of ATM, TRF2, POT1 and ATR 
compound mutant cells demonstrated that TRF2 specifically inhibits ATM, whereas 
POT1 specifically inhibits ATR (Denchi and de Lange, 2007). TRF2 directly binds to a 
region of ATM encompassing the Ser1981 autophosphorylation site and inhibits ATM 
activation (Karlseder et al., 2004). As TRF2 is specifically localised to telomeres, this 
achieves the specific inhibition of ATM at telomeric repeats without compromising 
ATM’s ability to respond to DNA damage elsewhere on the chromosome.  
 
As one of the major functions of the telomere and shelterin complex is to prevent 
recognition by the DNA damage response, it was surprising and somewhat counter-
intuitive to discover many DNA damage proteins localise to the telomere. The MRN 
complex localises to the telomere via its interaction with TRF2; and NBS1 was shown 
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to localise to telomeres specifically in S-phase (Zhu et al., 2000). Conversely, TRF2 
does not localise to irradiation induced DNA repair foci. ATM and ATR also localise to 
the undamaged telomeres in G2 of the cell cycle (Verdun et al., 2005). DNA damage 
response proteins have been proposed to be important for telomere maintenance. The 
MRN complex promotes 5’ end resection of newly-replicated telomeres, generating 
incompatible 3’ overhangs which are readily bound by POT1 and hence blocking 
potential NHEJ mediated fusion (Deng et al., 2009).  
 
Further support that components of the DNA damage machinery have essential roles in 
telomere maintenance comes from the observation cells derived from A-T or NBS 
patients experience accelerated telomere shortening (Vaziri et al., 1997; Ranganathan et 
al., 2001). Moreover, compound mutant atm-/- terc-/- late generation mice exhibit 
increased telomere shortening, reduced stem cell compartments and increased genomic 
instability compared to the single terc-/- mutant. Remarkably, intestine-specific deletion 
of p53 in G4 terc-/- mice reduced lifespan, despite partial restoration of the intestinal 
stem cell pool (Begus-Nahrmann et al., 2009). Thus accumulation of stem cells with 
critically short telomeres is ultimately deleterious to the organism, highlighting the 
importance of telomere maintenance to viability.  
 
Together, these observations suggest a complex interplay between telomeres and the 
DNA damage response machinery. On the one hand, telomeres must be shielded from 
recognition by DNA damage factors to avoid end-to-end chromosome fusions. But, 
unexpectedly, telomeres also require the DNA damage machinery for efficient 
replication and end processing. 
 
1.6.4 The telomere replication problem 
An exciting recent discovery is telomeres are genomic fragile sites. Deletion of trf1 
from MEFs led to increased replication fork stalling upon telomeric repeats, with 
subsequent ATR activation and a fragile-site phenotype in metaphase. TRF1 recruits the 
helicases BLM and RTEL, presumably to resolve higher order DNA structures which 
cause DNA polymerase to stall (Sfeir et al., 2009). In agreement with this, G3 terc-/- 
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ATRS/S (ATR deficient Seckel mouse) display increased telomere fusions, recombination, 
and shorter telomeres, suggesting ATR suppresses telomere fragility and recombination 
(McNees et al., 2010). Moreover, the homologous recombination protein BRCA2 
localises to the telomere during G2/S, and its deletion results in telomere shortening and 
increased pH2AX foci at telomeres (Badie et al., 2010). Paradoxically, it appears the 
DNA damage response protein BRCA2 is required for efficient telomere replication, 
and its loss leads to DNA damage and activation of the DNA damage response. This 
recent trio of papers underscores the dual nature of the DNA damage machinery at the 
telomere - the telomere needs the specialised proteins of the DNA damage response for 
efficient replication, but also must be protected from recognition as a double-strand 
break by the DNA damage response. 
 
Two recent papers suggest a novel role for telomeres as ‘genotoxic stress sensors’ 
(Fumagalli et al., 2012; Hewitt et al., 2012). Both papers induced DNA damage by H202, 
NCS or IR, and observed the persistence of long-lived DNA damage foci at telomeres. 
Fumagalli and colleagues then demonstrated telomeric proteins confer telomeres with 
resistance to repair. Neither an endonuclease induced DSB next to telomeric repeats nor 
a DSB adjacent to tethered TRF2 was repaired. These studies demonstrate the 
persistence of DNA damage markers at telomeres in murine and primate cells, 
irrespective of telomere length. This raises the intriguing possibility telomeres act as 
‘genotoxic’ sensors and persistent DNA damage at telomeres can instigate senescence. 
However, it has not yet been demonstrated that DNA damage at the telomeres of non-
proliferating, terminally differentiated cells prompts entry into senescence.  
 
1.7 Aims of the thesis 
The ATM interacting protein ATMIN is required for ATM signalling in response to 
agents that induce changes in chromatin structure, but is dispensable for ATM 
signalling after double strand breaks. However, the physiological relevance of this non-
canonical ATM signalling pathway was unclear. The first aim of my thesis was to 
characterise physiological functions for ATMIN. To this end, I analysed ATMIN 
function in a range of murine models; including B cell lymphoma, the developing 
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embryo, oncogene-induced-senescence in intestinal tumourigenesis, and telomere 
dysfunction in the ageing brain.  
 
ATM signalling proceeds via ATMIN or NBS1 in a stimulus dependent manner. The 
mechanism of ATM co-factor choice was enigmatic. The second aim of my thesis was 
to investigate the mechanism and consequence of ATM co-factor choice. To achieve 
this I examined NBS1- and ATMIN- dependent ATM signalling in both the adult 
intestine and MEFs. 
 
Moreover, we were also interested to identify novel ATM regulatory proteins. The third 
aim of my thesis was to identify and characterise novel regulators of ATM signalling. 
Thus, I performed an shRNA based screen for proteins that regulate ATM signalling, 
from which DMAP1 was the most interesting candidate. DMAP1’s role in the DNA 
damage response was characterised.  
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Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 Reagents and Consumables 
The consumables and reagents used in the course of this study were purchased from 
the companies listed or the Cancer Research-UK London Research Institute (LRI) 
Central Services: 
 
0.5 ml, 1.5 ml, 2 ml tubes   Eppendorf (Cambridge, UK) 
100bp DNA ladder    Life Technologies (NY, USA) 
1 kb DNA ladder    Life Technologies (NY, USA) 
1 ml, 5 ml, 50 ml syringes    BD Plastipak (Oxford, UK) 
5 ml, 10 ml, 25 ml serological pipettes Corning (Corning, USA) 
15 ml, 50 ml tubes     Corning (Corning, USA) 
18G, 19G needles       BD Microlance (Oxford, UK) 
6 cm diameter dishes (adherent cells)  Corning (Corning, USA) 
10 cm diameter dishes (adherent cells) Corning (Corning, USA) 
25 cm2 flasks (adherent cells)   Corning (Corning, USA) 
75 cm2 flasks (adherent cells)   Corning (Corning, USA) 
150 cm2 flasks (adherent cells)   Corning (Corning, USA) 
25 cm2 flasks (suspension culture)   Sarstedt (Leicester, UK) 
75 cm2 flasks (suspension culture)   Greiner bio-one (Stonehouse, UK) 
6-well plate (flat bottom)   BD Falcon (Oxford, UK) 
24-well plate (flat bottom)    BD Falcon (Oxford, UK) 
96-well plate (flat bottom)    BD Falcon (Oxford, UK) 
96-well plate (non-sterile)    Nunc (Rochester, USA) 
Acetic acid     Fisher Scientific (Loughborough, UK)  
Adenovirus     Gene Transfer Vector Core (Iowa USA) 
Agarose     Bioline (London, UK) 
Ammonium chloride    LRI/CR-UK (London, UK) 
Ammonium persulfate   Sigma-Aldrich (Poole, UK)  
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Ampicillin     Sigma-Aldrich (Poole, UK)  
Aphidicolin     Sigma-Aldrich (Poole, UK) 
ATM inhibitor     Calbiochem (Darmstadt, Germany) 
B27 Supplement    Life Technologies (NY, USA) 
Bleomycin     Sigma-Aldrich (Poole, UK) 
Bovine serum albumin   Sigma-Aldrich (Poole, UK) 
BrdU      Sigma-Aldrich (Poole, UK)  
Calcium Phosphate Transfection Kit  Promega (Southampton, UK) 
Cell strainer (45 µm Nylon)   BD Falcon (Oxford, UK) 
Chromatography paper (3 mm)  Whatman (Brentford, UK) 
Calf Intestinal Phosphatase (CIP)  New England Biolabs (NEB, Hitchin, UK) 
Colcemid     Sigma-Aldrich (Poole, UK) 
Coverslips     Menzel-Glaeser (Braunschweig, Germany) 
Cuvettes     Fisher Scientific (Loughborough, UK) 
DAPI      Sigma-Aldrich (Poole, UK)  
ddH2O      LRI/CR-UK (London, UK)  
DirectPCR Lysis Reagent   Viagen Biotech (Los Angeles, USA)  
Disodium tetraborate    AppliChem (Darmstadt, Germany) 
DMEM     Life Technologies (NY, USA) 
DMSO      Sigma-Aldrich (Poole, UK) 
DTT      Sigma-Aldrich (Poole, UK) 
DyeEx® 2.0 Spin Kit    QIAGEN (Crawley, UK) 
Dynabeads M-280 Streptavidi  Life Technologies (NY, USA) 
ECL Western Blotting Detection Reagents GE Healthcare (Little Chalfont, UK)  
EDTA      Sigma-Aldrich (Poole, UK) 
EGF (human)      PeproTech (London, UK)  
EGTA      Sigma-Aldrich (Poole, UK)  
Ethanol     Fisher Scientific (Loughborough, UK)  
Ethidium Bromide    Sigma-Aldrich (Poole, UK) 
FACS tubes     Becton Dickinson (Oxford, UK)  
FGF-basic (human)     PeproTech (London, UK)  
Fluorescent Mounting Medium  DAKO (Ely, UK) 
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Foetal calf serum (FCS)    PAA (Yeovil, UK) 
GoTaq PCR DNA Polymerase  Promega (Southampton, UK) 
Glycerol     Sigma-Aldrich (Poole, UK)  
Glycine     Sigma-Aldrich (Poole, UK) 
Harris`s haematoxylin    LRI/CR-UK (London, UK)  
HAT Assay Kit (Colourimetric)  Abcam (Cambridge, UK) 
Hydrochloric acid    Fisher Scientific (Loughborough, UK)  
Hydrogen peroxide    Sigma-Aldrich (Poole, UK)  
Isopropanol     Fisher Scientific (Loughborough, UK) 
Illustra GFX DNA Purification Kit GE Healthcare (Little Chalfont, UK)  
Industrial methylated spirit (IMS)  LRI/CR-UK (London, UK)  
Kanamycin     Sigma-Aldrich (Poole, UK) 
L-Glutamine     Life Technologies (NY, USA) 
L-Glycine     Sigma-Aldrich (Poole, UK)  
LB medium     LRI/CR-UK (London, UK) 
Liopfectamine-2000    Life Technologies (NY, USA)  
Marvel skimmed milk powder  A1 Laboratory Supplies Ltd (Enfield, UK) 
Mayer`s haematoxylin   LRI/CR-UK (London, UK) 
Magnesium Chloride    LRI/CR-UK (London, UK) 
β-mercaptoethanol    Sigma-Aldrich (Poole, UK) 
Methanol     Fisher Scientific (Loughborough, UK)  
Microscope slides    Menzel-Glaeser (Braunschweig, Germany)  
N-2 supplement    Life Technologies (NY, USA) 
Neurobasal Medium    Life Technologies (NY, USA) 
NeuroCult® Differentiation Supplement StemCell Technologies (London, UK)  
Neutral buffered formalin (NBF)  LRI/CR-UK (London, UK) 
NEN blocking reagent    PerkinElmer (MA, USA) 
Nuclear fast red    Vector Laboratories (Peterborough, UK)  
Ponceau S     Sigma-Aldrich (Poole, UK) 
Paraffin wax     Tissue Tek (Basingstoke, UK)  
Paraformaldehyde    Sigma-Aldrich (Poole, UK)  
PBS      Life Technologies (NY, USA) 
Chapter 2 Materials and Methods 
 73 
Penicillin/Streptomycin   Life Technologies (NY, USA)  
Phenylmethylsulfonyl fluoride (PMSF)  Sigma-Aldrich (Poole, UK)  
Propium Iodide    Sigma-Aldrich (Poole, UK)  
Protogel (30%)    National Diagnostics (Hessle, UK)  
Poly-L-ornithine    Sigma-Aldrich (Poole, UK)  
PNA probe Alexa 488–OO-(CCCTAA)3 Panagene (South Korea) 
Protease Inhibitor    Sigma-Aldrich (Poole, UK) 
Protein A-Sepharose    Sigma-Aldrich (Poole, UK) 
Protein-G Sepharose    Sigma-Aldrich (Poole, UK) 
Proteinase K     Melford Laboratories (Ipswich, UK)  
Protein Assay Dye Reagent   Bio-Rad (Hemel Hempstead, UK)  
Opti-MEM     Life Technologies (NY, USA) 
QIAGEN Plasmid Maxi Kit   QIAGEN (Crawley, UK) 
QIAprep Spin Miniprep Kit   QIAGEN (Crawley, UK) 
Rainbow markers    GE Healthcare (Little Chalfont, UK)  
Restriction endonucleases   New England Biolabs (NEB, Hitchin, UK)  
Ribonuclease     Sigma-Aldrich (Poole, UK)  
RIPA buffer     New England Biolabs (NEB, Hitchin, UK)  
RNase-Free DNase Set   QIAGEN (Crawley, UK 
RNeasy Mini-kit    QIAGEN (Crawley, UK)  
Senescence Histochemical Staining Kit Sigma-Aldrich (Poole, UK) 
Sodium Acetate    Sigma-Aldrich (Poole, UK)  
Sodium Azide     Sigma-Aldrich (Poole, UK)  
Sodium Chloride    LRI/CR-UK (London, UK)  
Sodium Dodecyl Sulphate   Sigma-Aldrich (Poole, UK)  
Sodium Fluoride    Sigma-Aldrich (Poole, UK) 
Sodium Orthovanadate   New England Biolabs (NEB, Hitchin, UK)  
Superscript III cDNA synthesis kit  Life Technologies (NY, USA) 
SYBR Green     Life Technologies (NY, USA) 
T4 DNA ligase    New England Biolabs (NEB, Hitchin, UK)  
Taq PCR Core Kit    Qiagen (Crawley, UK) 
TEMED      Sigma-Aldrich (Poole, UK)  
Chapter 2 Materials and Methods 
 74 
Tetracycline     Sigma-Aldrich (Poole, UK)  
Trichostatin A (TSA)     Sigma-Aldrich (Poole, UK) 
Tris      Sigma-Aldrich (Poole, UK)  
Trisodium Citrate    Sigma-Aldrich (Poole, UK)  
Triton X-100     Sigma-Aldrich (Poole, UK)  
Trypan Blue     Sigma-Aldrich (Poole, UK)  
Trypsin     Life Technologies (NY, USA) 
Vi-Cell™ sample vial    Beckman Coulter (High Wycombe, UK) 
X-ray film, Fuji    Fisher Scientific (Loughborough, UK) 
 
2.1.2 Media and Buffers 
Antibody Dilution Buffer (IF-FISH) 
Tris (pH 7.5)      20 mM  
BSA,       2% (w/v) 
Fish Gelatin      0.2% (v/v) 
NaCl       150 mM 
Triton X-100     0.1% (v/v) 
Sodium Azide     0.1% (w/v) 
 
ATM Lysis Buffer    final concentration.: 
HEPES (pH 7.4)     20 mM 
NaCl      150 mM 
Tween 20     0.2% 
MgCl2      1.5 mM 
EGTA      1 mM 
supplemented with: 
DTT      2 mM 
NaF      50 mM 
PMSF      1 mM 
Na3VO4     1 mM 
Complete Protease Inhibitor Cocktail  1% 
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Base Buffer 
HEPES (pH 7.4)     10 mM 
NaCl      50 mM 
MgCl2      10 mM 
supplemented with: 
DTT      1 mM 
NaF      50 mM 
PMSF      1 mM 
Na3VO4     1 mM 
Complete Protease Inhibitor Cocktail  1% 
 
Blocking buffer (in situ hybridisation) 
Blocking Reagent (Roche)   10% 
Maleic Acid Buffer    90% 
 
Blocking Buffer (Immunofluorescence)  final concentration: 
FCS      10% 
Triton X-100     0.1% 
PBS      89.9% 
 
Blocking Buffer (Immunohistochemistry) final concentration 
Goat Serum     10% 
BSA      1% 
PBS      89% 
 
Citrate Buffer 
Trisodium citrate    2.94 g  
HCl (0.2 M)      22 ml  
ddH2O      up to 1 l 
 
Detection buffer (in situ hybridisation) 
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5M NaCl      1 ml 
1M MgCl      2 ml 
0.5M Tris-HCl (pH 9.5)    10 ml 
Levamisol (2 mM final conc.)   24 mg 
ddH2O      up to 50 ml 
 
DMEM (complete Media) 
DMEM     445 ml 
(+ 4.5 g/l glucose, + l-glutamine, + pyruvate) 
FCS      50 ml 
1% (v/v) Penicillin/Streptomycin (10000 U/ml) 5 ml 
 
DNA Extraction Buffer  
DirectPCR Lysis Reagent (mouse tail) 95 µl 
Proteinase K (10 mg/ml)    5 µl 
 
DNA Extraction Buffer (Isoproponal Method) 
Tris-HCl pH 8.8    50 mM 
EDTA      100 mM 
NaCl      100 mM 
SDS      1% 
Proteinase K (10 mg/ml, Melford)  0.5 mg/ml 
 
High Salt Buffer 
Tris–HCl (pH 7.4)     100 mM 
NaCl      600 mM 
supplemented with: 
DTT      1 mM 
NaF      50 mM 
PMSF      1 mM 
Na3VO4     1 mM 
Complete Protease Inhibitor Cocktail  1 % (v/v) 
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Hypotonic Swelling Buffer   final concentration 
NaCl      50 mM 
FCS      1% (v/v) 
Glucose     0.45% (v/v) 
dissolved in sterile PBS 
 
Hybridisation Buffer   final concentration: 
Deionized formamide    50% (v/v) 
Dextran sulfate     10% (v/v) 
Denhardt’s Solution     1x 
Tris-HCl pH7.5     10 mM 
NaCl       600 mM 
EDTA       1 mM 
SDS       0.25% (w/v) 
tRNA       1 mg/ml 
diluted in DEPC water 
 
KCM buffer (IF-FISH) 
KCl      120 mM 
 NaCl       20 mM  
Tris (pH 7.5)      10 mM  
Triton X-100     0.1% (v/v) 
 
Lysis Buffer 
Tris–HCl (pH 7.2)     80 mM 
NaCl      150 mM 
NP-40      0.2% (v/v) 
Glycerol     10% (v/v) 
supplemented with: 
NaF      50 mM 
Na3VO4     1 mM 
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β-glycerophosphate    1 mM 
Complete Protease Inhibitor Cocktail  1% (v/v) 
 
NB + GF (adult neurospheres; for 500 ml) 
Neurobasal Medium    474.8 ml 
2% (v/v) B27 Supplement   10 ml 
1% (v/v) L-Glutamine (200 mM)  5 ml 
1% (v/v) Penicillin/Streptomycin (10000 U/ml) 5 ml 
1% (v/v) N-2 supplement   5 ml 
20 ng/ml EGF (100 µM)   100 µl 
20 ng/ml FGF-basic (100 µM)  100 µl 
 
NB + GF + laminin (adherent NSCs; for 500 ml) 
Neurobasal Medium    474.8 ml 
2% (v/v) B27 Supplement   10 ml 
1% (v/v) L-Glutamine (200 mM)  5 ml 
1% (v/v) Penicillin/Streptomycin (10000 U/ml) 5 ml 
1% (v/v) N-2 supplement   5 ml 
20 ng/ml EGF (100 µM)   100 µl 
20 ng/ml FGF-basic (100 µM)  100 µl 
Laminin     0.5 mg 
 
Phosphate buffered saline (PBS)  final concentration:  
KCl      3 mM  
NaCl      136 mM  
Na2HPO4 • 2 H2O    8 mM  
KH2PO4     15 mM 
 
PNA hybridization solution   final concentration: 
Deionized Formamide   70% (v/v) 
NEN blocking reagent    0.25% (v/v) (PerkinElmer) 
Tris (pH 7.5)     10 mM  
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Na2HPO4     4 mM 
Citric Acid      0.5 mM  
MgCl2      1.25 mM  
 
PNA Wash A     final concentration: 
Formamide      70% (v/v)  
Tris (pH 7.5)     10 mM 
 
PNA Wash B     final concentration:  
Tris (pH 7.5)     50 mM  
NaCl      150 mM  
Tween-20     0.08% (v/v) 
 
Protein loading buffer (Laemmli buffer) final concentration 
Tris-HCl (pH 6.8)     63 mM 
SDS (w/v)      2% (w/v) 
Glycerol (v/v)     10% (v/v) 
bromophenol blue (w/v)    0.0025% (v/v) 
β-mercaptoethanol (v/v)    2.5% (v/v) 
 
6% Resolving Gel 
ddH2O      13.2 ml 
30% acrylamide mix    5.0 ml 
1.5 M Tris (pH 8.8)     6.3 ml 
10% SDS     250 µl 
10% ammonium persulfate (APS)   250 µl 
TE MED     20 µl 
 
10% Resolving Gel 
ddH20      9.9 ml 
30% acrylamide mix    8.3 ml 
1.5 M Tris (pH 8.8)     6.3 ml 
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10% (w/v) SDS    250 µl 
10% (w/v) ammonium persulfate (APS)  250 µl 
TE MED     20 µl 
 
12% Resolving Gel 
ddH2O      8.2 ml 
30% acrylamide mix    10.0 ml 
1.5 M Tris (pH 8.8)    6.3 ml 
10% (w/v) SDS    250 µl 
10% (w/v) ammonium persulfate (APS) 250 µl 
TE MED     20 µl 
 
Sodium acetate buffer 
1 M sodium acetate    99 ml 
1 M acetic acid    960 µl  
ddH2O      up to 1 l 
 
10x SD S-PAGE Running buffer 
Tris      300 g 
Glycine     1400 g 
20% SDS (v/v)     250 ml  
ddH2O      up to 10 l 
 
1x S emi-dry transfer buffer  final concentration.:  
Tris      24 mM  
Glycine     192 mM  
Methanol (v/v)     20%  
SDS (v/v)      0.01% 
 
20x SSC 
NaCl       17.53 g 
Sodium Citrate     8.82 g 
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DEPC water, pH 5.0     80 ml 
 
5% Stacking gel 
ddH2O      6.8 ml 
30% acrylamide mix    1.7 ml 
1.0 M Tris (pH 6.8)     1.25 ml 
10% (w/v)  SDS    100 µl 
10% (w/v) ammonium persulfate (APS)  100 µl 
TE MED     10 µl 
 
50x TAE buffer 
Acetic acid     57.1 ml  
Na2EDTA x 2 H2O    37.2 g  
Tris (0.2 M)      242 g  
ddH2O      up to 1 l 
 
20x Tris buffered saline Tween-20 (TBS-T) 
NaCl (5 M)      3 l  
Tris (1 M; pH 7.5)     2 l  
Tween-20     200 ml  
ddH2O     up to 10 l 
 
2.1.3 Oligonucleotides 
The following oligonucleotides were used for this study. All oligonucleotides were 
synthesised by Sigma Aldrich (Poole, U.K.) 
 
Table 1: Genotyping Primers 
Amplified 
DNA 
Primer Sequence Product size 
atm Mutant Forward:  
5’- CTT GGG TGG AGA GGC TAT TC-3’ 
Mutant Reverse:  
5’- AGG TGA GAT GAC AGG AGA TC-3’ 
Wildtype: 
147bp 
 
Mutant: 
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Wildtype Forward: 
5’-GCT GCC ATA CTT GAT CCA TG-3’ 
Wildtype Reverse: 
5’-TCC GAA TTT GCA GGA GTT G-3’ 
280bp 
atmin Forward: 
5’-TCA GCA TCT TCT CCA GAG AGA CAG-3’ 
Reverse: 
5’-CAC ATG TGT ACA GCA CAT TCA TTG-3’ 
Delta: 
5’-CTC AGG GTA CAC ATA CTA TGC TTG C-3’ 
Wildtype: 
430bp 
Floxed: 
515bp 
Deleted: 
400bp  
CD19-Cre Forward: 
5’-CCA CAG AGG GAG GCA ATG TTG TGC-3’ 
Wildtype Reverse: 
5’-GTC CTT GAA AGG GGG CCT CTT CTG GC-
3’ 
Mutant Reverse: 
5’-ACG ACC GGC AAA CGG ACA GAA GCA-3’ 
Cre: 
303bp 
Control: 
226bp 
Cre Forward: 
5’-CGG TCG ATG CAA CGA GTG ATG AGG-3’ 
Reverse: 
5’-CCA GAG ACG GAA ATC CAT CGC TCG-3’ 
Cre: 
600bp 
nbs1 Forward:  
5′-CAG GGC GAC ATG AAA GAA AAC-3′, 
Reverse: 
5′- AAT ACA GTG ACT CCT GGA GG-3 
Delta: 
5′-ATA AGA CAG TCA CCA CTG CG-3′ 
Wildtype: 
320bp 
Floxed: 
380bp 
Delta: 
590bp 
p53 Forward:  
5'-CAC AAA AAC AGG TTA AAC CCA G -3’ 
Reverse:  
5'-GAA GAC AGA AAA GGG GAG GG-3’ 
Delta: 
5’-AGC ACA TAG GAG GCA GAG AC-3'  
Wildtype: 
410bp 
 
Mutant: 
490bp 
LSL-K-RasG12D Forward Wildtype: 
5' GTC GAC AAG CTC ATG CGG G-3’ 
Forward Mutant: 
5' GTC GAC AAG CTC ATG CGG G-3’ 
Reverse: 
5' CCA TGG CTT GAG TAA GTC TGC-3’ 
Wildtype: 
500bp 
 
Mutant: 
550bp 
LSL-ROSA26-
YFP 
Forward Wildtype: 
5’-GGA GCG GGA GAA ATG GAT ATG-3’ 
Forward Mutant: 
5’-AAG ACC GCG AAG AGT TTG TC-3’ 
Reverse: 
5’- GGA GCG GGA GAA ATG GAT ATG-3’ 
Wildtype: 
600bp 
Mutant: 
320bp 
terc Forward Wildtype: 
5´-CTA AGC CGG CAC TCC TTA CAA G-3´ 
Forward Mutant: 
Wildtype: 
250bp 
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5´-GGG GCT GCT AAA GCG CAT-3´ 
Reverse: 
5´-CTA AGC CGG CAC TCC TTA CAA G-3´ 
Mutant: 
180bp 
 
The following primers were used for qPCR analysis (see page 104). 
Table 2: qPCR Primers 
Gene Primers 
β-actin Forward: 5’- ATG CTC CCC GGG CTG TAT-3’ 
Reverse: 5′- CAT AGG AGT CCT TCT GAC CCA TTC -3′ 
dec1 Forward: 5’-GGC GGG GAA TAA AAC GGA GCG A-3’ 
Reverse: 5’-CCT CAC GGG CAC AAG TCT GGA A-3’ 
dmap1 Forward: 5′-ACG GAG CAA TGT TCTT CCA C-3′ 
Reverse: 5′-CAG GCA CCT GCA CAGT CTT A-3’ 
gapdh Forward: 5’-TGA AGC AGG CAT CTG AGG G-3` 
Reverse: 5`-CGA AGG TGG AAG AGT GGG AG-3` 
tip60 Forward: 5’- CAG GAC AGC TCT GAT GGA ATA C -3’ 
Reverse: 5’- AGA GGA CAG GCA ATG TGG TGA G-3’ 
 
The following primers were used for sequencing: 
Table 3: Sequencing Primers 
Vector Sequencing Primer 
pENTR 5’- TTG TAA AAC GAC GGC CAG T-3’ 
pSUPER 5’- AAT ACG ACT CAC TAT AG-3’ 
pCMV 5`-GGA CTT TCC AAA ATG TCG-3` 
 
The following nucleotide sequences were designed to target the indicated genes for 
shRNA mediated knockdown.  
 
Table 4: Target shRNA sequences  
Gene Region Targeted Sequence (sense orientation)  
ALKBH7 ORF 5’-GCA GAG GAG GAG ACG CTG A-3’ 
 3’-UTR 5’-ACA CCA GAT TTG TGA ATA A-3’ 
Ctage1 ORF 5’-CAA AGA AAG AGG AGA ATC A-3’ 
 3’-UTR 5’-TGA CAT TGC TTG TTT GTA A-3’ 
DMAP1 ORF (sequence #1) 5’-CGG AAG AAG GAG CGG GAG A-3’ 
 ORF (sequence #2) 5’-CGG AGG AGG GCA AGG ACT A-3’ 
 ORF (sequence #3) 5’-GGA CTA AGG CAG AAA CTG A-3’ 
 3’-UTR 5’-AAA TAG AGC TGC TGA GTT G-3’ 
Mycbp2 ORF 5’-GCA GAT AGG CAT AGT GAA A-3’ 
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 3’-UTR 5’-CCA AAT ACC ATG TAC ATA A-3’ 
Nthl1 ORF 5’-GGA GGA GCA AGG TGA AAT A-3’ 
 3’-UTR 5’-TGG CTT TAC GCT TCA GGA A-3’ 
Rsf1 ORF (sequence #1) 5’-GAA CAG AAA GAA AGT GAA A-3’ 
 ORF (sequence #2) 5’-GCC AAT TGG TCG AGA CAA A-3’ 
 ORF (sequence #3) 5’-GCA CAA AGA TTG AGT CCA A-3’ 
 3’-UTR 5’-AGT AAC AGC CTT TGT GAA A-3’ 
Scaper ORF 5’-GCA CAG CAG CTA AGG GAA A-3’ 
 3’-UTR 5’-GGG TGA AAG GAG ACA TAA A-3’ 
SNF2h ORF 5’-TCC GAG GAT TAA ACT GGC T-3’ 
Tip60 ORF (sequence #1) 5’-GCA ATG AGA TTT ACC GCA A-3’ 
 ORF (sequence #2) 5’-GGA GAA AGA ATC AAC GGA A-3’ 
 3’-UTR 5’-GTA CAG AGG GCT GGT GAT T-3’ 
Znf507 ORF 5’-TGA AAG AGT TGC AGG ACA A-3’ 
 3’-UTR 5’-GGA AAG ATC TCT AAA TTC A-3’ 
 
2.1.4 Antibodies 
Table 5: Primary Antibodies 
Primary 
Antibody 
Species Application, 
Dilution 
Supplier, Cat Number 
53BP1 Rabbit, 
polyclonal 
IF 1:400 Santa Cruz (CA, USA) 
sc22760 
53BP1  IHC  
ATM Mouse, 
monoclonal 
WB 1:1,000 
IP 5 µg 
Santa Cruz (CA, USA) 
sc23931 
pS1987-ATM Mouse, 
monoclonal 
WB 1:500 (mouse 
and human cells) 
IF 1:400 
Cell Signalling, (Hitchin, 
UK), #4526 
pS1981-ATM Rabbit, 
monoclonal 
WB 1:1,1000 
(human cells) 
Abcam (Cambridge, UK), 
ab81292 
pS1981-ATM Rabbit, 
monoclonal 
WB 1:1,1000 
(human cells) 
Epitomics (California, 
USA), 2152-1 
β-Actin Rabbit, 
polyclonal 
WB 1:5,000 Sigma (Poole, UK) A5060 
B220-Biotin Rat, 
polyclonal 
 IHC 1:200 BD Pharmingen (Oxford, 
UK), 553086 
B220-APC Rat, 
polyclonal 
FACS 1:100 BD Pharmingen (Oxford, 
UK), 553092 
BrdU Rat, 
polyclonal 
IHC 1:1000 AbD Serotec (Oxford, 
UK) 0BT0030CX 
CD4-Biotin Mouse, 
monoclonal 
Negative Selection 
1:100 
BD Pharmingen (Oxford, 
UK), 553045 
CD8a-Biotin Mouse, 
monoclonal 
Negative Selection 
1:100 
BD Pharmingen (Oxford, 
UK), 553029 
Chapter 2 Materials and Methods 
 85 
CD43-FITC Rat, 
polyclonal 
FACS BD Pharmingen (Oxford, 
UK), 561856 
pS317-Chk1 Rabbit, 
polyclonal 
WB 1:1,000 Cell Signalling, (Hitchin, 
UK), #2344 
Chromogranin Rabbit, 
polyclonal 
IHC 1:200 Abcam (Cambridge, UK) 
pERK (p44/42 
MAPK) 
Rabbit, 
polyclonal 
WB 1:1000 Cell Signalling, (Hitchin, 
UK), #9201 
pERK (p44/42 
MAPK) 
Rabbit, 
polyclonal 
IHC 1:100 Cell Signalling, (Hitchin, 
UK), 4370 
Dec1 Mouse, 
monoclonal 
WB 1:1000 Santa Cruz (Calne, UK) 
sc101023 
pS139-H2AX Mouse, 
monoclonal 
WB 1:1,000 
IF 1:400 
IHC 1:1000 
Millipore (Watford, UK) 
05636 
pS139-H2AX Rabbit, 
polyclonal 
WB 1:1,000 
IF 1:400 
Millipore (Watford, UK) 
05636  
pS139-H2AX Mouse, 
monoclonal 
IF-FISH 1:400 Biolegend (CA, USA) 
613402 clone 2F3 
H4K16-Ac Mouse, 
monoclonal 
WB 1:500 Millipore (Watford, UK) 
05-1232 
HA Rabbit, 
polyclonal 
IP 1:200 
WB1:2,000 
Sigma (Poole, UK) H6908 
IgM-PE Rat FACS BD Pharmingen (Oxford, 
UK), 553409 
KAP-1 Rabbit, 
polyclonal 
WB 1:1,000 Bethyl Labs 
(Montgomery, USA) 
A300-274A 
KAP-1 Rabbit, 
polyclonal 
WB 1:1,000 Abcam (Cambridge, UK) 
ab10484 
pS824-KAP-1 Rabbit, 
polyclonal 
WB 1:1,000 Bethyl Labs 
(Montgomery, USA) 
A300-767A 
Ki67 Rabbit, 
polyclonal 
IHC 1:125 DAKO (Ely, UK) 
Mac1-Biotin Mouse, 
monoclonal 
Negative Selection 
1:100 
BD Pharmingen (Oxford, 
UK), 553309 
MCM6 Goat, 
polyclonal 
IHC 1:200 Santa Cruz (CA, USA) sc-
9843 
MYC Rabbit, 
polyclonal 
IP 1:200 
WB 1:2,000 
IF 1:400 
Sigma (Poole, UK) C3956 
NK1.1-Biotin Mouse, 
monoclonal 
Negative Selection 
1:100 
BD Pharmingen (Oxford, 
UK), 553163 
p21 Rabbit, 
polyclonal 
WB 1:1,000 Santa Cruz (CA, USA) sc-
8349 
p53 Mouse, WB 1:1,000 Santa Cruz (CA, USA) sc-
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monoclonal 126 
pS15-p53 Rabbit, 
polyclonal 
WB 1:1,000 Cell signalling (Hitchin, 
UK) 9284 
pSer10-H3 Rabbit, 
polyclonal 
FACS 1:200 Cell Signalling (Hitchin, 
UK) 06-570 
SMC1 Rabbit, 
polyclonal 
WB 1:1,000 Abcam (Cambridge, UK) 
ab9262 
pS957-SMC1 Mouse, 
monoclonal 
WB 1:1,000 Millipore (Watford, UK) 
05-786 
pS966-SMC1 Rabbit, 
polyclonal 
WB 1:1,000 Bethyl Labs 
(Montgomery, USA) 
A300-050A 
TCRβ-Biotin Mouse, 
monoclonal 
Negative Selection 
1:100 
BD Pharmingen (Oxford, 
UK), 553169 
TCRγδ-Biotin Mouse, 
monoclonal 
Negative Selection 
1:100 
BD Pharmingen (Oxford, 
UK), 553176 
Ter119-Biotin Mouse, 
monoclonal 
Negative Selection 
1:100 
BD Pharmingen (Oxford, 
UK), 553672 
Tubulin (α) Mouse, 
monoclonal 
WB 1:5,000 Abcam (Cambridge, UK) 
ab7291 
turbo-GFP Mouse, 
monoclonal 
WB: 1,1000 Origene (Maryland, USA) 
TA155041 
 
Table 6: Secondary Antibodies 
Secondary 
Antibody 
Species Application, 
Dilution 
Supplier, Cat Number 
Alexa Fluoro 488, 
anti Mouse 
Donkey anti-
Mouse IgG 
IF 1:400 Life Technologies (NY, 
USA) A21245 
Alexa Fluoro 488, 
anti Mouse 
Goat anti-
Mouse IgG 
IF 1:400 Life Technologies (NY, 
USA) A11029 
Alexa Fluoro 488, 
anti Rabbit 
Donkey anti-
Rabbit IgG 
IF 1:400 Life Technologies (NY, 
USA) A21206 
Alexa Fluoro 488, 
anti Rabbit 
Goat anti-
Rabbit IgG 
IF 1:400  
FACS 1:400 
Life Technologies (NY, 
USA) A11008 
Alexa Fluoro 546, 
anti Mouse 
Goat anti-
Mouse IgG 
IF 1:400 Life Technologies (NY, 
USA) A10036 
Alexa Fluoro 546, 
anti Rabbit 
Donkey anti-
Rabbit IgG 
IF 1:400 Life Technologies (NY, 
USA) A10040 
Alexa Fluoro 568 
anti Mouse 
Donkey anti-
Mouse IgG 
IF 1:400 Life Technologies (NY, 
USA) A10037 
Alexa Fluoro 568 
anti Rabbit 
Donkey anti-
Rabbit IgG 
IF 1:400 Life Technologies (NY, 
USA) A11011 
Alexa Fluoro 594, 
anti Mouse  
anti Mouse 
IgG 
IF-FISH 1:1000 Life Technologies (NY, 
USA) A11005 
Biotin-conjugated 
anti-Goat 
Rabbit, anti-
Goat IgG 
IHC 1:250 Vector Laboratories 
(CA, USA) BA-5000 
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Biotin-conjugated 
anti-Mouse 
Donkey anti-
Mouse IgG 
IHC 1:250 Jackson (Newmarket, 
UK) 715-066-150 
Biotin-conjugated 
anti-Rabbit 
Donkey anti-
Rabbit IgG 
IHC 1:250 Jackson (Newmarket, 
UK) 711-066-152 
Biotin-conjugated 
anti-Rat 
Rabbit, anti-
Rat IgG 
IHC 1:500 Jackson (Newmarket, 
UK) 112-065-167 
HRP-conjugated 
anti-Goat 
Mouse, anti-
Goat IgG 
WB: 1:10,000 Jackson (Newmarket, 
UK) 205-032-176 
HRP-conjugated 
anti-Mouse 
Goat, anti-
Mouse IgG 
WB: 1:10,000 Jackson (Newmarket, 
UK) 115-035-174 
HRP-conjugated 
anti-Rabbit 
Mouse, anti-
Rabbit IgG 
WB: 1:10,000 Jackson (Newmarket, 
UK) 211-032-171 
2.1.5 Vectors and Expression Plasmids 
The Flag-ATM construct was a gift from Tanya Paull (Lee and Paull, 2005) and the 
HA-Tip60 a gift from Bruno Amati (Taubert et al., 2004). The Myc-DMAP1 construct 
was obtained from Origene (catalogue number RC222239), comprising transcript 
variant-1 DMAP1 cDNA with an N-terminal Myc tag, under the control of a pCMV 
promoter in a vector containing an Ampicillin resistance cassette. This construct was 
also cloned into a Green Fluorescent Protein (GFP) destination vector (Origene), 
yielding N-terminally GFP tagged DMAP1, under the control of a pCMV promoter, in a 
vector containing an Ampicillin resistance cassette.  
 
2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Cell Lines 
HCT-116, 293A, 293T and Hela Ohio cells were obtained from the London Research 
Institute Cell Services. Cells were grown in DMEM (Life Technologies) supplemented 
with 10% (v/v) FCS, 20mM L-glutamine, penicillin and streptomycin (10,000 U/ml; 
Life Technologies). Cell lines were maintained at 370C, 5% C02, and at either 3% or 
20% 02. 
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2.2.1.2 Murine Embryonic Fibroblast Culture 
MEFs were cultured in a humidified incubator at 37°C, 5% CO2 and 3% O2. For some 
experiments, MEFs were cultured at 20% 02. Every three days MEFs were trypsinised 
and passaged 1:3 (see ‘Cell Passaging’, page 88). MEFs were cultured in DMEM (+4.5 
g/l glucose, + glutamine, + pyruvate; Life Technologies) medium supplemented with 
10% (v/v) FCS (Sigma) and 1% (v/v) penicillin and streptomycin (10,000 U/ml; Life 
Technologies). 
 
2.2.1.3 Cell Passaging 
Cells lines were routinely passaged twice a week at 1:5 or 1:10. Primary MEFs were 
passaged 1:3 every three days. For cell passaging, medium was aspirated, cells washed 
once with sterile PBS and incubated in 0.25% (w/v) trypsin/PBS at 37oC for five 
minutes. After trypsinisation, cells were resuspended in medium pre-warmed to 37oC. 
 
2.2.1.4 Cell Freezing 
Confluent cells were trypsinised (see Cell Passaging, page 88) then resuspended in 10 
ml medium. The single cell suspension was centrifuged for five minutes at 1,500 rpm. 
The supernatant was aspirated, and the pellet washed once by resuspension in 10 ml 
medium followed by a five minute centrifugation at 1,500 rpm. The supernatant was 
aspirated and pellet resuspended in 1.0 ml Freezing Buffer (90% medium, 10% DMSO) 
and transferred to a 2.0 ml CryoVial. Aliquots were immediately stored at -700C 
overnight then transferred to a liquid nitrogen tank for long-term storage the following 
day. Cells were frozen at an approximate concentration of 2x106 cells/ml. 
 
2.2.1.5 Cell Thawing 
Cryovials containing 1 ml cell aliquots were quickly transferred from their long-term 
storage in liquid nitrogen tanks to thaw in a 37oC waterbath. Thawed cells were 
immediately resuspended in 10 ml pre-warmed medium and centrifuged for five 
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minutes at 1,500 rpm. The pellet was washed once with 10 ml medium (five minutes at 
1,500 rpm), resuspended in 15 ml medium and transferred to a 75cm2 tissue culture 
flask. 
 
2.2.1.6 Lipofectamine-2000 Transfection 
Cells were transfected with Lipofectamine-2000 according to manufacturer’s protocol 
(Life Technologies). The day before transfection cells were plated in either 6 cm or 10 
cm dishes at an appropriate density to achieve 60-70% confluence on the day of 
transfection. 6 cm and 10 cm dishes were transfected with 10 µg and 30 µg plasmid 
DNA respectively. Appropriate combinations of plasmid DNA for each transfection 
were prepared at room temperature in 15 ml falcons and diluted to 1 ml in serum-free 
Opti-MEM (Life Technologies). A master mix containing 20 µl (6 cm dish) or 50 µl (10 
cm dish) Lipofectamine-2000 diluted to 1 ml Opti-MEM per transfection was 
concomitantly prepared. Both tubes were incubated at room temperature for five 
minutes, then combined and incubated for a further 20 minutes. After this, the 
transfection complex was diluted with Opti-MEM to a final volume of 3 ml (6 cm) or 8 
ml (10 cm dish). Cells were washed once in PBS prior to transfection complex addition. 
After four to six hours the complex was aspirated from the cells. Cells were washed 
once with PBS and then complete media was added to the dishes. 
 
Unless transfected cells were to be subsequently labelled with AlexaFlour488 for 
immunofluorescence (IF), pCMV-GFP DNA was included in the transfection mix as a 
transfection control, at 5% of the total DNA. Transfection efficiency was assessed 24 
hours after the removal of the transfection complex by quantifying the percentage of 
GFP positive cells using a Zeiss HBO-100 light microscope. 
 
When experiments required cells in 24-well plates (for example, cells adhered onto 
coverslips for IF) cells were transfected in 6 cm plates and split into a 24 well plate the 
following day. 
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2.2.1.7 Calcium Phosphate Transfection 
Large DNA constructs, such as Flag-ATM, were transfected by calcium phosphate 
transfection. Transfections were carried out according to manufacturer’s instructions 
(Promega), using 60% confluent 10 cm dishes of 293T cells. To avoid shearing the 
large plasmids 200 µl filter tips with the ends cut off were used to pipette DNA. Three 
hours before transfection, cell medium was aspirated and replaced with 8 ml of fresh 
medium. All transfection reagents were thawed, warmed to room temperature, and 
vortexed prior to use. Glass FACS tubes were used for preparation of transfection 
complexes. For each transfection two tubes were prepared. In tube A, 30 µg DNA was 
diluted in sterile H20 to a final volume of 438 µl, then 62 µl 2.0M CaCl2 was added. In 
tube B, 500 µl 2xHBS was slowly vortexed whilst adding the contents of tube A 
dropwise. The combined transfection solution was incubated at room temperature for 30 
minutes. The solution was thoroughly vortexed and immediately added dropwise, with 
swirling, to the cells. After overnight incubation at 37oC the medium was aspirated and 
replaced with new medium. 
 
2.2.1.8 Adeno Virus Infection 
Cells containing alleles flanked by loxP sites (e.g. atmin f/f) were infected with Adeno-
Cre-GFP virus to delete the floxed allele. Primary MEFs were infected at passage two. 
The day prior to infection, cells were passaged into 75 cm2 adherent flasks in 15 ml 
medium so as to be approximately 50% confluent on the day of infection. On the day of 
infection, 10 µl of either Adeno-Cre-GFP or Adeno-GFP (Gene Transfer Vector Core) 
was added to the cells. After 48 hours, the medium was replaced and the cells left for a 
further 48 hours recovery before experimental use. Infection efficiency was estimated 
by quantifying the percentage of GFP expressing cells, and the efficiency of 
recombination assessed by DNA isolation and genotyping for the floxed and delta 
alleles. All infection steps were carried out in a Category II Containment Suite.  
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2.2.2 Biochemistry 
2.2.2.1 Protein Extraction 
Cells were washed once in ice-cold PBS and either 20 µl (6 cm dishes) or 500 µl (10 cm 
dishes) of ice-cold Lysis Buffer added (recipe page 77). Cells were detached using a 
cell scraper, and pipetted into a 1.5 ml eppendorf tube. After 15 minutes on ice, cells 
were sonicated with three five second pulses at an amplitude of ten microns (MSE 
Soniprep SANYO). The whole cell lysate was centrifuged at 40C for ten minutes at 
13,2000 rpm (Eppendorf Centrifuge 5415 R). The supernatant was removed and either 
stored at -20oC for future use or used immediately. 
 
2.2.2.2 Bradford Assay 
The protein concentration of cell lysates was determined using the colourimetric based 
Bradford Assay. Protein Assay Dye Reagent (Bradford Reagent, Bio-Rad) contains the 
dye Coomassie Brilliant Blue G-250. The unbound form of the dye has an absorption 
spectrum maximum of 465 nm, whereas the bound form has an absorption spectrum 
maximum of 595nm. The increase in absorption at 595 nm is proportional to the amount 
of bound dye – and therefore protein concentration. A standard curve was constructed 
by adding 1, 2, 4, 8, 16 and 32 µl of 1.0 mg/ml BSA to 1 ml Bradford Reagent (diluted 
1:5 in ddH20). Similarly, 2 µl of protein sample was added to cuvettes containing 1 ml 
diluted Bradford Reagent. Absorption was measured spectrophotometrcially (Ultrospec 
3100 pro, GE Healthcare). Cell lysate protein concentration was determined by 
reference to the standard curve. Protein amounts across an experimental set of samples 
were then standardised to the same concentration and volume by dilution in appropriate 
volumes of lysis buffer. 
 
2.2.2.3 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electophoresis 
(SDS-PAGE) 
Protein loading buffer (Laemmli buffer, recipe page 79) was added 1:5 to protein 
samples. Samples were boiled at 1000C for ten minutes on a heat block (Techne Dri-
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Block DB-2D). Meanwhile, the appropriate percentage resolving gel solution was 
prepared (recipe page 79). Immediately after preparation, the resolving gel solution was 
poured into assembled glass plates for vertical electrophoresis (C.B.S. Scientific) to fill 
approximately three-quarters of the gel plates. After gel polymerisation a 5% stacking 
gel solution (recipe page 81) was prepared, added to the top of the gel chamber and the 
desired size gel comb placed in the stacking gel prior to its’ polymerisation (C.B.S. 
Scientific). Once polymerised, the gel chamber was secured to an Adjustable Slab Gel 
Kit (C.B.C Scientific). The tank was filled with 1xSDS-PAGE Running Buffer (recipe 
page 80); and Rainbow markers (GE Healthcare) and samples loaded. 
 
2.2.2.4 Western Blot 
After the SDS gel had run for an appropriate time to separate proteins to the desired 
resolution the gel was transferred onto a PVDF membrane (Amersham) using a semi-
dry blot chamber (Hoefer Scientific Instruments). The PVDF membrane was washed 
once each in Methanol (Fisher scientific), ddH20 and finally Transfer Buffer (recipe 
page 80). Three layers of blotting paper (Whatman) pre-soaked in Transfer Buffer were 
placed in the transfer chamber, followed by the membrane, gel, and a further three 
layers of pre-soaked blotting paper. Proteins were transferred for three hours at 120 mA. 
All subsequent membrane blocking, antibody incubation and washing steps were 
performed on a shaker. After transfer, membranes were incubated with 5% (w/v) 
skimmed milk [(A1 Laboratory Supplies Ltd), dissolved in TBS-T] for 20 minutes at 
room temperature. Following this step to block unspecific binding, membranes were 
incubated with primary antibody diluted 1:1000 in 5% (w/v) skimmed milk, at 4oC 
overnight. The following day, membranes were washed with four ten minute TBS-T 
washes at room temperature. Secondary antibody incubation was performed for 90 
minutes at room temperature with HRP-conjugated secondary antibodies (Jackson 
Laboratories) diluted 1:5000 in 5% (w/v) skimmed milk. Then, membranes were 
washed for a further four times in TBS-T. Excess liquid was removed from the 
membrane using blotting paper (Whatman) and the dried membrane incubated for 2 
minutes with a 1:1 mix of ECL Detection Solutions 1 and 2 (GE Healthcare). Fuji X-ray 
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films (Fisher Scientific) were laid upon the membranes in developing cassettes for 
various periods of time and films developed in an X-ray developer (Jungwon). 
 
2.2.3 DNA Damage Treatments 
2.2.3.1 Irradiation 
Irradiation experiments were performed using a Cs137 Gamma Irradiator at 2.1 Gy/min. 
Cells and mice were irradiated at the indicated doses. Mice were irradiated with lead 
shielding, cells without. 
 
2.2.3.2 UV 
Medium was aspirated immediately before treatment. Cells were treated with 5 J m-2 
using a UV Stratalinker 2400 (Stratagene). After treatment, new medium was quickly 
added to the cells. The treated cells were harvested after a sixty minute recovery at 37oC. 
 
2.2.3.3 Hypotonic Shock 
Cells were washed twice with sterile PBS then incubated with Hypotonic Swelling 
Buffer (recipe page 77) for 60 minutes. 
 
2.2.3.4 H202 
Oxidative stress treatments were performed using 250 µM H202 (Fisher Scientific). H202 
dilutions were prepared in medium from a stock solution immediately prior to treatment. 
Cells were washed twice with PBS then H202 added for the indicated length of time. 
 
2.2.3.5 Bleomycin 
Cells were treated with 5 µM bleomycin (Sigma, B5507) diluted in complete medium. 
Unless indicated otherwise, cells were treated for 30 minutes.  
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2.2.3.6 Neocarzinostatin  
Neocarzinostatin (Sigma, N9162) was added to cells at a final concentration of 200 
ng/ml for the indicated length of time. 
 
2.2.3.7 Aphidicolin 
Sub-confluent cells were incubated in medium containing 5 µM aphidicolon (Sigma, 
A4487) for two hours.  
 
2.2.4 Cellular Biology 
2.2.4.1 Cell Culture Treatments 
For some experiments, cells were incubated with small molecules prior to treatment or 
harvesting. ATM kinase inhibitor (Calbiochem), dissolved in DMS0, was added at a 
final concentration of 10 nM one hour prior to DNA damage treatment. TSA (Sigma) 
was added at a final concentration of 5 µM for the indicated time. DMSO containing 
medium was added to control cells.  
 
2.2.4.2 BrdU Incorporation 
BrdU (5-bromo-2-deoxyuridine) is a synthetic analogue of thymidine and is 
incorporated into newly replicated DNA during S phase. The percentage of cells 
incorporating BrdU in a given time period is a measure of a cell population’s 
proliferation. Cells were grown in medium containing 10 µM BrdU (Sigma) for 
30minutes, trypsinised and washed once in ice-cold PBS by centrifugation (1,500 rpm, 
five minutes, 4oC) The resultant cell pellet was fixed, whilst vortexing, in ice-cold 70% 
(v/v) ethanol. Fixed cells were washed twice in PBS (1,500 rpm, five minutes, 4oC) and 
resuspended in 2M HCl at room temperature for 30 minutes, with mixing at intervals. 
Cells were washed twice with PBS then incubated with 2 µl anti-BrdU antibody (Becton 
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Dickinson) for 20 minutes in the dark. Cells were washed once with PBS-T, and 
incubated with secondary antibody for 20 minutes in the dark. After one more PBS 
wash 50µl ribonuclease (Sigma) and 150µl propium iodide (Sigma) were added to the 
cell pellet for 30 minutes in the dark. The cells were analysed using a LSR II Flow 
Cytometer (BD) and the data analysed using Flow Jo (TreeStar). 
 
2.2.4.3 Immunoprecipitation 
Cells were harvested 48 hours after transfection (see Protein Extraction, page 91) and a 
Bradford Assay performed (see Bradford Assay, page 91). For each 
immunoprecipitation 500 µg of protein was diluted in a final volume of 500 µl Lysis 
Buffer (recipe page 79). From each protein lysate a 10% input control (50 µl) was 
removed prior to immunoprecipitation. Lysates were incubated overnight, at 4oC, on a 
rotating wheel with either 5 µg primary antibody or 5 µg IgG control (Life 
Technologies). The following morning, 40 µl of a 1:1 mix of ProteinA-Sepharose and 
ProteinG- Sepharose was washed three times with ice-cold Lysis Buffer. For all steps 
involving the pipetting of Sepharose Beads, 200 µl tips with the tips cut off were used to 
avoid shearing the Sepharose beads. Each wash step comprised of resuspending the 
beads in 1 ml Lysis Buffer by gentle inversion three to five times, then centrifugation at 
2,500rpm for three minutes at 4oC. After the final wash the pellet was resuspended in 50 
µl of Lysis Buffer then added to the overnight incubation of primary antibody and 
protein extract. The lysates were incubated for a further two hours, at 4oC, on a rotating 
wheel. The captured immunocomplexes were washed a further four times with 1 ml 
Lysis Buffer per wash. After the final wash, pelleted immunocomplexes were 
resuspended in Lysis Buffer, and a 1:5 dilution of Protein Loading Buffer. Samples 
were boiled for ten minutes at 1000C on a heat block (Techne Dri-Block DB-2D) prior 
to gel loading.  
 
2.2.4.4 ATM Co-Immunoprecipitation Assays 
For experiments involving the immunoprecipitation of ATM, a modified protocol was 
used due to ATM’s large molecular weight. The calcium phosphate method was used 
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for transfection (see page 90) and cells harvested in ATM lysis buffer (recipe page 74). 
Instead of three washes with Lysis Buffer, immunoprecipitates were instead washed 
three times in ATM lysis buffer (recipe page 74), once in High Salt Buffer (recipe page 
76), and one wash in Base Buffer (recipe page 75). 
 
2.2.4.5 FACS Analysis 
All FACS analysis was carried out in collaboration with the LRI FACS facility. 
Fluorescence-activated cell sorting measurements were performed using an LSR II 
Flow Cytometer (BD). Analysis was carried out using FlowJo (Tree Star) software.  
 
Cell lines were harvested for FACS by trypsin treatment (see Cell Passaging, page 88) 
then resuspended in medium and centrifuged at 4oC for five minutes at 1,500 rpm. The 
pellet was resuspended in 4 ml sterile PBS and centrifuged a second time. After 
supernatant aspiration the pellet was resuspended in 500 µl 70% (v/v) ethanol (Fisher 
Scientific), pre-chilled to 4oC. This cell-fixing and permeabilisation step was performed 
by adding 500 µl 70% (v/v) ethanol dropwise to cells, whilst vortexing the cells at a 45o 
angle. 
 
For both cell cycle analysis and sub-G1 cells were washed twice in PBS, by five minute 
centrifugation at 2,000 rpm. The cell pellet was treated with 50 µl Ribonuclease (stock 
100 µl/ml) to ensure only DNA, and not RNA, is stained. Finally, 200 µl of 50 µg/ml 
propidium iodide (PI) was added. A FACS plot of PI staining versus cell size allows 
discrimination between the different cell cycle phases. Cells undergoing apoptosis have 
fragmented DNA, and are identified by quantifying the ‘sub G1’ population - those cells 
with PI staining below what is expected for a cell in G1.  
 
For BrdU analysis (see BrdU Incorporation, page 94) cells were washed twice in PBS, 
by five minute centrifugation at 2,000 rpm then re-suspended in 2M HCl, then left at 
room temperature for 20 to 30 minutes with mixing at intervals. Then, the cells were 
washed twice more in PBS then once in PBS-T. Next, the cell pellet was incubated with 
2 µl anti-BrdU antibody (Sigma) in the dark for 20 minutes. After one wash in PSB-T, 
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cells were stained with 50 µl secondary antibody for 20 minutes in the dark. Next, cells 
were washed once in PBS then incubated with 50 µl ribonuclease and 150 µl PI in the 
dark for 30 minutes. A FACS plot of BrdU versus PI readily identifies those cells that 
have incorporated BrdU, and are therefore in S-phase.  
 
2.2.4.6 HAT Assays 
Cells were transfected in 10 cm plates using Lipfectamine-2000 and harvested 48 hours 
later. A Bradford assay was performed, and 1 mg of protein extract was diluted to 500 
µl using Lysis Buffer (see Bradford Assay, page 91). A 10% input sample (50 µl) was 
removed prior to immunoprecipitation. Cells were immunoprecipitated (see 
Immunoprecipitation, page 95) using either HA (Sigma H6908), Myc (Sigma, C3956) 
or IgG control (Invitrogen, 02-6102) antibodies. Washed immunocomplexes were 
resuspended in 50 µl of Lysis Buffer. The Histone Acetyl Transferase (HAT) activity of 
the immunoprecipitate was measured with a colourimetric Histone Acetyltransferase 
Activity Assay Kit (Abcam 65352) according to the manufacturer’s protocol. Briefly, 
20 µl of the immunoprecipitate was diluted to a final volume of 40 µl in ddH20. A 
positive control of 10 µl nuclear extract (supplied in kit) was also diluted to a final 
volume of 40 µl in dd H20. An assay mix of 50 µl of 2x HAT Assay Buffer, 5 µl HAT 
Substrate I, 5 µl HAT Substrate II and 5 µl NADH Generating Enzyme was prepared, 
and 65 µl added to the sample, and positive control, in a transparenet 96 well plate 
(Nunc). To account for background, 65 µl of the assay mix was added to 40 µl ddH20. 
The plate was incubated at 37oC for four hours, and the optical density at 440nm read 
for each well using a SpectraMax Plate Reader. All samples were normalised to the 
background reading. To control for equal immunoprecipitation, samples and input were 
resolved on a 10% SDS-PAGE electrophoresis gel and the resulting membrane probed 
for the protein of interest (see Western Blot).  
 
2.2.4.7 The G2 Trap 
The G2 Trap was used to assess G2/M checkpoint functionality. Cells were transfected 
using the Lipofectamine-2000 method then irradiated 48 hours later. Immediately after 
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irradiation cells were placed in medium containing 40 nM Nocodazole (Sigma, M1404) 
or DMSO and cultured for 18 hours. Then, the medium was carefully pipetted from the 
cells and placed in a FACS tube. Cells were washed once with PBS and trypsinised, and 
resuspended in the medium removed from the cells prior to trypsin treatment. This 
suspension was returned to the FACS tube, and centrifuged at room temperature for five 
minutes at 1,500 rpm. The pellet was resuspended in 4 ml sterile PBS and centrifuged a 
second time. After supernatant aspiration the pellet was resuspended in 500 µl 70% 
(v/v) ethanol (Fisher Scientific), pre-chilled to 4oC. This cell-fixing step was performed 
by adding 500 µl 70% (v/v) ethanol dropwise to cells, whilst vortexing the cells at a 45o 
angle. Fixed cells were stored at 4oC then stained for FACS analysis (see page 96). 
Cells were stained with pSer10-H3 antibody (Cell signalling, 06-570) followed by 
incubation with Alexa647 secondary antibody (Life Technologies, A-31571).  
 
2.2.4.8 Clonogenic Survival Assay 
For post-irradiation survival analysis cells were irradiated at doses ranging from 0-40 
Gy. Cells were immediately trypsinised and resuspended in 5 ml medium. The single 
cell suspension was counted using a Vi-Cell XR cell counter (Beckman Coulter). By 
serial dilution, solutions of 250 cells/ml and 1000 cells/ml were prepared. One ml of 
these solutions was added to 6 cm plates to a final volume of 3ml medium. Each cell 
solution was plated in triplicate. Seven days after irradiation the number of colonies per 
plate was counted by eye. Note that in experiments involving inhibition of ATM, the 
ATM inhibitor was not added to the resuspended cells after irradiation.  
 
2.2.4.9 β-galactosidase senescence assay 
Cellular senescence was assessed using the Senescent Cells Histochemical Staining Kit 
(Sigma, CS0030), according to manufacturer’s instructions. Cells were incubated in 
staining mixture overnight at 370C in a non-C02 enriched environment. The following 
day, cells were washed three times with PBS and analysed by light microscopy (AX10 
Imager.A1, Carl Zeiss). Cells with β-galactisodase activity at pH6.0 are senescent, and 
stain blue. 
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2.2.4.10 Immunofluorescence 
Twenty-four hours after transfection in 6 cm plates, cells were trypsinised and passed 
into a 24-well plate containing coverslips. Cells were grown for a further 24 hours to 
adhere onto the coverslips. In some cases, cells were treated prior to fixation (for 
example, IR). Cells were washed once with ice-cold sterile PBS, then fixed in 500 µl 
4% (w/v) paraformaldehyde (PFA) for 20 minutes at room temperature. After fixation, 
cells were washed three times with PBS and were either stained immediately or stored 
in PBS at 4oC for up to a week before permeabilisation and staining. Each wash step 
consists of immersion in the wash solution for five minutes, on a shaker, at room 
temperature. Cells were permeabilised by incubation in 0.5% (v/v) Triton/PBS for three 
minutes at room temperatures. In some cases cells were fixed by two hours in a 1:1 pre-
chilled ethanol:acetone solution at -20oC. If fixed by this method, a separate 
permeabilisation step was unnecessary.  
 
After three PBS washes cells were incubated in Blocking Buffer (recipe page 75) for 30 
minutes at room temperature, on a shaker. Coverslips were then incubated with primary 
antibody diluted 1:400 in Blocking Buffer on a shaker; for either two hours at room 
temperature or overnight at 4oC. Following primary antibody binding, coverslips were 
washed three times in Blocking Buffer. Secondary antibody, diluted 1:400 in Blocking 
Buffer, was added for one hour at room temperature, with shaking. Cells were washed 
with PBS and incubated with 1:10,000 DAPI (Sigma) for two minutes at room 
temperature, washed twice in PBS then mounted in DAKO fluorescent mounting 
medium (Ely). 
 
2.2.4.11 IF-FISH 
Cells were treated with 20 ng/ml colcemid (Sigma) for 30 minutes, then trypsinised (see 
page 88) and resuspended in hypotonic solution (0.2% (w/v) KCl, 0.2% (w/v) trisodium 
citrate) at room temperature, at a concentration of approximately 1x105 cells/ml. After a 
ten minute incubation, cells were cytocentrifuged onto SuperFrost Plus slides (Menzel-
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Glaser) at 450g for 10 minutes in a Shandon Cytospin 4. Next, cells were fixed for ten 
minutes in 4% (v/v) PFA, washed twice in ddH20, then permeabalised in KCM buffer 
(recipe page 77) for ten minutes. Cells were then blocked for 15 minutes at 37 °C with 
100 g ml-1 DNase-free RNase A (Sigma) in antibody dilution buffer (recipe page 74). 
Slides were then incubated with primary antibody diluted in antibody dilution buffer 
(recipe page 74) for one hour at room temperature. After three five-minute washes in 
PBS-T (0.1% (v/v) Tween-20/PBS) at room temperature, slides were incubated in 
secondary antibody diluted in antibody dilution buffer (recipe page 74) for thirty 
minutes at room temperature, in the dark. All subsequent steps were performed in the 
dark. Slides were washed with three five-minute washes in PBS-T (0.1% (v/v) Tween-
20/PBS) at room temperature then fixed for ten minutes in 4% (w/v) PFA. Fixed slides 
were dehydrated through the following steps; three minutes in 70% (v/v) ethanol, two 
minutes in 90% (v/v) ethanol and two minutes in 100% ethanol.  
 
Air-dried slides were overlaid with 0.3 µg/ml PNA probe Alexa 488–OO-(CCCTAA)3 
PNA probe (Panagene) in PNA hybridisation solution (recipe page 78) and incubated at 
80 °C for three minutes then overnight at room temperature. Finally, stained slides were 
washed with two ten minute washes in PNA Wash A (recipe page 79) then three five 
minute washes in PNA Wash B (recipe page 79). 50 ng/ml DAPI was added to the final 
wash, cells rinsed once in ddH20 then mounted using DABCO (Sigma). Cells were 
imaged using a Zeiss Axio Imager M1 microscope, and an AxioCam MRm digital 
camera (Carl Zeiss).  
 
2.2.5 Molecular Biology 
2.2.5.1 DNA Isolation 
Murine ear-snips were used for genotyping. DNA was extracted by incubation in 95 µl 
DirectPCR Lysis Reagent (Viagen) and 5 µl Proteinase K (10mg/ml, Melford) at 56 oC 
overnight. The following day samples were heated at 85oC for 45 minutes to inactivate 
Proteinase K. Samples were allowed to cool to room temperature, then centrifuged at 
5,000 rpm for five minutes. Subsequently, 2 µl was used in each genotyping PCR 
reaction and the lysate stored at -20oC. 
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For downstream applications requiring higher purity DNA preparations, such as cloning 
and sequencing, the isopropanol method was used for DNA isolation. 500 µl DNA 
Extraction Buffer (recipe page 76) was added to the tissue sample or cells. After 
overnight incubation at 56oC samples were vortexed for ten seconds. Then 200 µl 5M 
NaCl was added and after ten seconds of vortexing samples were centrifuged at room 
temperature for ten minutes at 13,2000 rpm (Eppendorf Centrifuge 5415 D). The 700 µl 
supernatant was removed, and added to 500 µl isopropanol. The combined solution was 
vortexed for ten seconds and centrifuged at room temperature for ten minutes at 
13,2000 rpm. Subsequently, the supernatant was discarded and pellet air-dried at room 
temperature for 15 minutes. The dried pellet was dissolved in 100 µl ddH20 and 
incubated at 37oC for 30 minutes on a shaker (Eppendorf Thermomixer). DNA 
concentration was determined using the NanoDrop Spectrophotometer (Thermo 
Scientific) and stored at -20oC for future use. 
 
2.2.5.2 Genotyping PCR 
Depending on the allele to be genotyped, one of the following genotyping PCR mixes 
was prepared: 
 
terc Genotyping PCR: 
1 x GoTaqPCR buffer (Promega) 5 µl (5 x stock) 
MgCl2     3 µl (25mM stock) 
dNTPs (0.25 mM)    0.2 µl (25 mM stock) 
Primer forward (1 µM)  0.2 µl (100 µM stock) 
Primer reverse (1 µM)  0.2 µl (100 µM stock) 
Primer delta (1 µM)   0.2 µl (100 µM stock) 
GoTaq Polymerase (0.2U)  0.2 µl (5U/ µl stock) 
dd H20:     14 µl 
DNA     2 µl 
Total Volume:    25 µl 
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All other Genotyping PCRs: 
1 x CoralLoad PCR Buffer (Qiagen)  2 µl (10 x stock) 
1 x Solution Q    4 µl (5 x stock) 
dNTPs (0.25 mM)   0.2 µl (25 mM stock) 
Primer forward (1 µM)  0.2 µl (100 µM stock) 
Primer reverse (1 µM)   0.2 µl (100 µM stock) 
Taq-Polymerase (0.2 U)  0.2 µl (5 U/µl stock) 
ddH2O    11.2 µl 
DNA     2 µl 
Total Volume:    20ul 
 
Depending on the genomic region to be amplified, one of the following PCR 
programmes was used: 
 
Table 7: atm Genotyping PCR Programme 
Step Temp (oC) Time Notes 
1 94 3 min  
2 94 20 sec  
3 64 30 sec* * minus 0.5oC per cycle 
4 72 35 sec go to step 2 for 12 cycles 
5 94 20 sec  
6 58 30 sec  
7 72 35 sec go to step 5 for 25 cycles 
8 72 2 min  
9 4 end  
  
Table 8: terc Genotyping PCR Programme 
Step Temp (oC) Time Notes 
1 95 10 min  
2 94 1 min  
3 55 1 min  
4 72 1 min go to step 2 for 28 cycles 
5 72 6 min  
6 4 end  
 
Table 9: LSL-K-RasG12D Genotyping PCR Programme 
Step Temp (oC) Time Notes 
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1 94 3 min  
2 94 30 sec  
3 60 45 sec  
4 72 1 min go to step 2 for 35 cycles 
5 72 10 min  
6 4 end  
 
Table 10: Genotyping PCR Programme for all other alleles: 
Step Temp (oC) Time Notes 
1 94 3 min  
2 94 30 sec  
3 60 45 sec  
4 72 45 sec go to step 2 for 30 cycles 
5 72 10 min  
6 4 end  
 
2.2.5.3 Agarose gel electrophoresis 
PCR products were resolved on a 3.0% (w/v) agarose (Bioline) gel dissolved in 1xTAE 
with 1:1,000 ethidium bromide (10 mg/ml, Sigma-Aldrich). DNA separation took place 
at 120 V for 90 minutes. To define band size, 10 µl of a 100kB DNA ladder (Life 
Technologies) was also loaded. The resolved gel, and PCR product size, was visualised 
by UV illumination using a UV Transluminator (UVP). 
 
2.2.5.4 RNA Isolation 
The RNeasy Mini (QIAGEN) kit was used for RNA extraction, according to the 
manufacturers’ instructions. Half a confluent 6 cm dish was used for each RNA 
preparation from cells. For RNA isolation from murine spleens approximately half a 
spleen was used for each preparation. To isolate RNA from intestinal tissue crypts 
and/or villi were extracted from 4 cm long intestine sections. Samples were 
homogenised by 8-10 passages through a 19-gauge needle (BD). The RNase-Free 
DNase Set (QIAGEN) was used for On-Column DNA digestion, according to the 
manufacturers’ protocol. After extraction, RNA concentration and purity was 
determined using a NanoDrop Spectrophotometer (Thermo Scientific). A successful 
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RNA preparation should have a OD260/0D280 ration between 1.8 and 2.0. The isolated 
RNA was stored at -80oC. 
 
2.2.5.5 cDNA Synthesis 
The concentrations of RNA for cDNA synthesis were standardised using RNase-free 
water. Approximately 1 µg of RNA was used in each cDNA reaction. Superscript III 
First-Strand cDNA synthesis kit (Life Technologies) was used for cDNA synthesis, 
according to manufacturer’s instructions. Random hexamer primers were used. A 
control reaction, not containing Reverse Transcriptase, was performed in parallel on 
each sample. After synthesis, cDNA was stored at -20oC. 
 
2.2.5.6 Quantitative RT-PCR 
Firstly, cDNA was diluted 1:5 in ddH20. 1 µl of this solution was used for each qRT-
PCR. Each reaction was performed in triplicate, in a 96 well plate, according to the 
following reaction mix: 
 
1 x qRT-PCR Mix: 
Primer 1 (10 µM Stock)   0.5 µl 
Primer 2 (10 µM stock)   0.5 µl 
Platinum SYBR Green  12.5 µl 
ddH20     10.5 µl 
cDNA     1 µl 
 
After preparation the plate was centrifuged at 4oC for five minutes at 2,000 rpm. The 
starting amount of template cDNA for each primer pair was measured by SYBR Green 
incorporation (Platinum Quantitative PCR SuperMix-UDG w/ROX, Life Technologies). 
The starting amount of cDNA in the reaction was accounted for by normalisation to 
either GAPDH or β-globin Ct levels according to the formula: 
 
Sample Expression = 2-(Sample Ct - Control Ct) 
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To eliminate unspecific products, primer dimer formation and contamination a 
dissociation curve was performed and a ‘no DNA’ control reaction was included for 
each primer set. Data was analysed with SDS 2.3 Software (Applied Biosystems).  
 
 
2.2.5.7 shRNA Cloning Strategy 
For each gene to be targeted, 19 nucleotide shRNA sequences against the open reading 
frame (ORF) and 5’-Untranslated Region (5’-UTR) were designed using the 
Dharmacon Design Centre. The sense and anti-sense orientations of the target 19 
nucleotide sequence were incorporated into 64 nucleotide long oligomers as indicated 
below: 
Forward Primer: Gatcccc-Sense-ttcaagaga-Antisense-tttttggaaa 
Reverse Primer: Agcttttccaaaaa- Sense-tctcttgaa-Antisense-ggg 
 
These forward and reverse 64 nucleotide oligomers were annealed and cloned into the 
pSUPER vector. The terminal nucleotides at either end of this oligomer are the same as 
the overhangs left by BglII or HindIII restriction enzyme digestion. 
  
Firstly, the matching forward and reverse oligomers were annealed. Briefly, 4 µl of each 
100 µM primer was added to 42 µl ddH20 and heated at 95oC for four minutes, ten 
minutes at 70oC, then slowly cooled to room temperature. Secondly, the annealed 
oligomers were phosphorylated for 30 minutes at 37oC in the following reaction: 
 
Annealed Oligomers   2 µl 
1mM ATP    1 µl 
10x PNK Buffer   1 µl 
T4 PNK    1 µl 
ddH20     5 µl 
 
After completion PNK was heat inactivated 70oC for ten minutes. 
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The pSUPER vector was digested with HindIII and BglII (NEB) to create compatible 
DNA overhangs for ligation with the annealed oligomers, in the following reaction mix, 
at 37oC overnight: 
 
BglII      2 µl 
HindIII     2 µl 
pSUPER (1µg/µl)    4 µl 
10x Buffer 2 (NEB)    3 µl 
ddH20      19µl 
 
The next day, 2 µl Antartic Phosphatase (NEB), 4 µl 10x Antartic Phosphatase Buffer 
(NEB) and 2 µl ddH20 were added to the reaction, to remove the 5’-phosphate from the 
digested vector and prevent re-ligation. The reaction was incubated at 37oC for a further 
30 minutes, then heat inactivated for five minutes at 65oC.  The entire reaction was 
loaded onto a 1% (w/v) Agarose gel and run for one hour at 90 V. The band 
corresponding to digested vector was cut out and purified using the Gel Band 
Purification Kit (GE Healthcare), according to manufacturer’s instructions.  
 
Annealed oligomers were ligated into digested pSUPER overnight at 16oC, according to 
the following reaction: 
T4 DNA Ligase    1 µl 
10x T4 DNA Ligase buffer   1 µl 
Phosphorylated, annealed oligomers  4 µl 
Digested pSUPER    1 µl 
ddH20      3 µl 
 
The next day, 2 µl ligation mix was used for transformation of XL10-Gold Bacteria (see 
page 107). Transformed bacteria were grown overnight on Ampicillin containing Agar 
plates. The following day colonies were picked, grown overnight in Ampicillin (100 
µg/ml) containing LB medium, and bacteria pelleted for DNA extraction. A double 
digest with EcoR1 and HindIII was used to determine if the insert was present. When 
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separated on a 3% (w/v) Agarose gel, positive clones have a 360bp band - whereas 
empty vectors have a 300bp band. Positive clones were sequenced to ensure the insert 
contained the correct, mutation-free, sequence.  
 
2.2.5.8 Bacterial Transformation and Plasmid Preparation 
DH5α bacteria were used to amplify plasmid DNA. For each transformation, 50 µl 
bacteria were thawed on ice in 1.5 ml eppendorf tubes. Then, approximately 10-50 ng 
DNA (in a maximum 5 µl volume) was added to the bacteria. DNA and bacteria were 
mixed by gently tapping the eppendorf several times then left on ice for 30 minutes. 
Next, the bacteria were heat-shocked for 30 seconds at 42oC on a heatblock (Eppendorf 
Thermomixer Compact).  After a two minute recovery on ice 1ml pre-warmed SOC 
medium was added. Bacteria were grown at 37oC for one hour to allow transcription 
and translation of the antibiotic resistance gene present on the plasmid. Bacteria were 
then transferred to 200 ml antibiotic containing LB and grown overnight at 37oC in 500 
ml flasks, with shaking. The following morning bacteria were harvested by 
centrifugation at 3,000 rpm for 20 minutes. Plasmid DNA was isolated from pelleted 
bacteria using a Plasmid Maxi Kit (QIAGEN), according to manufacturer’s protocol. 
 
For the amplification of DNA ligation reactions XL10-Gold bacteria (Aligent) were, 
with minor protocol adjustments. Briefly, 100 µl bacteria were used, and 2 µl β-
mercaptonal was added to the bacteria ten minutes prior to DNA addition. 
 
For the amplification of large DNA constructs, such as Flag-ATM, SURE-2 Competent 
cells (Aligent) and a modified protocol were used to minimise the likelihood of plasmid 
recombination. Transformed bacteria were grown for 48 hours in 2 l flasks, at 30oC in 
200ml SOC with gentle shaking. Pipette tips with the ends cut off were used for the 
handling of these plasmids to avoid the risk of plasmid shearing.   
 
Chapter 2 Materials and Methods 
 108 
2.2.5.9 DNA Sequencing 
DNA sequencing was performed using the Sanger method - the terminal incorporation 
of labelled nucleotides. Approximately 400 ng DNA was used in the following reaction 
mix: 
 
BigDye Terminator Reaction Mix (BDT)  8 µl 
10uM Sequencing Primer    0.32 µl 
DNA        ≅400 ng 
ddH20       up to 20 µl 
 
The PCR reaction consisted of 28 cycles of the following steps: 
1. 95oC for 30 seconds 
2. 55 oC for 30 seconds 
3. 60 oC for four minutes 
Terminally labelled PCR products were purified using the DyeEx 2.0 Spin Kit 
(QIAGEN), according to manufacturer’s instructions. Samples were sequenced by the 
LRI Equipment Park. Sequence reads were analysed using ApE 1.17 Plasmid Editor. 
 
2.2.6 Animal Work 
2.2.6.1 Animal Maintenance 
All mice were housed in the LRI Biological Resource Units, at either Lincoln’s Inn 
Fields or Clare Hall Laboratories. Schedule 1 Methods, as described in the Animal 
Scientific Procedures Act 1986, were used to cull all mice. For brain studies, mice were 
culled by C02 asphyxiation method. Cervical dislocation was used to cull mice for all 
other experiments. All murine studies were carried out according to UK Home Office 
guidelines and approved by the London Research Institute Animal Ethics Committee. 
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2.2.6.2 Mouse lines 
Transgenic mice with combinations of the following mutant alleles were used in this 
study: 
Mouse Line Reference 
atm+/- (Xu et al., 1996) 
atmin∆/∆ (Kanu and Behrens, 2007) 
atminf/f (Kanu et al., 2010) 
CD19-Cre (Rickert et al., 1997) 
LSL-K-RasG12D (Jackson et al., 2001) 
nbs1f/f (Frappart et al., 2005) 
Nestin-Cre (Raivich et al., 2004) 
p53f/f (Jonkers et al., 2001) 
PGK-Cre (Behrens et al., 1999) 
Rosa26-LSL-YFP (Srinivas et al., 2001) 
Villin-Cre (el Marjou et al., 2004) 
Villin-CreERT (el Marjou et al., 2004) 
 
Starting generation (G0) terc+/- mice were obtained from Leonard Rudolph (Rudolph et 
al, 1999). These were intercrossed with atminf/f; Nestin-Cre animals to obtain starting 
generation (G0) atminf/f; terc+/-; Nestin-Cre and atminf/f; terc+/- cohorts. These mice 
were intercrossed to obtain atminf/f;terc-/- and atminf/f;terc-/-Nestin-Cre first generation 
(G1) animals, and so on for second and third generations. A cousin-mating breeding 
scheme was used to avoid generation of sub-strains.  
 
2.2.6.3 BrdU injection 
To determine which cells were proliferating, mice were given an intraperitoneal 
injection of 100 µg/g bodyweight 5-bromo-2’-deoxyuridine (BrdU; Sigma; stock: 20 
mg/ml in endotoxin free-PBs). Injected animals were culled and analysed 90 minutes 
post injection. 
 
2.2.6.4 Tamoxifen Injection 
To express Cre recombinase in Villin-CreERT animals mice were intraperitoneally 
injected with tamoxifen. Three injections of 5 µl/g bodyweight (stock solution 20 mg/ml, 
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dissolved in peanut oil) were given at the same time each day for three consecutive days. 
Recombination efficiency was assessed by histological detection of Rosa26-LSL-YFP 
reporter expression, genotyping PCR and western blot of isolated tissue. The 20 mg/ml 
tamoxifen stock solution was prepared by dissolving 400 mg tamoxifen (Sigma) in 20 
ml peanut oil (Sigma). To completely dissolve the tamoxifen, 5-6 cycles of 30 minutes 
on a rotating wheel then 30 minutes at 37oC were followed, with vortexing.  
 
2.2.6.5 Generation of Primary Murine Embryonic Fibroblasts 
Embryos were removed at E12.5 and immediately transferred into chilled sterile PBS. 
Using a dissecting microscope, the placenta and yolk sac were discarded. The head and 
tail were removed and transferred to separate 1.5 ml eppendorfs for subsequent DNA 
extraction and genotyping. The heart, liver and lungs were removed and remaining 
embryo placed in a 6-well plate containing 4 ml DMEM (recipe page 76). The embryo 
was passed 8-10 times through a 1 ml syringe (BD) and an 18-gauge needle (BD) to 
create a single cell suspension. 
 
2.2.6.6 Adult Neurosphere Isolation 
Mice were culled by C02 asphyxiation and the brain removed, and cut coronally 
between the midbrain and forebrain. The forebrain was embedded with the olfactory 
bulb uppermost in molten 5% (w/v) low melting point agarose (dissolved in PBS; Life 
Technologies). Coronal 230µm brain sections were cut using a vibratome (Leica 
VT1000). Sections containing the sub-ventricular zone (SVZ) were retained, and 
transferred into PBS using a Pasteur pipet with the tip cut off. Using a dissecting 
microscope, the SVZ of each section was carefully dissected from both hemispheres. 
These were pooled in 200 µl PBS, in an 1.5 ml eppendorf tube. Tissue was dissociated 
by cutting with a scalpel and pipetting, and the resulting cell suspension centrifuged for 
five minutes at 1,000 rpm, at room temperature. The supernatant was discarded, and the 
pellet resuspended in 500 µl neurobasal medium (recipe page 79). The entire 500 µl 
single cell suspension was transferred to a 6-well plate containing 3.5 ml neural basal 
medium and left for at least a week to allow neurospheres to form before passaging.  
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2.2.6.7 Primary Neurosphere Culture 
Primary adult neurospheres were cultured at 37oC, 3% 02, 5% C02 in neurobasal 
medium (recipe page 79). The undifferentiated primary neurospheres were grown as 
suspension cultures in non-adherent plates or flasks (|BectonDickinson (BD) Falcon; 
Sarstedt). Every four to five days the culture was passaged by centrifugation for five 
minutes at 1,000 rpm, then gentle pipetting to dissociate the neurosphere. The resultant 
single cell suspension was passed 1:3 into fresh medium. 
 
2.2.6.8 Neurosphere formation assay 
Neurosphere cultures were centrifuged for five minutes at 1,000 rpm and the pellet 
resuspended in complete neurobasal medium (recipe page 79). A single cell suspension 
was obtained by pipetting and counted using Improved Neubauer counting chamber 
(Weber). The average number of viable cells in the four large quadrants multiplied by 
1x104 yields number of cells times 104/ml. In a 96-well plate (BD), 1000 and 100 cells 
per well were plated in triplicate, by serial dilution. After ten days the number of newly 
formed neurospheres were counted.  
 
2.2.6.9 Murine B-Cell Isolation 
Mice were culled by cervical dislocation and the spleen immediately placed in chilled, 
endotoxin-free PBS. Approximately half the spleen was processed for B-cell isolation. 
A cell suspension was prepared by passing the spleen, in PBS, through a 40 µM cell 
strainer into a 50 ml falcon. The volume was topped up to 50ml with endotoxin-free 
PBS and the cell solution centrifuged for four minutes at 4oC, at 1,500 rpm. The 
supernatant was discarded and pellet resuspended in 1 ml Ammounium Chloride for 60 
seconds to lyse the red blood cells. The Ammonuim Chloride was diluted by addition of 
45 ml PBS and the cells centrifuged for four minutes at 4oC, at 1,500 rpm. A bright red 
cell pellet after this centrifugation step indicated incomplete red blood cell lysis in 
which case the Ammounium Chloride step was repeated. Then, the pellet was 
resuspended in 1 ml primary antibody solution (endotoxin-free PBS/1% (v/v) FCS 
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containing a 1:100 dilution of the following biotin conjugated antibodies: CD4, CD8, 
Ter119, Mac1, NK1.1, TCRγδ and TCRβ [BD Pharmagin]). After 60 minutes at 4oC on 
a rotating wheel, 100 µl streptavidin-bead slurry (Life Technologies) was washed twice 
in endotoxin-free PBS/1% (v/v) FCS, using a magnetic strip, and added to the cells. 60 
minutes later streptavidin-biotin complexes were aggregated using a magnetic strip and 
the supernatant - containing B cells isolated by negative selection - pipetted into a 1.5 
ml eppendorf. The B cells were centrifuged at 1,500 rpm for five minutes at 4oC, and 
were either used immediately or stored at -80oC for future use.  
 
2.2.6.10 Isolation of Intestinal Tissue 
Mice were culled by cervical dislocation and the intestines removed. The cecum was 
separated from the rest of the intestine, and discarded. The colon and small intestine 
were flushed with ice-cold PBS to remove faecal contents. Intestines were cut 
longitudinally into similar size sections, placed on a gut roller and cut open. At this 
point, sections of approximately 4 cm were removed from the small intestine and colon 
for biochemistry. The remainder of the intestine was fixed overnight in 10% NBF (w/v), 
and then transferred to 70% (v/v) ethanol. For biochemistry, it is necessary to separate 
the villi and crypts from the muscle layer. Sections were incubated in 15 ml falcons, on 
ice, in 30 mM EDTA, for two to three hours with regular vortexing. Then, the 
remaining gut tissue was removed and the epithelial cells centrifuged at 1,500 rpm, for 
five minutes, at 4oC. Pelleted crypt and villi cells were washed once in PBS then either 
used immediately or stored at -80oC for future use. 
 
2.2.7 Histology 
All tissue embedding and staining was performed by the LRI Experimental 
Histopathology Service. 
2.2.7.1 Tissue Fixation and Processing 
Isolated tissues were fixed in 10% (w/v) NBF overnight, and transferred into 70% (v/v) 
ethanol the following day. For paraffin embedding fixed tissue was incubated at 40oC in 
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a series of dehydration steps - 30 minutes in 70% (v/v) ethanol, one hour in 85% (v/v) 
ethanol, one hour in 95% (v/v) ethanol then one hour in 100% (v/v) ethanol. Dehydrated 
tissue was then cleared in xylene three times at 40oC for one hour then immersed in 
paraffin wax (Tissue Tek) at 60oC for one hour. Next, samples were embedded in 
paraffin wax in embedding cassettes (Tissue-Tek) and cooled for 30 min at 4°C. Once 
cooled, embedded cassettes were either stored at room temperature for future use or cut 
immediately. A manual microtome (RM2235, Leica) was used to cut 4 µM thick 
sections. Cut sections were mounted on Superfrost Ultra Plus charged slides (Menzel-
Glaeser).  
 
2.2.7.2 Haematoxylin and eosin Staining  
Haematoxylin stains basophilic structures, including nucleic acids and ribosome, blue. 
Conversely eosinophilic structures, including proteins, are stained pink by eosin. 
Therefore in haematoxylin and eosin (H&E) stained sections the nucleus appears blue 
and cytoplasm pink. All the following steps were performed at room temperature. 
Paraffin-embedded tissue sections were dewaxed by three minute incubation in xylene. 
Sections were hydrated by a series of three minute incubation steps - twice in 100% 
ethanol, twice in 70% (v/v) ethanol and finally twice in ddH20. Sections were stained in 
Harris’s haematoxylin for five minutes then washed under running water for five 
minutes. Washed sections were differentiated for five seconds in 1% (v/v) acid alcohol 
(1% HCl/ 70% (v/v) ethanol) then washed under running water for five minutes. 
Afterwards, the sections were incubated in 1% (w/v) eosin Y for five minutes then 
washed again under running water for five minutes. Finally, sections were dehydrated 
by two three-minute washes in 70% (v/v) ethanol then two in 100% (v/v) ethanol. 
Sections were cleared with two three-minute immersions in xylene then mounted using 
DPX mounting medium (DAKO). 
 
2.2.7.3 Immunohistochemistry 
Paraffin embedded sections were dewaxed by immersion in xylene for 3 minutes. Next, 
sections were hydrated by the following series of three minute incubation steps - twice 
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in 100% ethanol, twice in 70% (v/v) ethanol and finally twice in water. For antigen 
retrieval Citrate Buffer (recipe page 75) was pre-heated at full power in a microwave for 
five minutes, then the sections added and heated for a further ten minutes. Sections were 
cooled to room temperature then incubated for ten minutes in 1.6% H202/PBS (v/v) and 
washed in three, three minute PBS washes. Unspecific binding was blocked by 30 
minutes room temperature incubation in Blocking Buffer (recipe page 75). The section 
was then incubated for one hour or overnight in primary antibody (see Table 5). 
Sections were washed for three times in PBS, for five minutes per wash. Washed 
sections were incubated with biotin tagged secondary antibodies, diluted in 1% (w/v) 
BSA/PBS for one hour at room temperature. Next, samples were washed a further three 
times in PBS, for five minutes each wash and subsequently incubated in 
diaminobenzidine/H2O2 (DAB solution; Biogenex) for three to five minutes. The 
staining reaction was terminated by washing the sections in ddH20. If desired, sections 
were counterstained in Mayer’s haemotoxyin for five minutes.  The sections were 
dehydrated by washing twice in 70% (v/v) ethanol then twice in 100% ethanol. Prior to 
mounting, sections were cleared with two three-minute immersions in xylene then 
mounted using DPX mounting medium (Raymond A. Lamb). 
 
Some staining protocols did not involve antibody-based staining. For the detection of 
alkaline phosphatase-positive enterocytes in the intestine, nitro blue tetrazolium (NBT; 
Roche)/5-bromo-4-chloro-3-indolyl phosphate (BCIP; Roche) solution was employed. 
The nuclei were counterstained with nuclear fast red (Vector Laboratories). Alcian blue 
(AB; Sigma)/periodicacid-Schiff (PAS; Sigma) staining specifically marked mucous 
glycoconjugate-containing goblet cells. 
 
2.2.7.4 In-situ Hybridisation 
Paraffin embedded tissue was sectioned at 8 µM then dewaxed by two five minute 
immersions in xylene. Dewaxed sections were hydrated through a series of five minute 
washes; twice in 100% ethanol, once in 95% (v/v) ethanol, once in 70% (v/v) ethanol 
then once in ddH20. After a PBS wash, slides were incubated in 10 µg/ml proteinase K, 
diluted in 100 mM Tris-HCl pH7.5/50 mM EDTA at 37oC for 15 minutes then washed 
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in 0.2% (w/v) glycine/PBS and fixed in 4% (w/v) PFA for ten minutes. Sections were 
then washed three times in PBS and incubated in 4xSSC buffer for two minutes (recipe 
page 80).  
 
Sections were pre-hybridised, without the probes, for one hour in a 57oC humidified 
chamber in hybridization buffer (recipe page 77). Next, 1 ng/ml probe was added and 
denatured at 75oC for 15 minutes, then cooled on ice for five minutes before overnight 
hybridisation at 57oC. The next day the following washes were performed; ten minutes 
in 60°C 5xSSC, 30 minutes in 60°C 50% (v/v) formamide/2xSSC, 30 minutes in 60oC 
2xSSC, twice in 60oC 0.2xSSC for 30 minutes, then five minutes in room temperature 
maleic buffer and finally in blocking buffer at room temperature for thirty minutes (for 
recipes see pages 80, 75).  
 
Sections were then incubated at 37oC for two hours in sheep anti-DIG alkaline 
phosphatase-conjugated antibody (Roche; diluted 1:1000 in blocking buffer). 
Subsequently, sections were washed twice at room temperature in maleic acid buffer for 
fifteen minutes then incubated for five minutes in detection buffer. For development, 
sections were incubated in 1 ml detection buffer (recipe page 75) supplemented with 4.5 
µl nitro blue tetrazolium (NBT; Roche) and 3.5 µl 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP; Roche) in the dark. The reaction was terminated by incubation of the 
sections in detection buffer, and after one wash in ddH20 sections were mounted in 
VectaMountAQ (Vector Laboratories).  
 
The atmin in situ hybridisation (ISH) probe was designed and generated by Dr 
Nnennaya Kanu, and the olfm4 ISH probe was designed and generated by Dr Markus 
Diefenbacher. 
2.2.8 Statistical Analysis 
The Student’s unpaired t-test was used to assess statistical significance. For survival 
analysis, the Log Rank Mann Whitney test was used. A p-valve of <0.5 was considered 
statistically significant. 
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Chapter 3. Investigation of ATMIN function in 
oxidative stress signalling, telomere dysfunction 
and intestinal hyperplasia 
Mutation in DNA damage repair genes can lead to systemic disorders, with different 
tissues exhibiting distinct phenotypes. ATM mutation in the brain causes 
neurodegeneration and ataxia, whereas mutation in the immune system predisposes to 
cancer. One aim of my PhD was to investigate physiological functions of ATMIN using 
a range of in vivo models. 
 
3.1 ATMIN is required for endogenous DNA damage repair 
3.1.1 DNA damage accumulation in ATMIN deficient cells 
The atminf/f mouse, generated by Dr Nnennaya Kanu, permits the tissue-specific 
deletion of ATMIN function (Kanu and Behrens, 2007). LoxP sites flank exon four, 
which encodes the terminal 601 amino acids of 818 amino acid ATMIN, including the 
ATM interaction motif, SQTQ motifs and the most C-terminal zinc finger (Figure 16a). 
 
atminf/f mice were crossed with mice expressing Cre recombinase under the control of 
the 3-phosphoglycerate kinase promoter (PGK-Cre) (Lallemand et al., 1998), achieving 
germline atmin deletion (atmin∆/∆). Recombination of the atmin locus was confirmed by 
genotyping PCR of embryonic tail and brain genomic DNA (Figure 16b). Deletion of 
atmin is embryonically lethal at approximately E16.5. Histological analysis of atmin∆/∆ 
embryos at E15.5 shows clear differences. atmin∆/∆  embryos are significantly smaller 
than their littermates, exhibit midbrain exencephaly and craniofacial, heart, and lung 
defects (Figure 17).  
 
The embryonic lethality of several DNA damage response genes, including BRCA1, is 
rescued by p53 co-deletion (Xu et al., 2001). I set up p53+/-; atmin∆/+ breeding pairs to 
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investigate if a similar rescue occurred with ATMIN. However, in contrast to the 
predicted frequency (n=12) no p53+/-; atmin∆/∆  or p53-/-; atmin∆/∆ offspring were 
obtained in over 60 pups, as assessed by genotyping at weaning age (Figure 16c). Hence, 
p53 deletion does not rescue the atmin∆/∆ embryonic lethality. A recently published 
paper (Jurado et al., 2010) subsequently confirmed this observation. 
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Figure 16: The embryonic lethality of atmin∆/∆ is not rescued by p53 co-deletion 
a) Schematic of the targeted atmin locus. Expression of Cre recombinase results in 
recombination between the loxP sites, i.e. deletion of exon four.  b) Genotyping PCR 
for the atmin locus. DNA was extracted from the head and tail of E12.5 embryos. The 
lower delta (∆) band indicates atmin deletion. c) The expected and observed genotypes, 
at weaning, of 63 offspring from atmin∆/+; p53 +/- breeding pairs. Number of offspring 
per genotype is represented as proportional of total offspring. Student’s t-test was used 
for statistical analysis (***p<0.001). 
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Figure 17: Accumulation of DNA damage in atmin∆/∆ embryos  
a) H&E staining of sagittal E15.5 atmin+/+ and atmin∆/∆ sections, and a higher-
magnification image of the brain. b) Representative images of E15.5 hindbrains 
immunostained for pH2AX. Arrows indicate cells containing pH2AX foci. c) 
Quantification of (b); specifically of cells containing three or more pH2AX foci; n=3 
embryos. d) Representative caspase-3 staining in the hindbrains of E15.5 embryos. 
Arrows indicate caspase-3 positive cells. e) Quantification of (d); n=3 embryos. 
Student’s t-test was used for statistical analysis (*p<0.05). 
 
 
ATMIN interacts with the DNA damage kinase ATM, so we postulated ATMIN 
contributes to the repair of endogenous DNA damage. I quantified pH2AX foci in the 
hindbrain of atmin∆/∆ E15.5 embryos. At this developmental stage the smaller embryo 
size and neural defects of atmin∆/∆ are evident, yet embryos are viable (Figure 17a). The 
hindbrains of E15.5 control atmin+/+ embryos had an average of 7.5% cells containing 
pH2AX foci. Conversely, atmin∆/∆ embryos had over double the wildtype level of DNA 
damage, with 17.0% atmin∆/∆ cells positive for pH2AX (Figure 17b, c). I next examined 
the extent of cell death in the hindbrain of E15.5 embryos by quantifying cells positive 
for the apoptotic marker caspase-3. Interestingly, atmin∆/∆ embryos do not have a higher 
proportion of apoptotic cells compared to atmin+/+embryos (Figure 17d, e). Indeed, both 
genotypes had fewer than 0.5% caspase positive cells. Therefore, the elevated DNA 
damage in atmin∆/∆ embryos does not correlate with increased cell death, and is thus 
unlikely to be the sole cause of atmin∆/∆ embryonic lethality.  
 
To further investigate the impact of ATMIN loss on endogenous DNA damage levels, I 
generated atmin∆/∆ and littermate atmin+/+ control MEFs. Primary MEFs were cultured 
for four passages at either physiological (3%) or atmospheric (20%) oxygen levels then 
stained for the DNA damage markers pS1987-ATM and pH2AX. After four passages at 
20% 02, 62% of atmin∆/∆ cells contained pH2AX foci - in contrast to just 38% of control 
(atmin+/+) cells. There was no significant difference between pH2AX positive cells in 
passage two atmin∆/∆ and atmin∆/∆ MEFs. Thus it is evident atmin∆/∆ MEFs accumulate 
more DNA damage over time than atmin+/+ MEFs (Figure 18b, c).  
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Figure 18: High levels of endogenous DNA damage in atmin∆/∆ MEFs 
atmin+/+ and atmin∆/∆ MEFs were cultured at either 3% or 20% oxygen for four 
passages, then fixed and immunofluorescently co-stained for pH2AX and pS1987-
ATM. (a) Representative images of atmin+/+ and atmin∆/∆ cells at passage four. 
Quantification of atmin+/+ and atmin∆/∆ cells with pH2AX foci at (b) passage two and 
(c) passage four. (d) The percentage change in the proportion of pH2AX positive cells 
at passage four compared to passage two, for cells cultured at 20% oxygen. In all 
quantifications cells are considered positive if they have three or more foci. Student’s t-
test was used for statistical analysis (*p<0.05). 
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In both atmin∆/∆ and atmin+/+ MEFs cultured at 20% 02 DNA damage increased from P2 
to P4 (as measured by pH2AX foci). However, atmin∆/∆ cells exhibit a greater 
proportional increase in DNA damage than their atmin+/+ counterparts; a 62% increase 
in pH2AX positive cells compared to the 37% increase of the wildtype population 
(Figure 18d). Moreover, after four passages atmin∆/∆ MEFs cultured at high (20%) 
oxygen had accumulated more pH2AX positive cells than atmin∆/∆ MEFs cultured at 
low (3%) oxygen. This suggests that atmin loss sensitises cells to oxidative stress 
induced DNA damage. 
 
The two simplest models for the elevated DNA damage in atmin∆/∆ cells are either 
increased DNA damage incidence, or reduced DNA repair. To distinguish between 
these two possibilities I immunofluorescently co-stained P4 atmin+/+and atmin∆/∆ MEFs 
for pS1987-ATM and pH2AX (Figure 19a). Although there is no significant difference 
between the average number of pS1987-ATM foci per cell (Figure 19b), atmin∆/∆ MEFs 
have an average of 4.1 pH2AX foci per cell, significantly higher that the atmin∆/∆ 
average of 1.18 pS1987-ATM foci per cell (Figure 19c). The disparity between pH2AX 
and pS1987-ATM foci number in atmin∆/∆ cells is explained by the observation pS1987-
ATM was not recruited to pH2AX in 35% of cells (Figure 19d). The same phenotype - 
pH2AX foci that do not co-localise with pS1987-ATM  - is also observed in atminf/f 
MEFs after Adeno-Cre mediated atmin deletion (Figure 19e). Given pS1987-ATM foci 
number is unaltered in atmin∆/∆ cells, this suggests compromised ATM recruitment, or 
retention, to sites of DNA damage in ATMIN deficient cells. This implies that loss of 
ATMIN is detrimental to DNA repair, and atmin∆/∆ cells have a reduced rate of DNA 
repair.  
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Figure 19: Reduced pS1987-ATM and pH2AX co-localisation in atmin∆/∆ MEFs 
a) Representative images of atmin+/+ and atmin∆/∆ MEFs cultured at 20% oxygen for 
four passages then immunofluorescently co-stained for pH2AX and p1987-ATM. 
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Yellow arrows indicate co-localisation between pH2AX and p1987-ATM. White arrows 
indicate pH2AX foci that do not co-localise with p1987-ATM. Quantification of the 
number of (b) p1987-ATM and (c) pH2AX foci per cell. d) Quantification of the 
percentage of cells with pH2AX foci that do not co-localise with p1987-ATM. e) 
atminf/f MEFs cultured at 20% oxygen were infected with Adeno-GFP or Adeno-Cre 
(yielding atmin∆/∆ cells) at passage two, then stained for pH2AX and p1987-ATM at 
passage four. A minimum of 100 cells was counted per experiment and three 
independent experiments were performed. Student’s t-test was used for statistical 
analysis (*p<0.05). 
 
3.1.2 atmin∆/∆ MEFs undergo oxidative stress dependent premature 
senescence 
Given ATMIN deletion correlates with increased endogenous DNA damage, I wanted 
to investigate if its loss impaired cellular proliferation. In collaboration with Dr 
Nnennaya Kanu atmin∆/∆ and atmin+/+ proliferation potentials were assessed by growth 
curve analysis. There is no significant difference between atmin∆/∆ and atmin+/+MEFs 
proliferation at early passage (P2), irrespective of oxygen concentration (Figure 20a). 
However, at later passage (P4) atmin∆/∆ MEFs have reduced proliferation compared to 
atmin+/+ MEFs (Figure 20b). Thus as well as increasing endogenous DNA damage, 
ATMIN deletion hinders proliferation. 
 
Persistent DNA damage can activate senescence programmes. Given atmin∆/∆ MEFs 
display sensitivity to oxidative stress and accumulate endogenous DNA damage, one 
would predict a higher senescence incidence in atmin∆/∆ compared to atmin+/+MEFs. To 
test this, in collaboration in Dr Nnennaya Kanu early (P1) and late (P4) passage MEFs 
were stained for senescence associated β-galactosidase activity (Figure 20c, d). At early 
passage (P1) atmin∆/∆ cells do not have a significantly higher percentage of senescent 
cells compared to atmin+/+ MEFs, whether grown at high (20%) or low (3%) oxygen 
culture conditions (Figure 20e). Conversely, 48% of high oxygen late passage atmin∆/∆ 
MEFs are senescent - significantly higher than the 14% senescent atmin+/+cells (Figure 
20d). Thus senescence induction in atmin∆/∆ MEFs can be rescued by either low (3%) 
oxygen conditions or by addition of the free radical scavenger N-acetyl-cysteine (NAC) 
(Dr Nnennaya Kanu, personal communication). Consequently, the premature 
senescence of atmin∆/∆ MEFs is at least partially due to oxidative stress. 
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Figure 20: ATMIN deficient cells undergo premature senescence upon oxidative stress 
0.04x106 a) passage two and b) passage four atmin+/+ and atmin∆/∆ cells were plated and 
viable cell number counted in triplicate each day for four days. Representative photos of 
atmin+/+ and atmin∆/∆ cells cultured at 3% or 20% oxygen, then stained for senescence 
associated β-galactosidase activity at c) passage one and d) passage four. e) 
Quantification of (c). f) Quantification of (d). Student’s t-test was used for statistical 
analysis (*p<0.05, **p<0.01). Experiments were performed in collaboration with 
Nnennaya Kanu. 
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3.2 ATMIN is required for telomere maintenance 
The increased incidence of pH2AX foci without co-localised pS1987-ATM observed in 
atmin∆/∆ MEFs is reminiscent of damaged telomeres. As ATM is recruited to damaged 
telomeres, it was reasonable to assume ATM’s co-factor ATMIN may also have a role 
at the telomere. To study a potential function for ATMIN at the telomere, we first 
wanted to examine the telomeres in ATMIN deficient cells. 
 
3.2.1 ATMIN is required to suppress DNA damage at the telomere 
Telomeres consist of thousands of ‘TTAGGG’ nucleotide repeats at the ends of 
chromosomes. A telomeric FISH probe against this sequence can be used to detect the 
location of telomeres, on either interphase cells or metaphase spreads. If performed in 
parallel with immunofluorescent staining for pH2AX, it is possible to determine if 
pH2AX foci are located at telomeric or intra-chromosomal regions. To elucidate a 
possible function for ATMIN at the telomere, I acutely inactivated ATMIN function by 
Adenoviral mediated infection of early passage atminf/f primary MEFs with Adeno-Cre 
virus, yielding atmin∆/∆ MEFs (see page 163).  
 
In collaboration with Tony Cesare and Jan Karlseder (Salk Institute, U.S.A.) IF-FISH 
for pH2AX and telomeric DNA was performed on interphase spreads from atmin∆/∆ and 
control atminf/f passage 4 primary MEFs (Figure 21a, b). Cells were maintained at low 
(3%) oxygen to minimise oxidative damage. Excitingly, this revealed an increase in the 
percentage chromosome ends co-localising with pH2AX (Figure 21c). Accordingly, the 
number of pH2AX positive telomeres per cell was significantly increased (Figure 21d). 
To exclude the possibility this was because loss of ATMIN increased chromosomal 
copy number, and thus the number of chromosome ends, the number of pH2AX 
positive telomeres was normalised to chromosome number (Figure 21e). Deletion of 
atmin increases the proportion of telomeres that co-localise with pH2AX, suggesting 
ATMIN is required to suppress DNA damage at telomeres.  
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Figure 21: ATMIN deficient cells have increased telomeric DNA damage 
a, b) Passage one atminf/f primary MEFS were infected with either Adeno-GFP or 
AdenoCre-GFP yielding atminf/f and atmin∆/∆ MEFS. Metaphase spreads were prepared 
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from P4 MEFs cultured at 3% 02 and IF-FISH for telomeric repeats (green) and pH2AX 
(red) was performed. Representative images are shown. c) The percentage of 
chromosome ends co-localising with pH2AX. d) Average number of telomeric ends co-
localising with pH2AX per metaphase spread, each dot represents a single metaphase. 
e) Average number of telomeric ends co-localising with pH2AX per metaphase spread, 
normalised to total chromosome number. Each dot represents a single metaphase. Three 
independent experiments were performed and a minimum of 25 metaphases quantified 
per experiment. Student’s t-test was used for statistical analysis (**p<0.01). Metaphase 
spreads were performed and quantitated by Dr Tony Cesare.  
 
 
3.2.2 Telomere dysfunction and ATMIN deficiency compromise neural 
stem cell function 
Each round of chromosome replication leads to telomere shortening. Telomeres can be 
extended by the enzyme telomerase. Unless the shorter chromosome ends are ‘filled-in’ 
multiple rounds of cell replication leads to critically short telomeres, activation of the 
DNA damage response and premature senescence and proliferation arrest. Telomerase 
deficient mice (terc-/-) are characterised by premature ageing, shorter telomeres and 
genomic instability (Rudolph et al., 1999). 
 
Late generation atm-/-; terc-/- compound mutants exhibit a more deleterious phenotype 
than the terc-/- mutant, including an impaired neural stem cell (NSC) compartment 
(Wong et al., 2003). Therefore interplay between ATMIN and telomerase in vivo was 
studied in the neuronal lineage. I generated cohorts of atminf/f; terc-/-; Nestin-Cre mice. 
Nestin-Cre is expressed in neural stem cells, thus atmin is specifically deleted in the 
neural lineage yielding atmin∆N/∆N; terc-/ -animals. Neuronal atmin deletion in atminf/f; 
Nestin-Cre mice was confirmed by atmin ISH in three month old mice (Figure 22a). 
Murine telomeres are up to 20kB long, far longer than human telomeres. Consequently, 
terc-/- mice show a severity of phenotype that correlates with generation number. For 
this study starting generation (G0; atminf/f; terc+/-; Nestin-Cre), first generation (G1; 
atminf/f; terc-/-; Nestin-Cre) and third generation (G3; atminf/f; terc-/-; Nestin-Cre) 
animals were primarily studied.  
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The original description of the terc-/- mouse characterised reduced fertility and reduced 
lifespan in late generation mutants (Rudolph et al., 1999). Accordingly, the litter sizes 
from atmin∆N/∆N; terc-/- correlated inversely with generation number (Figure 22b). The 
survival of G3 atmin∆N/∆N terc-/- and G3 atminf/f terc-/- littermates was monitored to 
establish if atmin deletion further reduced the lifespan of G3 terc-/- mutants.   
Although neuronal atmin deletion also reduces average lifespan (Kanu et al., 2010), 
there was no difference in age of death of the compound mutant (Figure 22b). Thus 
there is no combinational effect of atmin and telomerase deletion on lifespan.  
 
 
Figure 22: Telomerase loss does not alter the lifespan of atmin∆N/∆N mice 
a) Representative images of ISH for atmin in the brains of three month old mice. b) 
Average litter size from atminf/f terc-/- and atminf/f terc-/- Nestin-Cre breeding pairs of the 
indicated generation (n>10). Note G0/G1 offspring arise from breeding atminf/f terc+/- to 
atminf/f terc+/- Nestin-Cre mice. c) Survival analysis of G3 and atminf/f terc-/-(n=14)  and 
atminf/f terc-/- Nestin-Cre (n=8)  animals. Student’s t-test was used for statistical analysis 
(*p<0.05). 
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Figure 23: ATMIN deficiency impairs the self-renewal and growth of telomerase null 
NSCs 
a) Representative images of NSCs ten days after isolation, prior to passaging. b) 
Quantification of neurosphere diameter, as shown in (a). At least 50 neurospheres were 
counted per culture per experiment. c) Number of neurosphere formed one week after 
plating 100 cells. Student’s t-test was used for statistical analysis (*p<0.05). 
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Figure 24: Reduced NSC number in the brains of atmin∆N/∆N terc-/- mice 
a) Representative images of BrdU immunohistochemistry in the SVZ of mice injected 
with BrdU 90 minutes prior to cull. b) Quantification of the number of BrdU positive 
cells per section in the SVZ. At least 15 slides were counted per mouse; two mice per 
genotype. 
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To study the role of atmin at critically short telomeres I isolated adult neural stem cells 
from the subventricular zone (SVZ) of aged atminf/f terc-/- and atmin∆N/∆N terc-/-
littermates. It was immediately apparent from the adult neurosphere cultures that dual 
atmin and telomerase ablation led to reduced proliferation potential. Indeed, very few 
G3 atmin∆N/∆N terc-/- neurospheres formed after the first passage and virtually none after 
the second passage. To characterise this defect, I measured the size of primary 
neurospheres ten days after neural stem cell isolation. As expected, neurospheres from 
G3 atminf/f terc-/- mice were smaller that those from G0 (Figure 23a, b). Additionally, 
G3 atmin∆N/∆N terc-/- neurospheres were significantly smaller their G3 atminf/f terc-/-
counterparts (Figure 23a, b). To assess self-renewal capacity, neurospheres were 
dissociated into single cells, counted and plated by serial dilution. The late generation 
genotypes formed significantly fewer secondary neurospheres that the G0 cultures 
(Figure 23c). Again, the defect was exacerbated in the G3 atmin∆N/∆N terc-/- mutants 
compared to G3 atminf/f terc-/-, with the double mutant cells forming significantly fewer 
secondary spheres. This demonstrates atmin loss reduces the self-renewal capacity and 
proliferative potential of late generation terc-/- mutants. 
 
The majority of cells in the adult brain are post-mitotic. As they are not proliferative, 
they do not experience replication-dependent telomere shortening. In contrast, adult 
neural stem cells undergo cell division and thus can be specifically labelled by a short 
BrdU pulse. Quantification of the BrdU+ stem cells in the SVZ of adult mice revealed a 
reduction in the stem cell pool of G3 atmin∆N/∆N terc-/- compared to G3 atminf/f terc-/- 
littermate controls (Figure 24a, b). Together, this suggests ATMIN and telomerase co-
operate in telomere maintenance, and loss of ATMIN in the context of shortened 
telomeres is deleterious for the cell 
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3.3 ATMIN is not part of the oncogene induced senescence 
barrier in intestinal serrated hyperplasia 
Intestinal epithelial cell specific expression of the oncogene KRasG12D induces colonic 
serrated hyperplasia, characterised by senescence induction (Bennecke et al., 2010). 
However, there is an extremely low frequency of progression to carcinoma. Conversely, 
if KRasG12D is expressed in animals with compromised senescence pathways, such as 
the INK4a/Arf-/-model, 50% of animals develop adenomas of the colon within 12 weeks 
(Bennecke et al., 2010). As ATM has been shown to be part of the OIS barrier 
(Bartkova et al., 2005; Bartkova et al., 2006), it was interesting to investigate if loss of 
ATMIN or ATM impacted on KRasG12D induced intestinal tumourigenesis. 
 
3.3.1 Intestinal KRasG12D expression promotes hyperplasia, DNA damage 
and senescence 
The initial strategy to investigate ATMIN’s role in OIS was to generate atminf/f; LSL-
KRasG12D; Villin-Cre animals. Villin-Cre mice express Cre recombinase from the villin 
promoter, active in intestinal tissues from E12.5 onwards (Madison et al., 2002). The 
LSL-KRasG12D locus has a transcriptional stop site flanked by two loxP sites (LSL), so 
KRasG12D is only transcribed after Cre recombinase mediated excision of the LSL 
cassette. An advantage of the system is after recombination KRasG12D is under the 
control of its endogenous promoter. The use of atminf/f ensured concomitant atmin 
deletion and KRasG12D expression. ATMIN deletion was confirmed by genotyping PCR 
from villi and crypts isolated from the small bowel and colon (Figure 25a). KRasG12D 
expression was confirmed by analysing protein lysates isolated from murine colon for 
the phosphorylation of ERK (pT202/pY204-ERK), a downstream substrate of KRas 
(Figure 25b). Phosphorylation of ERK along the length of the villi and crypt was also 
assessed by immunohistochemical staining for pT202/pY204-ERK (Figure 25c). Thus 
Villin-Cre is an effective system for achieving simultaneous intestinal atmin deletion 
and KRasG12D expression.  
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Mice deleted for atmin in the intestine (atmin∆G/∆G) have normal intestinal architecture 
(Figure 26b), and animals aged to one year have no overt phenotype. Mice were culled 
at seven weeks for initial analysis of KRasG12D expression. H&E staining confirmed 
intestinal KRasG12D expression induced hyperplasia, and the colons of mice expressing 
KRasG12D contained serrated hyperplastic villi of a characteristic ‘Christmas-tree 
structure’ (Figure 26c, d). 
 
To assess the effect of KRasG12D on proliferation in the colon, mice were injected with 
BrdU 90 minutes prior to cull (Figure 27a). The percentage of BrdU positive cells per 
crypt was counted, and there was no significant difference between the proliferation of 
atminf/f, atmin∆G/∆G, KRasG12D and atmin∆G/∆G; KRasG12D colonic crypts. Wildtype 
proliferation rates in the colons of KRasG12D mice recapitulates observations in the 
original paper (Bennecke et al., 2010). The BrdU analysis demonstrated ATMIN 
deletion does not affect proliferation of KRasG12D expressing cells in the colon. 
 
One prediction of the OIS model is aberrant oncogene expression increases cellular 
DNA damage (Bartkova et al., 2005). I therefore assessed by the levels of the DNA 
damage marker pH2AX in the intestines of seven week old wildtype, atmin∆G/∆G, 
KRasG12D and atmin∆G/∆G KRasG12D mice (Figure 27c). As expected, KRasG12D 
expression correlates with increased pH2AX (Figure 27d). However, ATMIN deletion 
did not further increase the extent of DNA damage in KRasG12D expressing cells. 
 
The aim of this tumour model was to establish if ATMIN is required for senescence 
induction in oncogene expressing cells, so it was important to assess senescence in vivo. 
The senescence marker p21 is frequently upregulated in senescent cells. Indeed, by 
western blot analysis of intestinal tissue it is evident p21 protein levels increase upon 
KRasG12D expression (Figure 27e, lane 3). However, KRasG12D mediated upregulation of 
p21 was abrogated in atmin deficient cells (Figure 27e, lane 4). Interestingly, p21 
protein levels are decreased in atmin∆G/∆G cells, compared to atminf/f, littermate controls. 
High p21 protein levels are associated with, but not sufficient to conclude, senescence. 
Therefore I also looked at the transcriptional levels of the senescence marker Dec1 
(Collado et al., 2005), (Qian et al., 2008). As seen previously (Bennecke et al., 2010), 
intestinal KRasG12D expression results in an approximately two fold increase in Dec1 
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expression (Figure 27f). Dec1 transcriptional upregulation upon KRasG12D expression 
also occurs in the absence of ATMIN (Figure 27f). Thus although p21 is not 
upregulated in atmin∆G/∆G; KRasG12D cells, one cannot conclude senescence induction is 
abolished in atmin deficient cells. 
 
The KRasG12D; Villin-Cre model was also used to analyse the function of ATM in 
oncogene induced senescence. Cohorts of wildtype, atm-/-, KRasG12D; Villin-Cre and 
atm-/-; KRasG12D; Villin-Cre mice were analysed at seven weeks for proliferation, DNA 
damage and senescence markers. H&E staining of the colon demonstrated serrated 
hyperplasia in both KRasG12D and atm-/-; KRasG12D animals (Figure 28a). In agreement 
with observations in the atmin cohorts, KRasG12D expression did not significantly 
increase proliferation in the colon Figure 28b, c). Recapitulating observations in the 
atmin cohorts, KRasG12D expression increased pH2AX foci in both atm+/+ and atm-/- 
mice (data not shown). Moreover, there was no significant difference in expression of 
the senescence marker dec1 when KRasG12D and atm-/-; KRasG12D cohorts were 
compared (Figure 28d). Thus, it appears ATM is not required for the senescence 
programme activated by colonic KRasG12D expression. 
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Figure 25: Villin-Cre mediates intestinal RasG12D expression 
a) Genotyping PCR of DNA isolated from the intestines of the colon and small 
intestines of six week old atminf/f and atminf/f; VillinCre mice. b) Intestinal tissue from 
six week old mice of the indicated genotypes was isolated and cell lysates separated by 
10% SDS-PAGE. Membranes were probed with antibodies against actin and 
pT202/pY204ERK. c) Representative pT202/pY204-ERK immunohistochemistry from 
intestinal sections from six week old mice.  
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Figure 26: Intestinal KRasG2D expression induced colonic serrated hyperplasia  
Representative H&E stained sections from the colons of seven week old mice of the 
indicated genotypes. 
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Figure 27: ATMIN is not part of the OIS barrier induced by intestinal KRasG12D expression 
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a) Representative images of the colons of mice injected with BrdU 90 minutes prior to 
cull. b) Quantification of the percentage of BrdU positive cells per villi, as shown in (a). 
c) Representative images of pH2AX immunohistochemistry. d) Quantification of the 
percentage of cells per villi with three or more pH2AX foci. e) Cellular lysates from the 
colons of seven week old mice, separated by 12% SDS-PAGE and immunostained for 
p21 and actin. f) mRNA was isolated from the colons of seven week old mice, and 
qPCR analysis performed for dec1 mRNA. mRNA levels were normalised to GAPDH. 
In all experiments, a minimum of three mice per genotype were analysed. Students t-
test was used for statistical analysis, (*p<0.05, **p<0.01).  
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Figure 28: Senescence occurs in KRasG12D intestinal cells regardless of atm status 
a) Representative images of H&E stained villi, in the colons of seven week old mice 
with the indicated genotype. b) Representative Ki67 immunohistochemistry in the 
colons of seven week old mice. c) Quantification of the percentage of Ki67 positive 
cells per villus, as depicted in (b). d) mRNA was extracted from the colons of seven 
week old mice. dec1 expression is shown relative to gapdh mRNA levels. A minimum 
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of three mice were genotype were used in all analyses. Student’s t-test was used for 
statistical analysis (*p<0.05, **p<0.01). 
3.3.2 Non-intestinal KRasG12D expression is lethal 
To address whether ATMIN loss co-operates with KRasG12D expression to promote the 
progression to adenoma cohorts of atminf/f;Villin-Cre, atminf/f; LSL-KRasG12D; Villin-
Cre and LSL-KRasG12D; Villin-Cre mice, along with Cre negative controls, were 
generated for a tumour study. The initial aim was to allow the animals to age and 
monitor for symptoms of intestinal cancer. 
 
Unexpectedly, all animals with LSL-KRasG12D; Villin-Cre positive genotypes, regardless 
of ATMIN status, became sick at approximately eight weeks of age. All had to be 
culled sick by twelve weeks (Figure 29a). There was no significant difference between 
the median survival of the different genotypes (Figure 29b). Similar survival was 
observed with atm-/- KRasG12D cohorts (data not shown). However, histological analysis 
of the intestine revealed no progression beyond the serrated hyperplasia stage. Thus the 
morbidity was not due to intestinal KRasG12D expression. Indeed, further analysis of the 
cohorts revealed lesions and hyperplasia in multiple other organs, especially in the 
pancreas (Figure 29c). Indeed, GFP staining of Villin-Cre; ROSA26-LSL-YFP animals 
revealed significant activation of Villin-Cre in non-intestinal tissues such as pancreas 
(Dr Rocio Sancho, personal communication).  
 
The lethality of the LSL-KRasG12D; Villin-Cre mice and non-intestinal Cre expression 
was surprising as it is in contrast to previous reports (Bennecke et al., 2010). The 
difference in phenotype is most likely due to the two different Villin-Cre lines used. The 
previously published intestinal LSL-KRasG12D study used a differently designed Villin-
Cre construct (Madison et al., 2002); to the Villin-Cre line used for my study (el Marjou 
et al., 2004). It is highly likely the Villin-Cre line used in my study has significantly 
more non-intestinal, ‘leaky’, expression than the Villin-Cre line by Bennecke and 
colleagues.  
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3.3.3 atmin loss does not lead to intestinal adenoma in KRasG12D mice 
The average survival of any LSL-KRasG12D; Villin-Cre mice, irrespective of ATM or 
ATMIN status, was approximately 7-8 weeks. This premature lethality excluded the 
possibility of a long-term tumour study. To circumvent the lethality in the long-term 
tumour study I used the Villin-CreERT line, in which tamoxifen activatable Cre is 
driven by the villin promoter. Cohorts of mice (atminf/f, atminf/f; Villin-CreERT, Villin-
CreERT; LSL-KRasG12D and atminf/f; Villin-CreERT; LSL-KRasG12D) were injected with 
100µg tamoxifen per gram bodyweight for three consecutive days. Comparable cohorts 
were set up to investigate ATM’s role in tumour protection; atm-/-and atm-/-; Villin-
CreERT; LSL-KRasG12D. Recombination efficiency was assessed by histological 
staining of GFP in LSL-Rosa-YFP Villin-CreERT mice injected in concert with the 
experimental cohorts (Figure 30a).  
 
Cohorts were monitored for up to a year for any tumour symptoms. As expected, atm-/-
mice developed T-cell lymphoma at approximately three months (Figure 30b). Indeed, 
all of the atm-/-; Villin-CreERT; LSL-KRasG12D mice died of T-cell lymphoma at 
comparable ages to the atm-/- controls. Histological analysis of the intestines of these 
mice revealed although serrated hyperplasia was present in the colon, this had not 
progressed to adenoma (data not shown). This precluded longer-term analysis of a pro-
senescence role for ATM in KRasG12D intestines. 
 
On the contrary, neither atmin∆G/∆G nor atmin∆G/∆G; KRasG12D animals developed any 
sign of tumours when aged for one year. In agreement with published observations, no 
tumours were observed in the KRasG12D cohort (Bennecke et al., 2010). There was no 
significant different in their survival compared to tamoxifen-injected, Cre-negative 
littermate controls. This suggests atmin is not part of the oncogene induced senescence 
barrier induced by intestinal KRasG12D expression.  
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3.4 Concluding Remarks 
It is clear ATMIN has an important role in endogenous DNA damage repair; atmin 
deficient cells exhibit increased DNA damage levels (Figure 17, Figure 18), reduced 
pS1987-ATM recruitment to sites of damage (Figure 19), premature senescence and 
sensitivity to oxidative stress (Figure 20). Moreover, ATMIN is specifically required for 
telomere maintenance, atmin∆/∆ cells display increased damage at the telomere (Figure 
21) and atmin loss co-operates with telomerase deficiency to exacerbate neural stem cell 
dysfunction (Figure 23). However, the data presented in this chapter does not support a 
role for ATMIN in the OIS response (Figure 27, Figure 30). 
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Figure 29: Non-intestinal KRasG12D expression is lethal 
a) Survival curve of the indicated genotypes, at least five mice per genotype are shown. 
b) Median survival of the indicated genotypes. c) Representative H&E stained pancreas 
sections of seven week old mice. Two mice per genotype are shown. 
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Figure 30: ATMIN and ATM do not contribute to adenoma protection in KRasG12D mice 
a) Representative images of GFP immunostains performed on the intestines of LSL-
Rosa-YFP; Villin-CreERT mice. Animals were injected with three 100 µg/gram 
bodyweight tamoxifen injections over three consecutive days and culled five days after 
the final injection. b) Kaplan-Meier curve for mice of the indicated genotypes. All mice 
were injected with tamoxifen at six weeks old.  
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Chapter 4. ATMIN and p53 Interplay in B cell 
Lymphoma 
Mutation in DNA damage response proteins, including ATM and NBS1, specifically 
predispose patients to lymphomas compared to other cancer types. Yet, all cells contain 
the same DNA damage machinery and presumably experience similar levels of 
spontaneous DNA damage. This discrepancy is reconciled by consideration of 
programmed DNA damage. The programmed DNA breaks induced of the immune 
system presumably elevate the total DNA damage experienced by these cells and thus 
the likelihood of genomic instability and cancer. Great advances in the DNA damage 
response field have been made by studying the cellular response to exogenous DNA 
damage, but studying the function of DNA damage response proteins in cells 
experiencing programmed DNA damage is an invaluable model for a plethora of 
cancers and DNA damage syndromes. One aim of my PhD was to examine the 
consequences of ATMIN and p53 deletion in B cells. 
 
4.1 CD19-Cre enables B cell specific atmin and p53 deletion  
DNA double strand breaks are induced in B cells during V(D)J recombination and CSR. 
ATMIN is important for DNA repair in B cells; ATMIN deletion in B cells results in 
increased genomic instability and predisposition to B cell lymphoma (Loizou et al., 
2011). Conversely, NBS1657∆5 mice only develop B cell lymphoma in a p53-/- 
background (Reina-San-Martin et al., 2005). We were interested to see the effect of co-
deletion of p53 and ATMIN, so I generated cohorts of atminf/f; p53f/f; CD19-Cre, 
atminf/f; CD19-Cre and p53f/f; CD19-Cre mice. 
 
CD19-Cre mice carry a copy of Cre recombinase inserted into one copy of the CD19 
locus, so as expression of Cre recombinase is under the control of the endogenous 
CD19 promoter (Rickert et al., 1997). CD19 is specifically expressed in the B cell 
lineage from the pro-B stage onwards, and thus genes flanked by loxP sites are deleted 
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at the pro-B stage (Figure 31a). To confirm atmin deletion, I extracted DNA from the B 
cells of atminf/f; p53f/f; CD19-Cre mice and performed ATMIN genotyping PCR. The 
presence of the delta, and absence of the floxed, PCR band confirmed atmin deletion 
(Figure 31b). p53 deletion was examined by western blot. As expected, B cells from 
atminf/f; p53f/f; CD19-Cre (atmin∆B/∆B; p53∆B/∆B) do not express p53 protein (Figure 31c). 
Therefore CD19-Cre is a suitable system in which to study the consequence B cell 
specific atmin and p53 deletion.  
 
4.2 B cell development in young atmin∆B/∆B; p53∆B/∆B and 
p53∆B/∆B Mice 
The consequence of ATMIN and p53 co-deletion on B cell development had not 
previously been studied. It is plausible atmin∆B/∆B; p53∆B/∆B B cell maturation is 
impaired, generating fewer B cells and thus a reduced pool of cells with the propensity 
to be transformed. Therefore I analysed B cell development in six week old atmin∆B/∆B; 
p53∆B/∆B mice. Cells from the bone marrow of atmin∆B/∆B; p53∆B/∆B and atminf/f; p53f/f 
littermate controls were analysed in parallel by FACS for B220, CD43 and IgM marker 
expression. Three mice of each genotype were analysed. 
 
To gain a comprehensive picture of B cell development, I determined the percentage of 
B cells at the pro-B, pre-B, immature-B and mature re-circulating B cell stages (Figure 
31). There was no difference in the pro-B (CD43+ B220+) population of atmin∆B/∆B; 
p53∆B/∆B mice (Figure 32a,b). The pre-B cell population (B220+ CD43- IgM-) was also 
unaltered in the compound mutants (p=0.294) (Figure 32c,d). Although the percentage 
of immature B cells (B220+ CD43- IgM+) was reduced from 25.5% to 21.6% in 
atmin∆B/∆B; p53∆B/∆B bone marrow (Figure 32c,e), this reduction did not reach statistical 
significance (p=0.172). There was also no alteration in the percentage of re-circulating 
mature B cells (B220hi CD43- IgM+) the bone marrow of atmin∆B/∆B; p53∆B/∆B mice 
(Figure 32c,f). Taken together, this indicates that there is no significant impairment in 
the B cell development in bone marrow of atmin∆B/∆B; p53∆B/∆B mice. 
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Mature peripheral B cells reside in the germinal centres of the spleen. To address 
whether B cell specific loss of ATMIN and p53 affects the frequency of peripheral 
splenic mature B cells (B220+ IgM+), I performed FACS analysis of the spleens of six 
week old atmin∆B/∆B; p53∆B/∆B and atminf/f; p53f/f littermate controls in parallel. There 
was no significant difference between the percentage of mature splenic B cells (B220+ 
IgM+) (Figure 33a, b). Thus B cell specific ATMIN and p53 co-deletion does not impair 
B cell maturation. 
 
CD19-Cre mediated p53 deletion is not a previously published model. It was therefore 
necessary to validate B cell development in p53f/f; CD19-Cre mice. Bone marrow 
FACS analysis was performed on six week old p53∆B/∆B and p53f/f littermate controls in 
parallel. Comparison of the pro-B (CD43+ B220+) pool showed p53 loss does not alter 
the percentage of pre-B cells in the bone marrow (Figure 34a, b). Similarly, there was 
no difference in the percentage of pre-B cells in p53∆B/∆B bone marrow (Figure 34c, d). 
Loss of p53 does not alter immature B cell number (B220+ CD43- IgM+) (Figure 34c, e). 
Finally, analysis of the re-circulating mature B cell population (B220hi CD43- IgM+) 
confirmed no difference between p53∆B/∆B and p53f/f controls (Figure 34a, f). Taken 
together, these data suggests p53 deletion does not alter B cell development in the bone 
marrow.    
 
To gain a complete picture of B cell development in p53∆B/∆B animals, I also performed 
FACS analysis on the spleens of six week old p53∆B/∆B and p53f/f mice. Comparison of 
mature B cell populations (B220+ IgM+) demonstrated p53 deletion does not effect the 
percentage of mature B cells in the spleen (Figure 35,b). Thus, CD19-Cre mediated p53 
deletion does not impair B cell maturation.  
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Figure 31: B cell specific deletion of atmin and p53 
a) Cartoon schematic of B cell development from the haematopoietic stem cell in the 
bone marrow to the mature B cell in the spleen. The expression pattern of B cell 
markers, including CD19, is indicated. b) ATMIN genotyping PCR of B cells isolated 
by negative selection from six week old mice of the indicated genotypes. ‘F’ refers to 
the floxed allele, ‘∆’ to the deleted allele. c) B cells were isolated from six week old 
mice by negative selection, and protein extracts immunoblotted for p53.  
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Figure 32:  No striking B cell maturation defect in atmin∆B/∆B; p53∆B/∆B mice  
a) FACS analysis for B220 and CD43 on bone marrow cells from three mice per 
genotype. b) Quantification of (B220+ CD43+) pro-B cells. c) Analysis of the CD43- 
bone marrow population of three mice. d) Quantification of pre-B cells(B220+ CD43- 
IgM-), denoted ‘I’ in (c). e) Quantification of immature B cells (B220+ CD43- IgM+), 
denoted ‘II’ in (c). f) Quantification of (B220hi CD43- IgM+) re-circulating mature B 
cells, denoted ‘III’ in (c). Student’s t-test was used for statistical analysis, n=3 mice per 
genotype. 
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Figure 33: Normal mature B cell number in the spleens of young atmin∆B/∆B; p53∆B/∆B mice 
a) FACS analysis performed upon the spleens of six week old mice. Three mice per 
genotype were analysed. b) Quantification of (B220+ IgM+) mature B cells, as shown in 
(a). Student’s t-test was used for statistical analysis, n=3 mice per genotype. 
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Figure 34: p53 deletion does not impair B cell development 
a) Bone marrow FACS analysis for B220 and CD43. Three mice per genotype are 
shown. b) Quantification of (B220+ CD43+) pro-B cells. c) Analysis of the CD43- bone 
marrow population of three mice. d) Quantification of pre-B cells (B220+ CD43- IgM-), 
denoted ‘I’ in (c). e) Quantification of immature B cells (B220+ CD43- IgM+), denoted 
‘II’ in (c). f) Quantification of (B220hi CD43- IgM+) re-circulating mature B cells, 
denoted ‘III’ in (c). Student’s t-test was used for statistical analysis, n=3 mice per 
genotype. 
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Figure 35: Normal mature B cell number in the spleens of young p53∆B/∆B mice 
a) FACS analysis of six week old mice spleens. Three mice of each genotype were 
analysed. b) Quantification of (B220+ IgM+) mature B cells, as shown in (a). Student’s 
t-test was used for statistical analysis, n=3 mice per genotype. 
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4.3 p53 is required to suppress B cell lymphoma development 
p53 deletion resulted in onset of B cell lymphoma in approximately 60% of the p53∆B/∆B 
cohort, with an average onset of approximately seven months of age (Figure 36a). The 
B cell lymphomas in p53∆B/∆B animals are characterised by a dramatic increase in spleen 
size, as compared to p53f/f littermates (Figure 36b). H&E and B220 staining of the 
spleens from p53∆B/∆B mice with B cell lymphoma illustrated the disorganisation of the 
spleen, with the germinal centres almost indistinguishable from the red pulp regions 
(Figure 36c, d). 
 
The development of B cell lymphoma in p53∆B/∆B animals with enlarged, disorganised 
spleens was confirmed by the infiltration of B cells into multiple organs. The B cell 
lymphomas were highly metastatic, and typically spread to several organs including the 
lung, kidney and pancreas (Figure 37). In some cases solid, abdominal B cell masses 
formed. It is clear p53 functions to suppress the onset of B cell lymphoma. 
 
4.4 ATMIN deletion rescues B cell lymphoma onset in p53∆B 
mice 
To assess any combinatorial effect of atmin and p53 deletion of B cell lymphoma onset 
I monitored ageing cohorts of atminf/f; p53f/f; CD19-Cre and Cre-negative littermates for 
B cell lymphoma. Unexpectedly, atmin∆B/∆B; p53∆B/∆B had the same survival as Cre-
negative controls (Figure 38a). Only one atmin∆B/∆B; p53∆B/∆B animal developed B cell 
lymphoma, at 15 months of age. The survival curve shown only goes as far as 400 days, 
as at later timepoints many mice were culled for non-lymphoma illness, such as fighting 
wounds or skin disorders. The lymphoma-free status of any atmin∆B/∆B; p53∆B/∆B mice 
culled for other reasons was confirmed by a histopathologist. The spleens of 400 day 
old atmin∆B/∆B; p53∆B/∆B do not exhibit the loss of architecture characteristic of B cell 
lymphoma, and appear macroscopically by H&E very similar to atminf/f; p53f/f littermate 
controls (Figure 38b). There was no significant difference between the spleen size of 
one year old atmin∆B/∆B; p53∆B/∆B and atminf/f; p53f/f littermate controls (Figure 38c). 
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B220 staining indicates the germinal centres of 400 day old atmin∆B/∆B; p53∆B/∆B mice 
maintained a distinct architecture (Figure 38d, e). Together, these observations suggest 
ablation of ATMIN function rescues the B cell lymphoma observed in p53∆B/∆B mice.  
 
Although it is evident co-deletion of atmin and p53 rescues the B cell lymphoma 
observed in the single atmin∆B/∆B and p53∆B/∆B mutants, the compound mutants do not 
have a wildtype phenotype. Quantification of B220 positive cells in 400 day old 
atmin∆B/∆B; p53∆B/∆B spleens revealed reduced B cell numbers in the germinal centres 
(Figure 39a, b). This suggests that although B cell development is largely normal in 
young mice, old atmin∆B/∆B and p53∆B/∆B mutants have impaired B cell viability.  
 
4.5 Concluding Remarks 
The lymphoma-free survival of atmin∆B/∆B and p53∆B/∆B mutants (Figure 38) is highly 
surprising given solo deletion of either ATMIN (Loizou et al., 2011) or p53 (Figure 36) 
in B-cells predisposes to lymphoma. A subsequent study by a colleague, Dr Sophia 
Blake, demonstrated p53f/f Nestin-Cre, but not atminf/f ; p53f/f Nestin-Cre mice, develop 
gliomas. This suggests the cancer protection afforded by atmin deletion from a p53-null 
cell is not restricted to B cells. Observations by Dr Sophia Blake in MEFs suggest loss 
of ATMIN reduces the proliferation of p53∆/∆ cells. As further work by the Behrens 
group increases our understanding of the interplay between ATMIN and p53, it will be 
exciting to explore the therapeutic applications of inactivating ATMIN in a mutant p53 
cancer cell.  
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Figure 36: p53 is required to suppress B cell lymphoma 
a) Kaplan-Meier curve of p53f/f (n=14) and p53∆B/∆B (n=15) survival. b) Photographs of 
the spleens from 38 week old p53f/f and p53∆B/∆B mice. Scale bar 1 cm. Representative c) 
H&E and d) B220 staining of two p53∆B/∆B spleens and littermate control p53f/f  spleens. 
The Log Rank Mann Whitney test was used for statistical analysis (*p<0.05). 
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Figure 37: Multiple metastasis of p53∆B/∆B B cell lymphoma 
Histological analysis of a metastatic B cell lymphoma in a forty week old p53∆B/∆B 
animal. Representative H&E, B220 and Ki67 staining in the a) pancreas, b) lung and c) 
kidney are shown.  
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Figure 38: atmin deletion protects against B cell lymphoma in p53∆B/∆B mice 
a) Kaplan-Meier curve of atmin f/f; p53f/f (n=12) and atmin∆B/∆B; p53∆B/∆B (n=12) 
survival. b) Representative H&E sections from the spleens of 400 day old mice. c) 
Average spleen length of one year old mice, n=4 mice per genotype. Representative 
B220 immunostains on 400 day old spleens from (d) atmin f/f; p53f/f and (e) atmin∆B/∆B; 
p53∆B/∆B mice. Three mice per genotype are shown. Student’s t-test was used for 
statistical analysis (n.s. not-significant). 
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Figure 39: Reduced B cell cellularity in the spleens of old atmin∆B/∆B; p53∆B/∆B mice 
a) Representative B220 immunostains of 400 day old spleens. Two mice of each 
genotype are shown. b) Relative B cell cellularity in 400 day old mice. The number of B 
cells in 0.5mm2 sections of germinal centres was counted and normalised to wildtype. 
Student’s t-test was used for statistical analysis (*p<0.05), n=3 mice per genotype. 
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Chapter 5. Competition between ATMIN and NBS1 
regulates ATM signalling 
 
ATM’s two known co-factors, ATMIN and NBS1, both interact with ATM through a 
conserved C-terminal ATM interaction motif. ATM signalling proceeds via interaction 
with NBS1 after DSB induction and ATMIN after changes to chromatin structure (Kanu 
and Behrens, 2008). Although ATM deletion results in viable mice, loss of either 
ATMIN or NBS1 is embryonically lethal. The aim of my project was to investigate the 
mechanistic basis of ATM co-factor choice and the discrepancy between NBS1 and 
ATM null phenotypes. 
 
5.1 ATMIN deficiency rescues the proliferation arrest and 
senescence induction of NBS1 deleted MEFs 
To study ATMIN and NBS1 function I generated atminf/f, nbs1f/f and compound mutant 
nbs1f/f; atminf/f primary MEFs at E12.5. The early embryonic lethality of nbs1∆/∆ 
embryos at approximately E8.5 precluded the use of the straight knockout. Instead, I 
acutely inactivated nbs1 and atmin gene function by adenoviral mediated expression of 
Cre recombinase (Figure 40a). Floxed MEFs were infected with either Adeno-Cre or 
Adeno-GFP control virus for 48 hours, yielding the single mutant atmin∆/∆, nbs1∆/∆ and 
compound mutant nbs1∆/∆; atmin∆/∆ MEFs. Cells cultures were left for a further 48 hours 
to recover. DNA was then extracted from the infected cells and recombination 
efficiency assessed by genotyping PCR (Figure 40b). The presence of the ‘∆’ band, and 
absence of the ‘floxed’ band exclusively in the Adeno-Cre infected samples confirms 
adenoviral infection with Cre recombinase achieves efficient recombination of the 
atmin and nbs1 floxed alleles.  
 
Before embarking on a thorough analysis of the phenotype of recombined cells, I 
wanted to ensure that infection with Adeno-Cre did not significantly alter the cell cycle 
profile or genome copy number. FACS analysis for DNA content was performed on 
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Adeno-Cre and Adeno-GFP infected cells at the end of the 48 hour recovery period. 
Representative FACS plots are shown (Figure 40c, d). Expression of Cre recombinase 
does not alter cell cycle distribution (Figure 40e). Moreover, genome copy number, as 
measured by ‘4N’ content, is unaffected (Figure 40f). Thus, adenoviral mediated 
recombination of floxed MEFs is a good model system to analyse the effects of atmin 
and nbs1 deletion.   
 
Deletion of nbs1 from MEFs is reported to result in proliferation arrest (Yang et al., 
2006). As expected, deletion of nbs1 resulted in a rapid cessation of proliferation. Given 
low oxygen conditions are known to prolong the proliferative lifespan of primary MEFs 
(Parrinello et al., 2003), it is noteworthy that arrest of nbs1∆/∆ occurs even at low (3%) 
oxygen culture conditions. Surprisingly, after passaging wildtype, atmin∆/∆, and nbs1∆/∆; 
atmin∆/∆ cell cultures reached confluent densities, whereas proliferation arrest at 
subconfluent densities occurred in the nbs1∆/∆ mutants (Figure 41a). Growth curves 
expanded this observation; nbs1∆/∆; atmin∆/∆ compound mutant cells achieved a higher 
cumulative cell number than the nbs1∆/∆ mutants (Figure 41b). The deletion of atmin 
alone from early passage MEFs at 3% oxygen did not alter cumulative cell number 
(Figure 41b). This is in agreement with independent growth curves performed on 
atmin∆/∆ MEFs (Figure 20a). This growth curve analysis suggests atmin∆/∆, nbs1∆/∆; 
atmin∆/∆ and nbs1∆/∆ mutants have different proliferation potentials. 
 
To further characterise the defects of nbs1∆/∆ cells, proliferation was measured by 
quantifying BrdU incorporation. NBS1-deficiency reduced by half the number of BrdU 
positive cells, as measured by FACS analysis (Figure 41c). This proliferation defect was 
partially rescued in the nbs1∆/∆; atmin∆/∆ double mutant. A proliferation defect was not 
observed in atmin∆/∆ MEFs. The percentage of BrdU positive cells was also measured 
by immunofluorescent staining for BrdU (Figure 41d, e). In contrast to the 5.9% BrdU 
positive cells observed in the wildtype population, 3.3% nbs1∆/∆ cells were BrdU 
positive. Recapitulating the FACS data, the proliferation defect of nbs1∆/∆ cells was 
somewhat rescued in the double mutant, where 4.6% of cells were BrdU positive. Taken 
together, these BrdU analysis and growth curve demonstrate the cellular proliferation 
defect observed upon nbs1 deletion is partially rescued by concomitant loss of atmin. 
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The flattened, enlarged morphology and sub-confluent proliferation arrest observed in 
nbs1∆/∆ MEFs strongly suggests senescence. To confirm this, senescence associated β-
galactosidase staining was performed ten days after gene deletion (Figure 42a). 
Quantification of the percentage of positively staining (blue) cells confirmed increased 
senescence induction in nbs1∆/∆ MEFs; with 29.2% of cells senescent compared to 5.4% 
of wildtype cells (Figure 42b). Senescence induction was significantly reduced, to 
12.3%, in nbs1∆/∆; atmin∆/∆ mutants. It is noteworthy that at later passages, at 3% 
oxygen conditions, nbs1∆/∆; atmin∆/∆ MEFs still enter premature senescence (data not 
shown) - a similar phenotype to atm-/- primary MEFs (Xu and Baltimore, 1996).  
 
The reduced cumulative cell number observed in nbs1∆/∆; atmin∆/∆ mutant MEFs 
(Figure 41b) could be contributed to by increased apoptosis. I quantified the percentage 
of trypan blue positive cells in wildtype, nbs1∆/∆, atmin∆/∆ and nbs1∆/∆; atmin∆/∆ MEFs at 
days seven to ten after gene deletion. There was no significant reduction in the 
percentage of viable cells in either nbs1∆/∆ or nbs1∆/∆; atmin∆/∆ mutants (Figure 42c). 
Accordingly, the main phenotype of nbs1 deletion in primary MEFs is proliferation 
arrest and premature senescence, not increased cell death.  
 
Taking together these results, we can surmise that concomitant atmin and nbs1 deletion 
significantly ameliorates the proliferation defects and senescence induction observed in 
the nbs1∆/∆ primary MEFs. 
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Figure 40: An inducible system for atmin and nbs1 deletion in primary MEFS  
a) Timeline of Adenovirus infection of primary MEFs at passage two, and the 
timepoints of subsequent analyses performed. b) nbs1f/f; atmin f/f MEFs were infected 
with either AdenoCre-GFP or Adeno-GFP virus. Seven days later ATMIN and NBS1 
genotyping PCR was performed to confirm gene deletion. FACS analysis for cell cycle 
distribution of sub-confluent atmin+/+ primary MEFs seven days after (c) Adeno-GFP or 
(d) AdenoCre-GFP infection. e) Quantification of cell cycle phases depicted in (c, d). 
Percentage of cells with a DNA content of 4N or greater, as analysed in (c,d). 
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Figure 41: ATMIN co-deletion rescues the proliferation arrest of NBS1 deficient cells 
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a) Photographs of primary MEFs ten days after infection with either Adeno-GFP 
(atminf/f, nbs1f/f and nbs1f/f; atminf/f) or AdenoCre-GFP (atmin∆/∆, nbs1∆/∆ and 
nbs1∆/∆;atmin∆/∆). b) Seven days after Adenovirus infection 0.04x106 cells per well of 
the indicated genotypes were plated. Total cell number was counted in triplicate each 
day for the following four days. MEFs were cultured in medium containing 10µM BrdU 
for 30min, and the percentage of cells that had incorporated BrdU was analysed by c) 
flow cytometry or (d, e) IF staining for BrdU. The percentage of BrdU positive cells is 
expressed relative to wildtype. Student’s t-test was used for statistical analysis 
(*p<0.05). 
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Figure 42: ATMIN deficiency rescues the premature senescence of nbs1∆/∆ MEFs 
a) Ten days after infection the percentage of senescent cells was analysed by β-
galactosidase staining, (b) Quantification of (a). c) Percentage of viable cells, as 
assessed by trypan blue exclusion, at days seven to ten after gene deletion in primary 
MEFs. Student’s t-test was used for statistical analysis, n=3 independent experiments  
(*p<0.05). 
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5.2 ATMIN inactivation prevents the intestinal progenitor cell 
loss induced by NBS1 deficiency 
To investigate the phenotype of cells doubly deficient for ATMIN and NBS1 in more 
detail, the intestine was used as a model system. An inducible Villin-CreERT system 
was used to specifically induce gene deletion in adult intestinal epithelial cells. Cohorts 
of atminf/f; Villin-CreERT, nbs1f/f; Villin-CreERT, nbs1f/f; atminf/f; Villin-CreERT and 
Cre-negative controls were generated. To activate Cre recombinase expression and 
achieve deletion of the floxed alleles three consecutive daily injections of tamoxifen 
were administrated, yielding atmin∆G/∆G, nbs1∆G/∆G or nbs1∆G/∆G; atmin∆G/∆G mice. Five 
days after the final injection animals were sacrificed and DNA isolated from the villi 
and crypts of intestine. Genotyping PCR for the atmin and nbs1 loci confirmed efficient 
gene deletion in the intestines of nbs1f/f; atminf/f; Villin-CreERT animals (Figure 43a). 
Moreover, GFP intestinal staining for LSL-Rosa-YFP; Villin-CreERT mice subjected to 
the same tamoxifen injection regime demonstrated a high efficiency of recombination 
(Figure 43b). Thus, the Villin-CreERT model is a suitable system to study the 
consequences of atmin and nbs1 loss in vivo.  
 
Five days after intestinal nbs1 deletion H&E staining demonstrated structural 
disintegration of the intestinal mucosa (Figure 43c). The loss of integrity of the regular 
villi structure and reduced cell occupancy in the crypt is particularly evident at higher 
magnification (Figure 43d). In contract, the intestinal architecture of nbs1∆G/∆G; 
atmin∆G/∆G animals is largely intact (Figure 43c, d).  
 
I next wanted to investigate if nbs1 deletion influenced stem-cell commitment into 
different intestinal lineages. Fast Red staining highlighted the loss of villi integrity in 
nbs1∆G/∆G intestines, and the rescue in nbs1∆G/∆G; atmin∆G/∆G animals (Figure 44a). P.A.S. 
staining for goblet cells demonstrated a mild reduction, from 10.1 to 8.9, in the number 
of goblet cells per villi in the nbs1∆G/∆G intestine (Figure 44b, e). However this was not 
statistically significant (n=3, p=0.12). Chromogranin staining to detect endocrine cells 
demonstrated a mild reduction in the percentage of chromogranin-positive villi, from 
35.0% to 31.4% (Figure 44c, f). Sections were stained with lysozyme to detect Paneth 
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cells, which were still present in all four genotypes (Figure 44d). Taken together, this 
examination of the different intestinal lineages suggests neither nbs1 nor atmin deletion 
strongly effects intestinal stem cell lineage commitment.  
 
The intestine is a highly proliferative organ, and differentiated cells are rapidly 
replenished from the stem cell pool that resides at the base of the crypt. MCM6 is a 
marker of undifferentiated intestinal cells at the base of the crypt (Haigis et al., 2006). 
Five days after atmin and nbs1 gene deletion the total number of MCM6 positive cells 
per crypts had not significantly decreased (Figure 45a, c). However, only MCM6 
positive cells at the bottom of the crypts are part of the undifferentiated pool, not cells 
in higher positions. Examination of MCM6 positive cells at the base of nbs1∆G/∆G crypts 
revealed a marked reduction from 55.7% to 22.9% (p=0.0093) in progenitor cells 
(Figure 45b, d). Conversely, quantification of nbs1∆G/∆G; atmin∆G/∆G animals 
demonstrated a rescue of the nbs1∆G/∆G phenotype; compound mutants had 52.7% 
MCM6 positive cells in the base of their crypts, similar to wildtype levels (Figure 45b, 
d). Therefore loss of ATMIN prevents the progenitor cell deficiency induced by NBS1 
inactivation.  
 
The observation intestinal nbs1 deletion leads to progenitor cell loss suggests nbs1 
deletion may required for intestinal stem cell maintenance. To characterise this, ISH for 
the intestinal stem cell marker olfm4 was performed on intestines 24 hours and five days 
after gene deletion. 24 hours after nbs1 deletion the number of olfm4 positive cells per 
crypt had reduced from 5.0 to 3.5 (Figure 45e, f). The reduction in olfm4 positive cells 
is rescued in nbs1∆G/∆G; atmin∆G/∆G mice.  However, five days after gene deletion olfm4 
positive stem cells number per crypt was dramatically reduced in both nbs1∆G/∆G and 
nbs1∆G/∆G; atmin∆G/∆G mice (Figure 45g, h). There was a slight rescue in the number of 
crypts containing at least one olfm4 positive cell in the compound mutants compared to 
nbs1∆G/∆G deletion alone - 39.1% compared to 15.8% (Figure 45g, i). Nevertheless, it is 
evident that co-deletion of atmin and nbs1 does not fully rescue the intestinal stem cell 
loss induced by intestinal nbs1 deletion. 
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Figure 43: Loss of ATMIN partially rescues the loss of intestinal architecture induced by 
abrogation of NBS1  
a) atmin and nbs1 genotyping PCRs performed on intestinal DNA extracted from mice 
of the indicated genotypes five days after tamoxifen injection. b) Representative images 
of GFP stained tamoxifen-injected Villin-CreERT; LSL-RosaYFP intestines five days 
after gene deletion. Representative (c) low and (d) high magnification small intestine 
H&E sections of the indicated genotypes, five days after gene deletion. 
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Figure 44: Intestinal architecture of atmin∆G/∆G,  nbs1∆G/∆G,  and nbs1∆G/∆G; atmin∆G/∆G mice 
Representative (a) Fast-red, (b) AB/PAS, (c) chromogranin and (d) lysozyme stainings 
on the genotypes indicated in untreated conditions, five days after gene deletion. e) 
Quantification of Ab/Pas  positive cells per villus in the SB2 region. f) Quantification of 
the percentage of villi in the SB2 region with at least one chromogranin positive cells. 
At least three mice per genotype were analysed.  
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Figure 45: ATMIN loss partially rescues the intestinal stem cell defect induced by NBS1 
deletion 
a) Immunohistochemistry for MCM6-positive cells on representative small intestine 
sections of mice with the indicated genotypes, five days after VillinCre-ERT mediated 
deletion of atmin and nbs1. b) High magnification of MCM6 immunostained crypts, 
five days after gene deletion. c) Percentage of MCM6-positive cells in the crypts of the 
indicated genotypes, as shown in (a). d) Percentage of MCM6-positive cells in the base 
of the crypts, as shown in (b). e) Representative olfm4 ISH on small intestine sections of 
the indicated genotypes, 24 hours after gene deletion. f) Quantification of the number of 
olfm4 positive cells per crypt. g) Representative images of olfm4 ISH on the small 
intestines five days after gene deletion. h) Quantification of olfm4 positive cells per 
crypt, as shown in (g). i) Percentage of crypts with one or more olfm4 positive cell. 
Student’s t-test was used for statistical analysis (**p<0.01; *p<0.05). At least three 
mice per genotype were analysed.  
 
 
5.3 Competition between NBS1 and ATMIN dictates pathway 
choice of ATM signalling 
Depending on the DNA damage stimuli, ATM signalling proceeds via either ATMIN or 
NBS1. Both ATMIN and NBS1 contain a consensus ATM interaction motif at their C-
terminus (Kanu and Behrens, 2007). This indicates ATMIN and NBS1 interact with the 
same region of ATM and the binding of one precludes the binding of the other, i.e. 
ATMIN and NBS1 compete for ATM binding. This hypothesis is supported by 
observation of reduced co-immunoprecipitation, after IR, between ATM and NBS1 
upon Flag-ATMIN overexpression (T. Zhang, personal communication). This led to the 
‘ATM Competition Model’ - that competition between NBS1 and ATMIN for ATM 
binding regulates ATM pathway choice.  
 
One prediction of the ‘ATM Competition Model’ is increased interaction between 
ATM-NBS1 should augment irradiation induced ATM signalling. To test this 
hypothesis, I irradiated atmin∆/∆ MEFs and analysed ATM pathway activation by 
western blot. atmin∆/∆ MEFs exhibited increased irradiation-induced phosphorylation of 
pS1987-ATM, pS957-SMC1 and pS824-KAP1 (Figure 46a). Therefore, the absence of 
ATMIN increases the flux through the NBS1-dependent ATM pathway. 
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In collaboration with Christopher Bruhn and Zhao-Qi Wang (Fritz-Lipmann Institute, 
Germany) the reverse experiment was performed. Namely, nbs1∆/∆ MEFs were treated 
with hypotonic shock; an ATMIN dependent ATM stimulus. Western blot analysis 
demonstrated a mild increase in pS15-p53 and pS1987-ATM levels in nbs1 deleted cells 
(Figure 46b). Thus, the lack of NBS1 appears to increase ATMIN-dependent ATM 
signalling.  
 
 
 
 
 
Figure 46: The ATMIN and NBS1 dependent ATM signalling pathways inhibit each other 
a) atminf/f primary MEFs were treated with 5 Gy IR five days after infection with 
Adeno-GFP (wildtype) or AdenoCre-GFP (atmin∆/∆). Cells were harvested 60 minutes 
after IR and immunoblotted for the indicated antibodies. b) nbs1f/f Rosa-CreERT 
primary MEFs were spontaneously immortalised by the 3T3 method, then treated with 
tamoxifen to generate nbs1∆/∆ MEFs. Cells were harvested untreated (UT), one hour 
after 135mOsm hypotonic shock treatment (HS), or 15 minutes after 2 Gy IR (IR). Cell 
lysates were probed with the indicated antibodies. DHX9 is used as a loading control. 
The experiment shown in (b) was performed by a collaborator, Christopher Bruhn, at 
the Leibniz Institute for Age Research, Jena, Germany. * indicates an unspecific band. 
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5.4 Increased DNA damage and radiosensitivity of nbs1∆/∆; 
atmin∆/∆ cells and nbs1∆G/∆G; atmin∆G/∆G mice 
A hallmark of ATM deficient cells is elevated DNA damage levels under basal 
conditions. To elucidate the relative contributions of ATMIN and NBS1 to endogenous 
DNA damage repair I quantified DNA damage in untreated atmin∆/∆, nbs1∆/∆, and 
nbs1∆/∆; atmin∆/∆ MEFs. Cells were grown at low (3%) oxygen for seven days after 
Adeno-cre mediated gene deletion, then fixed and immunofluorescently stained for the 
DNA damage markers pH2AX and pS1897-ATM. Compared to wildtype cells, both 
atmin∆/∆ and nbs1∆/∆ mutants had increased number of cells with pH2AX foci. 
Strikingly, compound mutant nbs1∆/∆; atmin∆/∆ MEFs had a substantially higher number 
of cells with pH2AX foci (Figure 47a, b). Moreover, western blot analysis indicated 
increased pS15-p53 in atmin∆/∆ MEFs, indicative of DNA damage (Figure 47c).  
 
The phosphorylation of variant histone H2AX (pH2AX) is a marker for DNA damage, 
but does not necessarily indicate activation of the ATM signalling pathway. 
Quantification of cells with pS1987-ATM foci revealed background levels of ATM 
activation in wildtype, atmin∆/∆ and nbs1∆/∆ MEFs. All these three genotypes had 
approximately 10% of cells positive with pS1987-ATM, consistent with endogenous 
DNA damage levels (Figure 47a, b). Conversely, there were no detectable pATM foci 
in nbs1∆/∆; atmin∆/∆ double mutant cells (Figure 47a, b). This indicates either ATMIN or 
NBS1 is required for ATM activation; there is no other protein that can substitute for 
the dual deletion of the two ATM co-factors. 
 
Although unlikely, given the rescue of proliferation and senescence observed in nbs1∆/∆; 
atmin∆/∆ cells compared to nbs1∆/∆, it is formally possible co-deletion of atmin and nbs1 
rescues IR signalling defect of nbs1 deficient cells. To exclude this possibility I 
examined pS1987-ATM and pH2AX foci formation after IR. As expected, deletion of 
atmin, nbs1 or both did not hinder the pH2AX foci formation after irradiation. 
Irradiated wildtype and atmin∆/∆ MEFs activated pS1987-ATM (Figure 48a, b). In 
contrast, nbs1 deletion led to a substantial decrease to the formation of pATM foci. 
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However, the nbs1∆/∆; atmin∆/∆ double mutants did not form any pS1987-ATM foci 
after irradiation, despite inducing pH2AX foci formation (Figure 48a, b). Thus, co-
deletion of atmin and nbs1 abolishes ATM recruitment to sites of irradiation induced 
DNA damage, but H2AX phosphorylation still occurs.  
 
Given p1987-ATM foci do not form after IR in nbs1∆/∆; atmin∆/∆ MEFs, one would 
expect ATM and its downstream substrates are not phosphorylated. To confirm this, I 
performed a western blot analysis for pS1987-ATM, pS957-SMC1 and pS824-KAP1 
phosphorylation in irradiated mutant cells. As seen previously, atmin deletion augments 
the phosphorylation of these ATM substrates (Figure 48c). Furthermore, neither nbs1∆/∆ 
nor nbs1∆/∆; atmin∆/∆ MEFs show any detectable ATM substrate phosphorylation in 
irradiated cells (Figure 48). Indeed, even at very high radiation doses, 10 Gy and 20 Gy, 
there is no phosphorylation of pS284-KAP1 in nbs1∆/∆; atmin∆/∆ and nbs1∆/∆ cells 
(Figure 48d). Thus, atmin deletion does not recuse the DSB signalling defect of nbs1∆/∆ 
MEFs. 
 
Given nbs1∆/∆; atmin∆/∆ MEFs have total abrogation of IR-induced ATM signalling, it 
followed to assess the functionality of IR-induced DNA repair. Radiosensitivity was 
measured as the percentage of apoptotic (sub-G1) cells over 36 hours after 10 Gy 
irradiation (Figure 49a). nbs1∆/∆; atmin∆/∆ MEFs undergo increased apoptosis compared 
to wildtype cells. In line with published data, atmin∆/∆ deficient MEFs demonstrated 
mild radioresistance (Kanu and Behrens, 2007). To more clearly analyse the 
radiosensitivity of nbs1∆/∆; atmin∆/∆ MEFs, the radiosensitivity assay was repeated at 20 
Gy IR. At every timepoint after IR, nbs1∆/∆; atmin∆/∆ MEFs had a higher percentage of 
sub-G1 cells than observed in the wildtype population (Figure 49b). Representative 
FACS plots are shown (Figure 49c). The deletion of atmin renders MEFs mildly 
radioresistant; co-deletion of nbs1∆/∆ and atmin∆/∆ renders MEFs severely radiosensitive.  
 
The in vivo, as well as in vitro, functionality of DNA repair after IR was investigated. 
Whole-body irradiation of nbs1f/f; atminf/f and nbs1∆G/∆G; atmin∆G/∆G mice at the sub-
lethal doses 7 Gy and 10 Gy resulted in the dose-dependent lethality of nbs1∆G/∆G; 
atmin∆G/∆G mice (Figure 50a). Histological analysis of nbs1∆G/∆G; atmin∆G/∆G mice 24 
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hours after irradiation showed cell loss and extensive radiation injury (Figure 50b). 
Although pH2AX foci were observed in IR treated nbs1∆G/∆G; atmin∆G/∆G intestines 
(Figure 50c), no 53BP1 focus formation was observed (Figure 50d). To confirm the 
abrogation of ATM pathway activation in irradiated nbs1∆G/∆G; atmin∆G/∆G animals, 
intestinal cells were isolated and cell lysates prepared. Western blotting revealed a 
complete absence of pS1987-ATM, pS957-SMC1, pS824-KAP1 and pS15-p53 - i.e. no 
ATM pathway activation (Figure 50e). In summary, both in vivo and in vitro doubly 
deficient nbs1; atmin cells are radiosensitive and are unable to activate the IR-induced 
ATM signalling pathway. 
5.5 Concluding Remarks 
ATM activation proceeds by interaction with either ATMIN or NBS1. To investigate 
co-factor choice I studied nbs1∆/∆, atmin∆/∆; and compound mutant nbs1∆/∆; atmin∆/∆ 
MEFs and murine intestines. Unexpectedly, atmin deletion from nbs1∆/∆ cells partially 
rescues the premature senescence and proliferation defect of nbs1∆/∆ MEFs (Figure 41, 
Figure 42), and the progenitor pool loss of nbs1∆G/∆G intestines (Figure 45). There is 
competition between ATMIN and NBS1 for ATM. Loss of ATMIN increases IR-
induced, NBS1-dependent ATM signalling and loss of NBS1 increases hypotonic 
shock-induced, ATMIN-dependent ATM signalling (Figure 46). nbs1∆/∆; atmin∆/∆ 
compound mutant MEFs exhibit greater endogenous DNA damage than either of the 
single mutants (Figure 47), are radiosensitive (Figure 49) and display and no pS1987-
ATM autophosphorylation after IR (Figure 48). Hence ATMIN and NBS1 mediate all 
pS1981-ATM foci formation, and increased ATMIN-dependent ATM signalling 
explains the different phenotypes of nbs1- and atm-mutant cells. Thus antagonism 
between ATMIN and NBS1 is a crucial regulatory mechanism of ATM signalling and 
function. 
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Figure 47: nbs1∆/∆;atmin∆/∆ MEFs have high levels of endogenous DNA damage 
a) MEFs were infected with either Adeno-GFP (atminf/f, nbs1f/f and nbs1f/f;atminf/f) or 
AdenoCre-GFP (atmin∆/∆, nbs1∆/∆ and nbs1∆/∆;atmin∆/∆), cultured for seven days, then 
fixed without treatment and stained for pS1981-ATM and p139-γH2AX. b) 
Quantification of (a), cells containing four or more foci were counted as positive. c) 
Cells were harvested seven days after gene deletion and cell lysates separated by SDS-
PAGE and membranes probed for p53, pS15-p53 and tubulin.  
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Figure 48: nbs1∆/∆; atmin∆/∆ MEFs do not activate ATM signalling after IR 
MEFs were infected with either Adeno-GFP (atminf/f, nbs1f/f and nbs1f/f;atminf/f) or 
AdenoCre-GFP (atmin∆/∆, nbs1∆/∆ and nbs1∆/∆;atmin∆/∆), cultured for seven days then a) 
fixed 60 minutes after treatment with 5 Gy IR and stained for pS1981-ATM and p139-
γH2AX. b) Quantification of (a), cells containing four or more foci were counted as 
positive. Three independent experiments were performed. c) MEFs were treated with 5 
Gy IR and lysed after 60 minutes. Whole cell lysates were resolved on a 6% SDS-
PAGE gel and immunostained with the indicated antibodies. d) As for (c), except cells 
were harvested 60 minutes after treatment with either 10 or 20 Gy IR. 
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Figure 49: nbs1∆/∆;atmin∆/∆ cells are radiosensitive 
Cells were treated with a) 10 Gy or b) 20 Gy irradiation, and fixed at the indicated 
timepoints post-treatment. The percentage of subG1 cells was determined by flow 
cytometry analysis. c) Representative FACS plots for the experiment quantified in (b), 
which is an average of three independent experiments performed on independent MEF 
lines. 
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Figure 50: nbs1∆G/∆G;atmin∆G/∆G are radiosensitive 
a) Four days after VillinCre-ERT mediated deletion of atmin and nbs1, mice were 
treated with the indicated doses of irradiation (n=5 per genotype per dose). b) H&E, c) 
pH2AX and d) 53BP1 staining on representative intestines of mice with the indicated 
genotypes, untreated or 24 hours after treatment with 14Gy irradiation. e) Mice were 
culled two hours after 10 Gy IR, and protein lysates prepared from intestinal tissue. 
Lysates were resolved on a 6% SDS-PAGE gel and the membrane probed for pS1987-
ATM, pS957-SMC1, SMC1 and pS824-KAP1
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Chapter 6. DMAP1 is a novel regulator of ATM 
function 
6.1 An shRNA screen for novel ATM regulatory proteins 
ATM’s two known co-factors, NBS1 and ATMIN, both contain consensus ATM 
interaction motifs towards their C-termini. Many PI3-K interacting proteins, including 
Ku80 and ATRIP, share this conserved motif (Falck et al., 2005). It is therefore a 
reasonable assumption that other, as yet unidentified, proteins involved in DNA repair 
also contain the conserved ATM interaction motif. One aim of my PhD thesis was to 
identify novel ATM regulatory proteins in an shRNA based screen. Rather than a 
genome wide approach, the ATM interaction motif was the basis of a candidate based 
shRNA screen (Figure 51a). 
 
Firstly, Prosite was used to search the UniProtKB/Swiss-Prot database for proteins 
containing the sequence (A-X-[DE]-X-[IL]-X-X[DE]-[IL]). This retrieved 
approximately 40 proteins, including ATMIN and NBS1. The inclusion of ATM’s 
known co-factors in the search results is a positive control for the search criteria. A 
literature search was performed on the candidate proteins to determine those selected 
for further screening. The criteria employed for candidate selection were subcellular 
localisation (if known), the presence of other conserved protein domains and whether 
the ATM interaction motif was highly conserved. The species conservation of each 
potential ATM interaction motif was established using the UCSC genome browser. 
Fifteen proteins were selected for the biochemical phase of the screen. 
 
The second, biochemical, phase of the screen was the design and cloning of two 
shRNA’s for each candidate protein (see page 105). HCT-116 cells transfected with a 
pool of the two shRNAs were treated with 5 Gy IR or 5 µM aphidicolin. The magnitude 
of ATM pathway activation was assessed by western blot for the ATM substrate pS957-
SMC1. To ensure the SMC1 phosphorylation was ATM specific, cells were also pre-
treated with a small molecule ATM kinase inhibitor prior to IR treatment. 
Chapter 6 Results 
 
 188 
Representative results from two candidates, AlkBH7 and Znf507, are shown (Figure 
51b). 
 
 
 
Figure 51: An shRNA screen for novel ATM regulators 
a) Schematic overview of the screen for novel ATM regulatory proteins. b) Sample 
results from two ‘negative hits’. Cells were transfected with the indicated shRNAs, then 
after 48 hours were harvested one hour after 5 Gy IR, or after incubation in 5 µM  
aphidicolin for two hours. A subset of cells were pre-treated with ATM inhibitor one 
hour before irradiation. Whole cell lysates were resolved on a 6%SDS-PAGE gel and 
immunostained with the indicated antibodies. 
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6.2 DMAP1 is required for ATM signalling and function after IR 
A positive hit from the initial biochemical screen was DNMT1-associated protein 1 
(DMAP1). DMAP1’s conserved ATM interaction motif is shown schematically (Figure 
52a). To ensure the phenotype observed was not due to off-target shRNA effects, two 
further shRNAs targeted against dmap1 were cloned. dmap1 mRNA levels were 
significantly downregulated by each of the four individual shRNAs (Figure 52b). Loss 
of DMAP1 caused a substantial decrease to the extent of phosphorylation of the ATM 
substrates pS957-SMC1 and pS824-KAP1 after IR (Figure 52c). However, total ATM, 
KAP1 and SMC1 protein levels were unaltered. This suggests that DMAP1 is required 
for ATM signalling in response to DSBs. 
 
To investigate the role of DMAP1 in ATM recruitment to DSBs, the percentage of cells 
with pS1987-ATM foci at short time points after IR was assessed. Five minutes after IR, 
significantly fewer DMAP1 deficient cells had formed p1981-ATM foci compared to 
wildtype cells. This suggests that DMAP1 is required for the efficient formation of 
irradiation-induced foci. Conversely, 45 minutes after IR no difference in the 
percentage of cells with p1981-ATM foci was observed. This delay could reflect the 
shRNA mediated reduction, but not elimination, of DMAP1. Alternatively, it could be 
due to redundancy in the cellular DNA damage pathways. Interestingly, delayed DNA 
damage foci formation is also observed in NBS1 hypomorphic cells (Difilippantonio et 
al., 2007). 
 
To rule out cell cycle defects underlie the impaired DNA damage signalling in DMAP1 
depleted cells, siDMAP1 and siControl treated cells were assessed by FACS for their 
cell cycle profile (Figure 54). There was no significant difference between the cell 
cycle distribution of control and DMAP1 depleted cells. Thus, DMAP1 does not appear 
to regulate the cell cycle. 
 
In response to IR, ATM signals to arrest proliferating cells at the G2/M checkpoint. I 
performed a G2 Trap experiment on DMAP1 depleted cells to assess if DMAP1 is 
required for G2/M checkpoint activation after DNA damage. The G2 Trap experiment 
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uses the mitotic inhibitor nocodazole to arrest cells that pass through the G2/M 
checkpoint in mitosis. The proportion of cells in mitosis is determined by the FACS 
analysis for phosphorylated histone H3, pS10-H3. The percentage of pS10-H3 positive 
cells is a measure of those cells that have passed through the ATM dependent G2/M 
checkpoint. 
 
In line with the observation DMAP1 depleted cells have a normal cell cycle profile 
(Figure 54) in the presence of nocodazole untreated HCT-116 cells transfected with 
either siDMAP1 or siControl arrested in mitosis to the same extent (Figure 55a, b). In 
the absence of nocodazole, the loss of DMAP1 had no effect on the proportion of cells 
in mitosis. As expected five, ten, and 20 Gy irradiation decreased mitotic entry in a dose 
dependent manner, in both siControl and siDMAP1 treated cells. However, DMAP1 
depletion resulted in a higher proportion of cells entering mitosis at 10 and 20 Gy IR 
(Figure 55a, b). This indicates that DMAP1 is required for proper activation of the 
ATM-regulated G2/M checkpoint.  
 
Having established impaired checkpoint activation in DMAP1 depleted cells, I next 
wanted to investigate whether the impaired signalling had any impact on cell viability. I 
performed clonogenic survival assays. At each irradiation dose assayed, DMAP1 
depleted cells formed fewer colonies compared to control cells (Figure 55c). As a 
positive control for the importance of ATM signalling after irradiation, siControl 
transfected cells were pre-treated with a small molecule ATM kinase inhibitor before 
irradiation. Interestingly, the colony formation defect observed in DMAP1 deficient 
cells is of a similar magnitude to the defect in cells lacking ATM kinase activity (Figure 
55c). It is worth noting colony forming ability was assessed over seven days, over 
which the DMAP1 protein levels in siDMAP1 transfected cells presumably return to 
normal and the potency of the ATM inhibitor is reduced. Therefore this experiment 
directly assays the role of DMAP1, and ATM’s kinase activity, in the immediate 
cellular response to IR. The temporary nature of the ATM kinase inhibition very likely 
accounts for the increased clonogenic survival of ATM kinase inhibitor treated cells, 
compared to published observations of a more severe colony formation defect in atm-/- 
cells (Cox et al., 1978). 
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Figure 52: DMAP1 is required for ATM substrate phosphorylation after IR 
a) Sequence of the consensus ATM interaction motifs present upon human DMAP1, 
NBS1 and ATMIN. b) RT-PCR for dmap1 mRNA in HCT-116 cells 48 hours after 
transfection with one of four shRNAs targeted against dmap1. mRNA levels are 
normalised to shRNA control transfected cells. c) HCT-116 cells were transfected with 
control shRNA or one of four different shRNA’s against DMAP1. 48hr later cells were 
treated with 5.0 Gy IR, harvested after one hour and whole cell lysates immunostained 
for pS1981-ATM, ATM, pS957-SMC1, SMC1 pS824-KAP1 and KAP1.  
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Figure 53: Delayed IR-induced pATM focus formation in dmap1 deficient cells 
HCT-116 cells were treated with a pool of DMAP1 shRNAs and 48 hours later treated 
with 2.0 Gy IR. Cells were fixed at (a) five minutes and (b) 45 minutes after irradiation 
and immunofluorescently stained for pS1981-ATM. Quantification of cells with four or 
more pATM foci at (c) five minutes and (d) 45 minutes after irradiation. The p-value of 
three independent experiments was calculated using the student’s t-test (*p<0.05). 
 
 
 
 
 
 
 
 
 
 
Figure 54: Knockdown of dmap1 does not alter cell cycle progression  
FACS analysis of the cell cycle profile of a) siControl and b) siDMAP1 treated HCT-
116 cells 48 hours after transfection. c) Quantification of (b). Error bars represent the 
standard deviation of three independent experiments. 
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Figure 55: DMAP1 deficient cells are radiosensitive 
HCT-116 cells were transfected with DMAP1 or control shRNA, and after 48 hours 
were irradiated at the indicated doses. Cells were immediately incubated in the presence 
of either nocodazole or DMSO, and after 18 hours fixed and analysed for pS10-H3 by 
FACS analysis. Representative FACS plots are shown in (a), and quantification in (b). 
c) HCT-116 cells were transfected with siDMAP1 or control shRNA. 48 hours later 
DMSO or ATM inhibitor was added for one hour then cells were treated with the 
indicated radiation doses and counted. 250 cells were plated per condition and the 
number of colonies formed was counted seven days later. At least three independent 
experiments were performed and p values calculated using the student’s t-test, 
(*p<0.05; **p<0.01). 
 
6.3 DMAP1 is required for non-canonical ATM signalling 
Having established DMAP1 is important for irradiation induced ATM signalling, it was 
interesting to ascertain if DMAP1’s function was limited to DSB signalling. It was 
recently shown that ATM is activated by oxidative stress (Guo et al., 2010b). To 
investigate which ATM substrates are phosphorylated in response to oxidative stress, I 
performed a timecourse on H202 treated HCT-116 cells (Figure 56a). To elucidate a 
possible role of DMAP1 in oxidative stress signalling, DMAP1 depleted cells were 
subjected to H202 treatment. DMAP1 depleted cells exhibited markedly reduced levels 
of pS1981-ATM, pS957-SMC1 and pS824-KAP1 compared to control cells. (Figure 
56b). This suggests that DMAP1 contributes to ATM activation by oxidative stress.  
 
To address if DMAP1 is required for non-canonical ATM signalling, HCT-116 cells 
were exposed to hypotonic stress. Compared to control cells, DMAP1 depleted cells 
displayed reduced levels of pS1981-ATM and pS957-SMC1 (Figure 56b), suggesting 
DMAP1 is required for full ATM activation after both canonical and non-canonical 
ATM stimuli. 
 
As DMAP1 was originally identified in a screen for proteins containing P13-K 
interaction motifs, I wanted to determine if DMAP1 was required for ATR signalling. I 
treated cells with ultraviolent radiation (UV), which induces single strand DNA breaks, 
activating ATR. DMAP1 depletion did not alter the extent of pS957-SMC1 or pS317-
Chk1 phosphorylation after UV (Figure 56c). Inhibition of ATM’s kinase activity with 
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a small molecule kinase inhibitor had negligible effect on the induction of pS957-SMC1 
and pS317-Chk1 phosphorylation after UV. Thus it is clear that these are ATR, not 
ATM, dependent phosphorylation events and DMAP1 is dispensable for ATR 
signalling.  
 
Given DMAP1 is required for both canonical and non-canonical ATM signalling, it is 
conceivable DMAP1 overexpression is sufficient to trigger ATM substrate 
phosphorylation in the absence of DNA damage. Expression of a Myc tagged DMAP1 
construct (Myc-DMAP1) did not elevate basal phosphorylation of the ATM substrates 
pS957-SMC1 and pS824-KAP1 (Figure 57a). Conversely, DMAP1overexpression 
resulted in increased ATM substrate phosphorylation after both IR and hypotonic stress 
(Figure 57a). The overexpression of Myc-DMAP1 and GFP-DMAP1 (Figure 57b) was 
able to augment ATM substrate phosphorylation after oxidative stress. Thus DMAP1 
appears to be a rate-limiting factor in both DSB induced and non-canonical ATM 
signalling. 
 
The increased ATM substrate phosphorylation observed with DMAP1 overexpression 
(Figure 57a) led to the possibility that cells with higher DMAP1 levels repair DNA 
damage faster. To address this, Myc-DMAP1 overexpressing cells were fixed twenty-
four hours after treatment with 2.0 Gy irradiation and immunostained for pH2AX or 
pS1987-ATM (Figure 57c, d). There was no significant difference in the percentage of 
cells with either or pH2AX (Figure 57e) pATM (Figure 57f) foci. There was also no 
difference in the pATM foci intensity (Figure 57g). Therefore, although DMAP1 
overexpression increases the magnitude of ATM substrate phosphorylation at short time 
points after induction of DNA damage, it does not alter the persistence of DNA damage 
foci. 
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Figure 56: DMAP1 is required for non-canonical ATM signalling, but not for ATR 
signalling 
a) HCT-116 cells were treated with 250 µM H202 and harvested after the indicated 
timepoints. As a control some cells were harvested 45 minutes after 5 Gy IR. b) HCT-
116 cells were transfected with a pool of shRNAs against DMAP1 or shRNA control, 
then 48hr later were treated with 135 mOsm NaCl or 250 µM H202 for one hour. c) 
Cells were pre-treated for one hour with ATM inhibitor or DMSO then treated with 50 J 
m2 UV and harvested after 60 minutes. Whole cell lysates were resolved on a 6% SDS-
PAGE gel and membranes immunoblotted for pS1981-ATM, ATM, pS957-SMC1, 
SMC1, pS824-KAP1, KAP1, pS317-Chk1 and tubulin. 
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Figure 57: DMAP1 overexpression increase the magnitude of ATM signalling 
Chapter 6 Results 
 
 199 
HCT-116 cells were transfected with a, b) pcDNA, Myc-DMAP1 and c) GFP-DMAP1, 
and 48 hours later treated with 2.0 Gy IR, 135 mOsm NaCl, or 250 µM H202 then 
harvested after one hour. Whole cell lysates were resolved on a 6% SDS-PAGE gel and 
membranes immunoblotted for pS1981-ATM, pS957-SMC1, SMC1, pS824-KAP1 and 
KAP1. c, d) 293A cells were transfected with pcDNA or Myc-DMAP1 then irradiated 
at 2 Gy after 48 hours. Cells were left to recover for a further 24 hours before fixation 
and immunofluorescent staining for pH2AX, pATM and Myc. e) Percentage of cells 
containing three or more pH2AX foci 24 hours after IR, as shown in (c). f) Percentage 
of cells containing three or more pS1981-ATM foci, as shown in (d). g) Relative pATM 
foci intensity 24 hours after IR in cells transfected with the indicated constructs. At least 
100 cells per experiment were quantified per experiment. The p-value of three 
independent experiments was calculated using the student’s t-test.  
 
 
 
6.4 DMAP1 does not detectably interact with ATM 
The identification of DMAP1 in a screen for proteins containing an ATM interaction 
motif strongly suggested that DMAP1 and ATM would interact. I initially investigated 
a possible endogenous ATM-DMAP1 interaction by performing reciprocal co-
immunoprecipitations in untreated HCT-116 cells. However, despite a reproducible 
immunoprecipitation of Myc-DMAP1 and ATM, I could not detect the reciprocal 
protein (Figure 58a). In case an ATM-DMAP1 interaction does not occur in HCT-116 
cells for cell-line specific reasons I performed immunoprecipitations in a range of other 
cell lines, including 293A, 293T and Hela Ohio (data not shown). I could not detect co-
immunoprecipitation between ATM and DMAP1 under basal conditions in any cell line.  
 
ATM exists in undamaged cells as a dimer, and thus it is feasible DMAP1’s potential 
interaction motif binds a region of ATM shielded in the dimer conformation.  To 
address this I immunoprecipitated Myc-DMAP1 and endogenous ATM one hour after 5 
Gy irradiation, when ATM is in its monomeric form. However, there was no detectable 
co-immunoprecipitation (Figure 58b). I also performed immunoprecipitations at five 
minutes, 20 minutes and six hours after irradiation but did not detect an interaction 
between ATM and MycDMAP1 (data not shown). 
 
To exclude the possibility that I could not detect an interaction due to the technical 
difficulties in immunoprecipiating an endogenous protein of ATM’s large size 
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(~350kDa) I overexpressed Flag-ATM in 293A cells. I performed Flag IP’s in both 
control and Myc-DMAP1 expressing cells. Despite a reproducible ATM enrichment, I 
did not detect any Myc-DMAP1 in the Flag IP (Figure 58c). To address a model in 
which DMAP1 and ATM only interact after DNA damage I used irradiated cells, but 
did not see an interaction (Figure 58d). As in the endogenous ATM IP’s, I could not 
detect an interaction between DMAP1 and ATM at five minutes, 20 minutes, one hour 
and six hours after irradiation (data not shown). Hence, interaction between DMAP1 
and ATM does not appear to be DNA damage dependent. 
 
It is possible DMAP1 has a very transitory interaction with ATM during the initial 
phase of ATM activation. Often, inhibitors can trap proteins in conformations they 
normally only briefly adopt during a catalytic step. DMAP1 could interact with ATM 
before it autophosphorylates. I therefore irradiated cells pre-treated with an ATM kinase 
inhibitor, and harvested the cells at five and 60 minutes after IR. However, 
immunoprecipitation of Myc-DMAP1 did not yield ATM (Figure 58e, f).  
 
ATM activation by oxidative stress proceeds via a cysteine-linked dimer (Guo et al., 
2010b). To determine if DMAP1 interacts with this ATM conformation, I 
immunoprecipitated Myc-DMAP1 from cells after one hour of H202 treatment. However, 
ATM was not co-immunoprecipitated (Figure 58g). As histone acetylation is important 
for ATM activation (Li et al., 2010), I postulated a histone deacetylase inhibitor might 
prompt ATM to adopt conformation that interacts with DMAP1. I immunoprecipitated 
Myc-DMAP1 from cells pre-treated with the histone deacetylase inhibitor TSA, but did 
not co-immunoprecipitate ATM (Figure 58h). Therefore neither oxidative stress or 
histone deacetylation inhibition leads to detectable ATM-DMAP1 interaction.  
 
In summary, despite an extensive effort to co-immunoprecipitate ATM and DMAP1 
from several cell lines under a wide range of conditions, I was unable to detect an 
interaction between the two proteins. I was also unable to detect ATM binding to a 
peptide containing DMAP1’s putative ATM interaction motif (data not shown). 
Although this could be due to technical limitations, these results are consistent with a 
model in which ATM and DMAP1 do not directly interact. With ‘no interaction’ as a 
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working model, I next wanted to understand the role of DMAP1’s ATM interaction 
motif. 
 
To establish if DMAP1’s putative ATM interaction motif is required for its function in 
the DNA damage response, I generated a C-terminal truncation mutant, DMAP1∆C, 
which lacks the putative ATM interaction motif (Figure 59a). As overexpression of full 
length DMAP1 augments ATM substrate phosphorylation after DNA damage, I 
assessed if DMAP1∆C was also able to do this. Unexpectedly, despite lacking an ATM 
interaction motif DMAP1∆C overexpression was sufficient to increase the 
phosphorylation levels of the ATM substrates pS957-SMC1 and pS824-KAP1 after 
oxidative stress treatment (Figure 59b). and irradiation (Figure 59c). This, taken 
together with the lack of a detectable interaction between DMAP1 and ATM, suggests 
that an interaction between DMAP1 and ATM is not required for DMAP1’s role in 
ATM biology. 
 
Many of the proteins involved in the DNA damage response become localised into foci 
at the sites of DNA damage. These foci are readily detected by confocal microscopy, so 
I assessed if DMAP1 became recruited to DNA damage foci by immunofluorescence 
staining. In untreated cells, GFP-DMAP1 localises to the nucleus in a pan-nuclear 
distribution (Figure 60a). However, one hour after 5 Gy IR GFP-DMAP1 was still in a 
pan-nuclear distribution and did not co-localise with the DNA damage marker pH2AX 
(Figure 60b). To rule out the possibility the relatively large, 27kDa GFP tag impedes 
recruitment I also assessed if Myc-DMAP1, containing the smaller 11 amino acid Myc 
tag, co-localised pATM or pH2AX foci. Nevertheless, Myc-DMAP1 remained in a pan-
nuclear distribution after DNA damage (Figure 60c).  
 
It is plausible only a subset of the total cellular pool of DMAP1 localises to DNA 
damage foci, and the remaining pan-nuclear DMAP1 masks the foci-localised DMAP1.  
I generated Z-stacks covering the entire cell to thoroughly examine if GFP-DMAP1 co-
localised with pATM at short (one hour) or longer (24 hour) times after IR. However, 
although some GFP-DMAP1 foci were sometimes visible, these showed no significant 
degree of overlap with pATM (Figure 61a, b). These GFP-DMAP1 foci were also seen 
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at the same frequency in untreated cells (data not shown). I also performed the same set 
of experiments using Myc-DMAP1, with very similar results (data not shown).  
 
Nevertheless, I could not rule out the possibility DMAP1 is transiently recruited to 
damage sites immediately after IR treatment, at timepoints shorter than it is technically 
possible to observe. Therefore, I used NCS to induce DNA damage. NCS is a 
radiomimetic that binds the minor groove of the DNA double helix, promoting the thiol 
activation of NCS to a radical form that induces single and double strand DNA breaks. 
Firstly, I optimised a timecourse of NCS treatment and determined that pH2AX foci 
first start appearing at five minutes after drug addition, and continue to accumulate over 
time (Figure 62a). However, I was unable to see co-localisation of GFP-DMAP1 to 
pH2AX or 53BP1 at five or 30 minutes after addition of NCS. Therefore, it appears that 
DMAP1 is not recruited into DNA damage foci (Figure 62b). 
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Figure 58: DMAP1 and ATM do not appear to co-immunoprecipitate  
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a) HCT-116 cells were transfected with pcDNA or Myc-DMAP1 and harvested after 48 
hours. Cell lysates were immunoprecipitated with antibodies against ATM, Myc or IgG 
control. b) As for (a), except cells were treated with 5 Gy IR one hour before 
harvesting. c) 293A cells were transfected with combinations of pcDNA, Flag-ATM 
and Myc-DMAP1, harvested after 48 hours, and immunoprecipitated with antibodies 
against Flag, Myc or IgG control. d) As for (c), except cells one hour before harvesting 
cells were treated with 5 Gy IR. (e, f, g, h). 293A cells were transfected with pcDNA or 
MycDMAP1, harvested 48 hours after transfection, and immunoprecipitated with anti-
Myc antibody or IgG control. (e, f,) Cells were incubated with ATM inhibitor one hour 
prior to 5 Gy irradiation, and harvested after (e) five minutes or (f) one hour. Cells were 
treated with (g) 250 µM H202 for one hour or (h) 5 µM TSA for six hours before cell 
lysis. IP’s and the corresponding inputs (10%) were resolved by 6% SDS-PAGE and 
membranes immunoblotted for Myc and ATM.  
 
 
 
 
Figure 59: DMAP1’s C-terminus is not required for augmentation of ATM signalling 
a) Schematic of full length DMAP1 and the DMAP1∆C truncation mutation; the SANT 
domain and potential ATM interaction motif are indicated. HCT-116 cells transfected 
with the indicated constructs were treated (b) with 250 µM H202 or (c) 5 Gy IR and 
harvested one hour later. Whole cell lysates were separated by 6% SDS-PAGE and 
membranes probed with pS957-SMC1, SMC1, pS824-KAP1 and KAP1. 
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Figure 60: DMAP1 does not localise to DNA damage foci one hour after IR 
Representative images of HCT-116 cells transfected with GFP-DMAP1 (a) fixed 
without treatment or (b) one hour after 5 Gy IR and immunofluorescently stained for 
pH2AX. c) Cells transiently transfected with Myc-DMAP1 were fixed one hour after 
0.2 Gy irradiation and stained with antibodies against Myc and pH2AX.  
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Figure 61 DMAP1 does not localise to DNA damage foci at later timepoints after IR 
Consecutive Z-stack images for 293A cells transiently transfected with GFP-DMAP1 at 
(a) six hours and (b) 24 hours after 2 Gy IR. Fixed cells were stained with anti-pS1981-
ATM antibody.  
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Figure 62 DMAP1 does not localise to DNA damage foci at short timepoints after DSB 
induction 
a) HCT-116 cells were treated with 200 ng/ml NCS and fixed at the indicated times. 
Cells were immunofluorescently stained for pH2AX and 53BP1. b) Representative 
images of GFP-DMAP1 transfected cells treated with NCS for the indicated length of 
time. Cells were stained for pH2AX or 53BP1.  
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6.5 DMAP1 is required for histone H4 acetylation by Tip60 
DMAP1 has previously been identified as a subunit of the human NuA4 complex (Cai 
et al., 2003; Doyon et al., 2004). Another component of the NuA4 complex is the 
histone acetyltransferase Tip60, which has been shown to modulate its activity in 
response to DNA damage and acetylate a range of targets including histone H4 on 
lysine16 (H4K16Ac) (Wu et al., 2011). However, the relevance of DMAP1 activity for 
Tip60 function had not yet been analysed. 
 
I first wanted to determine if I could reproduce the published interaction between 
DMAP1 and Tip60, which used a mass spectrophotometry approach (Cai et al., 2003). I 
performed immunoprecipitations for GFP-DMAP1 and HA-Tip60 on 293A cells. HA 
immunoprecipitation from cells without transfected HA-Tip60 does not enrich for 
DMAP1. However, HA immunoprecipitation from HA-Tip60 expressing cells also 
enriched for GFP-DMAP1 (Figure 63a). Thus, Tip60 and DMAP1 interact.  
 
Having confirmed the DMAP1-Tip60 interaction in my system, I wanted to establish if 
DMAP1 played a role in regulating Tip60’s histone acetyltransferase (HAT) activity. I 
overexpressed HA-Tip60 in 293A cells, and performed an anti-HA 
immunoprecipitation. The washed immunoprecipitates were incubated with an artificial 
colourimetric substrate and the HAT activity determined using spectrophotometry. As 
expected, Tip60 immunoprecipitates had significant HAT activity (Figure 63b). The 
same assay was also performed on washed anti-GFP immunoprecipitates from GFP-
DMAP1 expressing cells. These immunoprecipitates also contained significant amounts 
of HAT activity (Figure 63c), suggesting DMAP1 associates with HAT activity. 
 
To establish if a DMAP1-Tip60 complex was responsible for the HAT activity 
associated with DMAP1, I performed the HAT assay on Myc-DMAP1 
immunoprecipitates from cells transfected with shRNA against Tip60. Knock-down of 
Tip60 significantly reduced the HAT activity associated with DMAP1 (Figure 63d). 
Tip60 depletion also reduced pS957-SMC1 phosphorylation to a similar extent as 
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DMAP1 depletion (Figure 63e). The extent of Tip60 knockdown by the shRNA Tip60 
hairpins was validated by qPCR (Figure 63f). 
 
H4K16 acetylation is mainly catalysed by the histone acetyltransferases MOF and 
Tip60 (Rea et al., 2007), (Kusch et al., 2004). Moreover, H4K16 acetylation has 
recently been shown to be necessary for efficient ATM activation and signalling (Wu et 
al., 2011). It therefore follows DMAP1 deficiency may affect ATM signalling by 
reducing the extent of H4K16 acetylation. To test this hypothesis, HCT-116 cells were 
treated with the radiomimetic drug bleomycin, which induces DSBs. Control cells 
displayed an increase in H4K16 acetylation after DNA damage. However, this increase 
was not observed in DMAP1 depleted cells (Figure 64a).  
 
The reduced H4K16Ac in DMAP1 depleted cells after DNA damage suggests 
artificially increasing histone acetylation levels could circumvent DMAP1’s function in 
the DNA damage response pathway. The organic compound Trichostatin A (TSA) 
selectively inhibits mammalian class I and II histone deacetylases (HDACs), increasing 
histone acetylation levels (Sharma et al., 2010), (Miller et al., 2010). DMAP1 depleted 
HCT-116 cells were incubated with TSA for six hours then treated with either 250 µM 
H202 or 5 Gy IR. This partially rescued the requirement for DMAP1 in H4K16 
acetylation (Figure 64b). Crucially, HDAC inhibition also rescued pS957-SMC1 and 
pS824-KAP1 levels after IR in both Tip60 and DMAP1 depleted cells (Figure 64c).  
 
DMAP1 depleted cells have delayed DNA damage repair foci formation at short time 
points after irradiation. Only 47% of siDMAP1 transfected cells had four or more 
53BP1 foci, compared to 93% of siControl transfected cells, five minutes after 2 Gy IR 
(Figure 65a, b). However, 87% of DMAP1 depleted cells pre-incubated with TSA had 
53BP1 foci formation five minutes after IR (Figure 65a, b). Thus treatment with histone 
deacetylase inhibitors rescues the delay in DNA damage foci formation observed in 
DMAP1 depleted cells. Depletion of DMAP1 had no affect on 53BP1 foci formation 45 
minutes after IR (Figure 65c). As TSA did not increase foci formation in untreated cells 
(Figure 65d), we can rule out the possibility TSA rescues the delayed foci formation by 
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increasing basal DNA damage. A DMAP1-Tip60 complex acetylates H4K16 after DNA 
damage - which is required for ATM signalling and DNA damage foci formation. 
 
6.6 Concluding Remarks  
Having established a role for DMAP1 in ATM signalling, I next wanted to generate a 
DMAP1 knockout mouse (dmap1-/-). One would expect the dmap1-/- mouse to be 
radiosensitive and cancer prone. It would be interesting to cross dmap1-/- into the Eu-
Myc lymphoma model, in which Tip60 is a haplo-insufficient tumour suppressor. Three 
independent clones of dmap1-/- ES cells were obtained from the KOMP consortium 
(Figure 66a) and injected at the blastocyst stage. However, despite extensive validation 
that the ES cells were dmap1-/- cells, no germline transmission was ever observed 
(Figure 66b). Three chimeras produced 86 offspring between them, none of which 
contained the DMAP knockout allele. The failure to achieve dmap1-/- germline is in 
agreement with a recently published paper describing the pre-implantation lethality of 
dmap1-/-mice (Mohan et al., 2011). 
 
Nonetheless, although it was not possible to address DMAP1’s function as a potential 
tumour suppressor gene in vivo, it is clear DMAP1 is an important component of the 
DNA damage response. DMAP1 deficient cells exhibit reduced ATM substrate 
phosphorylation after DSB induction (Figure 52) and oxidative stress (Figure 56); 
radiosensitivity and impaired checkpoint activation after IR (Figure 55). DMAP1 
interacts with the histone acetyltransferase Tip60 (Figure 63). Histone deacetylase 
inhibitors rescues ATM signalling in sidmap1 cells (Figure 65), suggesting DMAP1 is 
required for the acetylation of Tip60 targets, including H4K16, after DNA damage 
(Figure 64). DMAP1 is therefore a novel regulator of ATM signalling. 
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Figure 63: DMAP1 interacts with the histone acetyltransferase Tip60 
a) 293A cells were transfected with the indicated combination of pcDNA, HA-Tip60 
and GFP-DMAP1. 48 hours later cells were harvested and immunoprecipitated using 
either HA antibody or IgG control. Inputs (10%) and IP’s were immunoblotted for HA 
and GFP. Two different exposures of the HA immunoblot are indicated. b, c, d) 239A 
cells were transfected with the indicated combination of pcDNA, Myc-DMAP1, HA-
Tip60, siControl and siTip60. After 48 hours cells were immunoprecipitated with either 
HA antibody, Myc antibody or Ig control. Washed IPs were incubated with a 
colourimetric histone substrate, and HAT activity determined by spectrophotometer. 
Values were normalised to a reaction containing no IP. e) 293A cells were transfected 
with control, siDMAP1 or siTip60 shRNA then after 48 hours treated with 5 Gy IR and 
harvested one hour later. Whole cell lysates were resolved by 6% SDS-PAGE and 
membranes probed with pS1981-ATM, pS957-SMC1, SMC1 and tubulin. f) HCT-116 
cells were transfected with control shRNA or one of two different shRNA’s targeting 
Tip60. 48 hours later RNA was isolated and analysed for tip60 mRNA by RT-PCR.  
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Figure 64: DMAP1 is required for H4K16 acetylation after IR 
a) After 48 hours HCT-116 cells transfected with control or DMAP1 shRNA were 
treated with 5 µM bleomycin for 30 minutes. b, c ) Cells transfected with the indicated 
shRNAs pre-treated with 5 µM TSA or DMSO for six hours, then treated with 5 Gy IR 
or 250 µM H202 and harvested after one hour. Whole cell lysates were separated by (a, 
b) 15% or (c) 6% SDS-PAGE and immunoblotted for pS957-SMC1, SMC1, pS824-
KAP1, KAP1, tubulin, actin and H4K16Ac. 
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Figure 65: HDAC inhibitors rescue DNA damage foci formation in siDMAP1 cells 
a) HCT-116 transfected with control or dmap1 shRNA were cultured in the presence of 
either DMSO or TSA for six hours. Cells were treated with 2 Gy IR and fixed after five 
minutes. Cells were stained for 53BP1, representative images are shown. b) 
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Quantification of cells with four or more 53BP1 foci five minutes after 2 Gy IR, as 
shown in (b). c) HCT-116 transfected with control or dmap1 shRNA were irradiated 
with 2 Gy IR and fixed after 45 minutes. Cells were stained for 53BP1 and the 
percentage of cells with four or more 53BP1 foci quantified. d) HCT-116 transfected 
with control or dmap1 shRNA were cultured in the presence of either DMSO or TSA 
for six hours. Cells were fixed without treatment, stained for 53BP1 and the number of 
cells with four or more 53BP1 foci counted. The student’s t-test was used for statistical 
analysis (*p<0.05). 
 
 
 
 
 
Figure 66: The dmap1-/- mouse is pre-implantation lethal 
a) Schematic of the targeted dmap1 locus indicating location of genotyping primer pairs 
b) Genotyping PCR performed upon three representative chimera offspring, and DNA 
from the original ES cells. Two sets of primer detect correctly targeted dmap1 loci 
(LacZ/SU, Neo/SD) and one primer pair detects the presence of the targeting cassette 
(LacZ Internal). 
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Chapter 7. Discussion 
7.1 ATMIN and telomeres 
A key function of the shelterin complex is to shield telomeres from DSB recognition by 
the cellular DNA repair machinery. Paradoxically DDR components, including ATM, 
are required for telomere maintenance and are recruited to telomeres (Rudolph et al., 
1999; Karlseder et al., 2004). We therefore investigated ATMIN function at the 
telomere. Excitingly, we observed increased pH2AX at the telomeres of atmin∆/∆ MEFs 
(Figure 21) and impaired self-renewal and maintenance of late generation terc-/-; 
atmin∆N/∆N NSCs both in vivo and in vitro (Figure 23, Figure 24). Thus, we propose 
ATMIN is required for telomere maintenance.  
 
It was recently demonstrated that telomeric DNA damage is refractory to repair, and 
induces a long-term proliferation arrest (Fumagalli et al., 2012). ATMIN deficient cells 
have elevated DNA damage at the telomere and exhibit premature senescence (Figure 
20, Figure 21). Therefore it is tempting to speculate the premature senescence of 
atmin∆/∆ MEFs is at least partially due to increased telomeric damage.  
 
7.1.1 Model: ATMIN is required for efficient telomere replication 
It is unlikely ATMIN is required for protection of the telomere termini per se; atmin∆/∆ 
MEFs do not exhibit the extreme phenotypes of cells deficient for essential telomere 
protection proteins, such as end to end chromosome fusions of trf2∆/∆ MEFs (Sfeir and 
de Lange, 2012). Rather, the increased telomeric pH2AX foci in atmin∆/∆ MEFs 
suggests replicative stress at the telomere and is reminiscent of the trf1-/- phenotype 
(Sfeir et al., 2009). Telomeres are considered fragile sites because repetitive 
(TTAGGG) telomeric repeats pose a problem to the DNA replication machinery. 
Replication forks can stall upon very repetitive sequences, potentially resulting in loss 
of telomeric DNA distal to the fork and DDR activation. It has been shown that specific 
factors, including TRF1 (Sfeir et al., 2009) and WRN (Crabbe et al., 2004), are required 
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for efficient telomere replication. Our working model is that ATMIN is required for 
efficient telomere replication (Figure 67). 
 
 
 
 
 
Figure 67: ATMIN is required for telomere replication 
The repetitive sequences of telomeres can cause replication fork stalling. ATMIN is 
recruited to stalled replication forks, and recruits ATM. ATM signalling can promote 
repair of stalled forks and fork restart, ensuring telomeres are correctly replicated. 
However, in the absence of ATMIN stalled replication forks can collapse, forming a 
DSB and loss of all telomeric DNA distal to fork collapse. 
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7.1.2 ATMIN and telomeres: Open Questions and Future Plans 
ATMIN’s potential role in telomere replication could be further examined by directly 
establishing replicative stress at the telomeres of atmin∆/∆ cells. One approach is to 
perform Single Molecule Analysis of Replicated DNA (SMARD) on atmin+/+ and 
atmin∆/∆ MEFs. After sequential incubations in dNTP analogues, for example IdU and 
CldU, denatured telomeric DNA is isolated and linearly stretched onto glass sides 
(DNA combing). The pattern of IdU and CldU incorporation reveals the progression of 
replication forks along telomeric DNA. We predict atmin∆/∆ cells have increased 
replication fork stalling and a reduced rate of dNTP incorporation compared to atmin+/+ 
cells. Although informative, this experiment will not establish the molecular detail by 
which ATMIN aids telomeric replication.  
 
It is important to establish if ATMIN localises to the telomere. The lack of a good IF 
antibody against ATMIN precludes using IF-FISH to directly visualise ATMIN’s 
potential telomeric binding. Chromatin-IP for ATMIN, followed by Southern Blot for 
telomeric repeats, would establish if ATMIN binds telomeric DNA. It is known that an 
ATMIN/Rad18/WRNIP complex recruits ATM to stalled replication forks (Kanu et al, 
submitted). Thus, one could perform IF-FISH for WRNIP, Rad18 and pS1987-ATM in 
atmin+/+ and atmin∆/∆ MEFs to establish if these repair factors - especially ATM - are 
recruited to telomeres in an ATMIN-dependent mechanism. This model is in agreement 
with the reduced pS1987-ATM localisation to pH2AX sites observed in atmin∆/∆ MEFs 
(Figure 19). As it is likely a similar mechanism for ATMIN function will prevail at both 
telomeric and non-telomeric fragile sites, this is a good first approach to understand the 
mechanism behind ATMIN’s repression of telomeric DNA damage. 
 
One prediction of our model is the neurons of late generation terc-/-; atmin∆N/∆N mice 
exhibit shorter telomeres than age-matched terc-/-; atmin+/+ controls. We propose the 
pH2AX foci at atmin∆N/∆N telomeres mark single and double strand breaks arising 
through replication stress. This damage leads to loss of all telomeric DNA distal to the 
break site, and thus telomere shortening. We plan to address this in collaboration with 
the Leonard Rudolph group (Ulm, Germany). Quantitative FISH will be performed on 
late generation terc-/-; atmin∆N/∆N mice and littermate terc-/-; atmin+/+ controls. We 
Chapter 7 Discussion 
 
 219 
predict terc-/-; atmin∆N/∆N mice will exhibit significantly shorter telomeres. We do not 
think telomerase deficiency is absolutely required for telomere shortening in atmin-
deficient cells. Rather, telomerase loss will exacerbate the phenotype and make the 
difference in telomere length easier to detect in vivo.   
 
All ATM activity at the telomere is unlikely to proceed via ATMIN; the MRN complex 
is also recruited to telomeres (Verdun et al., 2005). pS1987-ATM foci formation upon 
siRNA mediated trf2 depletion is reduced in mre11∆/∆ MEFs, but not in Mre11 
nuclease-dead mutants (mre11H129N) (Deng et al., 2009). This indicates the MRN 
complex, but not its end-processing activities, is important for telomere maintenance. It 
will be interesting to elucidate ATMIN and NBS1 dependent ATM function at the 
telomere. One speculates that ATMIN’s role lies largely in protecting against 
replication stress, whereas NBS1 signals the presence of uncapped, DSB-resembling, 
telomeres.  
 
7.2 ATMIN is not part of the OIS barrier induced by intestinal 
KRasG12D expression 
ATM has been shown to be required for oncogene induced senescence (OIS) in 
xenograft experiments (Bartkova et al., 2006). We investigated a role for ATMIN and 
ATM in the OIS barrier in a transgenic mouse model for KRasG12D induced colorectal 
serrated hyperplasia (Bennecke et al., 2010).  
 
7.2.1 Senescence induction in atmin∆G/∆G; KRasG12D mice 
The senescence marker Dec1 was upregulated in both atmin∆G/∆G; KRasG12D and 
KRasG12D intestines, suggesting OIS pathways do not require ATMIN (Figure 27f). 
Unexpectedly, intestinal protein levels of the senescence marker p21 were lower in 
atmin∆G/∆G; KRasG12D compared to KRasG12D mice (Figure 27e). However, it would be 
premature to interpret this as a failure to induce senescence. Basal p21 levels were 
lower in the intestines of atmin∆G/∆G mice. Therefore there is still an increase in p21 
levels upon  KRasG12D expression in atmin∆G/∆G mice. Together with dec1 upregulation, 
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this suggests atmin deficient cells are still able to activate senescence programmes after 
KRasG12D expression. Further work is required to determine if reduced p21 levels in 
atmin∆G/∆G cells is a tissue-specific phenomena or reflects a regulatory loop between 
ATMIN and p21. ATMIN is part of the PCNA-interacting ATMIN-WRNIP-Rad18 
complex (Kanu et al, submitted). Perhaps loss of ATMIN increases binding between 
p21 and PCNA, leading to increased ubiquitination and degradation of PCNA-bound 
p21 (Abbas et al., 2008). A reduced level of tumour-protective p21 in ATMIN-deficient 
cells is in keeping with ATMIN’s role as a tumour suppressor (Loizou et al., 2011).  
 
In agreement with the biochemical observations, there was no difference in the survival 
of atmin∆G/∆G; KRasG12D and KRasG12D animals (Figure 30). ATMIN loss did not lead to 
progression from serrated hyperplasia to adenoma. Therefore we conclude ATMIN does 
not have an important function in senescence induced by intestinal KRasG12D expression. 
 
One cannot draw the same conclusion for ATM as atm-/-; KRasG12D animals succumbed 
to T-cell lymphoma at approximately three months, precluding a longer-term tumour 
study (Figure 30). However, dec1 upregulation in atm-/- ; KRasG12D intestines strongly 
suggests that atm deficient cells are able to induce senescence upon oncogene 
expression (Figure 28d). It is noteworthy that p53∆G/∆G; KRasG12D animals do not 
develop adenoma (Bennecke et al., 2010). Thus, given Ink4a/Arf-/-; KRasG12D animals 
do develop adenomas of the colon, Ink4a/Arf rather than ATM-p53 signalling is 
predominantly responsible for senescence induction upon intestinal KRasG12D 
expression.  
 
7.2.2 ATMIN, ATM and OIS: Open Questions and Future Directions 
This study does not suggest ATM is dispensable for OIS in every context. For example, 
although early onset T-cell lymphoma precluded long-term tumour study, Efeyan and 
colleagues observed higher tumour grades in the lungs of atm-/-; KRasG12D compared to 
atm+/+; KRasG12D controls (Efeyan et al., 2009). However, one cannot necessarily 
attribute this to breached OIS in atm-/- cells as senescent cells were not quantified. The 
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increased genomic instability of atm-/- cells could underlie the accelerated lung tumour 
development of atm-/-; KRasG12D mice. 
 
Senescence induction in response to oncogenic stress is subject to many tissue and 
oncogene-specific influences. For example, Skp2 inactivation in pten+/- mice induces 
senescence and protects against tumour progression in a p53-independent mechanism 
(Lin et al., 2010). Conversely, p53-dependent senescence induction protects against 
tumour progression in a pten-/- prostate cancer model (Chen et al., 2005). It is tempting 
to speculate ATM, and perhaps ATMIN, are required for senescence induction only in 
tumour models with p53- dependent, as oppose to Ink4a/Arf- dependent, senescence. 
 
 
7.3 ATMIN/NBS1: The Competition Model 
7.3.1 Doubly deficient nbs1∆/∆; atmin∆/∆ cells resemble an atm-/- phenotype 
Loss of ATMIN partially rescues the proliferation arrest and senescence induction of 
nbs1∆/∆ MEFs (Figure 41, Figure 42). Importantly, this rescue occurs despite greatly 
increased DNA damage in the nbs1∆/∆; atmin∆/∆ double mutant cells (Figure 47), 
excluding the possibility that DNA damage per se is solely responsible for the nbs1∆/∆ 
phenotype.  
 
It should be noted that co-deletion of ATMIN from nbs1∆/∆ cells does not wholly rescue 
the nbs1∆/∆ phenotype. Compound mutant nbs1∆/∆; atmin∆/∆ MEFs exhibit increased 
senescence and reduced proliferation potential compared to wildtype cells, with greatly 
increased DNA damage (Figure 41, Figure 42, Figure 47). Rather, these doubly 
deficient cells behave like atm-/- cells. The elevated pH2AX level in the compound 
mutants indicates ATMIN and NBS1 co-operate to maintain genomic integrity and are 
unable to substitute for each other. The complete absence of pS1987-ATM foci in the 
nbs1∆/∆; atmin∆/∆ compound mutants argues against the existence of a third ATM co-
factor. 
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Whereas atm-/- mice are viable, albeit infertile and tumour prone (Barlow et al., 1996), 
nbs1-/- mice die at approximately E3.5 (Zhu et al., 2001). The phenotypic differences 
between atm-/- and nbs1-/- mice has long-suggested ATM-independent functions for 
NBS1. For example, NBS1 is required for the nuclear localisation of Mre11 and Rad50 
(Williams et al., 2009). Defects resulting from NBS1’s ATM-independent functions 
will persist in nbs1∆/∆ cells regardless of ATMIN status. Accordingly, nbs1∆/∆; atmin∆/∆ 
MEFs and nbs1∆G/∆G; atmin∆G/∆G mice are radiosensitive and do not activate ATM after 
DSB induction (Figure 50).  
 
7.3.2 ATMIN and NBS1 compete for ATM interaction 
Difilippantonio and colleagues have previously shown increased pS1981-ATM after 
osmotic stress in nbs1∆/∆ B cells (Figure 5c, Difilippantonio et al., 2005). We also 
observed increased ATM activation after hypotonic shock in nbs1∆/∆ MEFs (Figure 46b) 
Similarly, atmin∆/∆ MEFs display increased ATM signalling after irradiation (Figure 
46a). 
 
In parallel to my in vivo and in vitro observations, my colleague Tianyi Zhang analysed 
ATM co-factor choice on a biochemical level. She observed increasing concentrations 
of ATMIN inhibited NBS1-dependent ATM substrate phosphorylation and 53BP1 foci 
formation after IR. However, overexpression of an ATMIN mutant lacking the ATM 
interaction motif did not inhibit IR-dependent ATM signalling. Crucially, ATMIN 
overexpression reduced the amount of NBS1 co-immunoprecipitated with ATM. 
 
7.3.3 NBS1 in the intestine 
Using the intestine as a model system, we were able to confirm in vivo a partial rescue 
of the nbs1∆G/∆G phenotype upon atmin deletion. In comparison to single mutant 
nbs1∆G/∆G mice, nbs1∆G/∆G; atmin∆G/∆G animals exhibit reduced degeneration of the 
intestinal mucosa (Figure 43).  
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Depletion of MCM6+ intestinal progenitors in nbs1-deficient intestines is partially 
rescued by ablation of ATMIN function (Figure 45d). However, the abundance of 
olfm4+ intestinal stem cells was drastically reduced five days after gene deletion in both 
nbs1∆G/∆G; atmin∆G/∆G and nbs1∆G/∆G intestines (Figure 45h). As MCM6 marks a wider 
progenitor pool than just olfm4+ stem cells, perhaps at longer timepoints after deletion 
the MCM6+ pool would also be depleted in nbs1∆G/∆G; atmin∆G/∆G crypts as the depleted 
stem cell pool is unable to replenish the progenitor pool. Interestingly, a higher 
percentage of nbs1∆G/∆G; atmin∆G/∆G crypts contained at least one olfm4+ cell compared 
to nbs1∆G/∆G single mutants (Figure 45i). This suggests that although atmin loss does not 
completely rescue the stem cell pool depletion of nbs1∆G/∆G intestines, atmin loss does 
increase the propensity of an NBS1 deficient crypt to maintain at least one stem cell.  
 
In summary, although ablation of ATMIN function from nbs1 deficient cells does 
somewhat rescue cellular function, ultimately these doubly deficient cells do not behave 
as wildtype and thus it is not a complete rescue of function.  
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Figure 68: The ATMIN/NBS1 Competition Model 
a) ATMIN and NBS1 compete for ATM binding. ATM signalling proceeds via either 
ATMIN or NBS1 in a stimulus dependent manner. b) In atmin deficient cells, increased 
NBS1-dependent ATM signalling contributes to premature senescence and proliferation 
arrest.  
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7.3.4 The Competition Model: Open Questions and Future Directions 
We propose the consequences of nbs1 deficiency extend beyond defective DSB-
signalling, and increased ATMIN-dependent ATM signalling in nbs1∆/∆ cells 
contributes to the defects observed in nbs1∆/∆ cells. Thus atmin ablation recues the 
cellular defects of nbs1∆/∆ cells caused by increased non-canonical, ATMIN-dependent 
ATM signalling (Figure 68). For example, p53 activation by the ATMIN-ATM pathway 
in nbs1∆/∆ cells could activate cell-cycle checkpoints and induce senescence. The 
competition of NBS1 and ATMIN for ATM interaction is a fundamental mechanism of 
ATM signalling, and disruption of this balance is deleterious to cells. 
 
The next step of this study would be to determine the molecular mechanism by which 
ATMIN and NBS1 compete for ATM binding. Both could bind ATM with comparable 
affinity and the proportion of ATM bound to either co-factor is simply determined by 
the stoichiometry between ATMIN and NBS1. Thus, we observe increased IR-induced 
ATM signaling in nbs1∆/∆ cells as a larger percentage of ATM molecules are bound to 
NBS1, and vice versa. Secondly, NBS1 and/or ATMIN could undergo posttranslational 
modification upon DSB induction. For example IR-regulated monoubiquitination of 
ATMIN could reduce its affinity for ATM, increasing NBS1-dependent ATM signalling.  
 
It would be interesting to elucidate other components of the non-canonical ATM 
pathway contributing to the defects of nbs1∆/∆ cells. For example, increased ATMIN-
dependent ATM activation of p53 could promote proliferation arrest. Both nbs1f/f  and 
nbs1 f/f; atmin f/f MEFs could be infected with lenti-shp53 prior to gene deletion. We 
predict p53 loss will partially rescue proliferation arrest in the nbs1-null MEFs 
 
Given atmin∆/∆ cells are radioresistant, the ‘Competition Model’ has some interesting 
therapeutic implications. For example, increasing ATMIN levels in non-cancerous 
tissues prior to radiation therapy should reduce their propensity undergo apoptosis, and 
hence reduce the detrimental side-effects and enable a higher dose of radiation to be 
tolerated by the patient. 
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7.4 ATMIN loss protects against lymphoma in p53∆B/∆B mice 
7.4.1 ATMIN deletion rescues B cell lymphoma onset in p53∆B/∆B mice 
Approximately 40% of atmin∆B/∆B mice develop B cell lymphoma at a mean age of six 
months (Loizou et al., 2011). We monitored cohorts of p53∆B/∆B and atmin∆B/∆B; p53∆B/∆B 
mice for cancer onset. B cell specific p53 deletion led to B cell lymphoma in 60% of the 
cohort, at a mean age of 7 months (Figure 36). Surprisingly, no B cell lymphoma was 
observed in a cohort of atmin∆B/∆B; p53∆B/∆B mice monitored for over a year (Figure 38). 
Thus, ablation of atmin function rescues the B cell lymphoma onset of p53-deficient 
mice.  
 
The simplest model for the lymphoma-free survival of atmin∆B/∆B; p53∆B/∆B mice is that 
loss of both p53 and ATMIN is detrimental to B cell development. If so, atmin∆B/∆B; 
p53∆B/∆B mice would have substantially fewer B cells and thus a reduced chance of a B 
cell accumulating sufficient cancer-promoting mutations. However, FACS analysis of 
the different stages of B cell development revealed no significant B cell development 
defect in either p53∆B/∆B or atmin∆B/∆B; p53∆B/∆B mice (Figure 32, Figure 33). The 
atmin∆B/∆B mouse is published to have a mild reduction in the immature B cell 
population (Loizou et al., 2011) recapitulating the atm-/- phenotype (Xu et al., 1996). 
Although atmin∆B/∆B; p53∆B/∆B mice demonstrated a reduced pre-B population compared 
to littermate atmin∆B/∆B; p53∆B/∆B controls, this difference did not reach statistical 
significance (p=0.172). However, the individual percentages were lower in atmin∆B/∆B; 
p53∆B/∆B mice, and I predict that increasing the number of mice analysed would lead to 
the mild defect reaching statistical significance. Notwithstanding, it is evident that 
atmin∆B/∆B; p53∆B/∆B mice do not display overt B cell maturation defects. 
 
7.4.2 ATMIN and p53 interplay in other tissues 
Consideration of my B cell lymphoma study alone does not permit a conclusion on 
whether the phenomenon of tumour-free doubly deficient atmin∆/∆; p53∆/∆ tissues is 
limited to the B cell lineage. Two colleagues, Nnennaya Kanu and Sophia Blake, have 
subsequently performed a similar brain-tumour study in cohorts of atmin∆N/∆N, p53∆N/∆N 
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and atmin∆N/∆N; p53∆N/∆N mice. Preliminary data suggests that whilst approximately a 
quarter of p53∆N/∆N mice develop glioblastoma, no cases were observed in either 
atmin∆N/∆N or atmin∆N/∆N; p53∆N/∆N cohorts. This study allows us to draw two important 
conclusions. Firstly, the cancer-free survival of atmin∆/∆; p53∆/∆ compound mutants is 
not restricted to B cells. Secondly, no cancer was observed in atmin∆N/∆N animals (Kanu 
et al., 2010). Thus we can infer ablation of atmin function from a p53-deficient cells 
protects against cancer development. Based only on the B cell data, one could have 
concluded loss of p53 protected against atmin∆/∆-driven lymphoma.  
 
Importantly, this does not appear to be a universal mechanism. Co-deletion of atmin and 
p53 from a KRasG12D lung cancer model did not prevent or slow tumour development 
(Sophia Blake, unpublished observations). I have also observed β-cell specific atmin 
deletion did not affect pancreatic cancer development in the Rip-TAg model, in which 
the large T antigen is expressed in β-cells (data not shown). Elucidation of the 
underlying mechanism by which atmin deletion rescues cancer onset in p53 deficient 
cells should shed light on the tissue specificities. 
 
7.4.3 ATMIN and p53: Open Questions and Future Directions 
There are two working models for the lymphoma free survival of atmin∆B/∆B; p53∆B/∆B 
mice. Both ATMIN and p53 are transcription factors, thus overlapping transcriptional 
targets could underlie the unique characteristics of atmin∆B/∆B; p53∆B/∆B cells (Figure 69). 
Whilst this is an attractive model, much experimental investigation is needed to validate 
it. It is probable that networks of ATMIN and p53 dependent transcription contribute to 
the lymphoma-free phenotype of atmin∆B/∆B; p53∆B/∆B cells. Therefore one future plan is 
to perform a microarray on B cells from six week old atmin∆B/∆B, p53∆B/∆B and 
atmin∆B/∆B; p53∆B/∆B mice. The interesting targets are those upregulated in p53∆B/∆B (and 
possibly atmin∆B/∆B cells) but that return to wildtype transcription levels in the 
compound mutant.  
 
An in vivo way to test ‘The Transcription Model’ would be to make use of a 
transcriptionally-dead ATMIN mutant. Mutations in ATMIN’s zinc-fingers abolish its 
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transcriptional activity. It would be interesting to cross this mutant with p53f/f; CD19-
Cre mice. If ATMIN’s transcriptional activity is required for suppression of p53-driven 
lymphoma, the ATMIN mutant should develop B-cell lymphoma at the same age as the 
p53∆B/∆B cohort. The phenotypic differences between atmin∆/∆ and atm-/- mice, especially 
the embryonic lethality of atmin∆/∆ but not atm-/- mice, illustrates that ATMIN has 
ATM-independent functions. For example, ATM-independent transcriptional regulation 
by ATMIN may explain its unusual relationship with p53. 
 
Indeed, compound atm-/-; p53-/- mutants develop lymphoma approximately two months 
prior to earlier than either of the single mutants (Westphal et al., 1997; Xu et al., 1998). 
This suggests the lymphoma rescue of atmin∆B/∆B; p53∆B/∆B mice is either independent of 
ATM function, or is dependent upon intact ATM signalling. 
 
Both ATMIN and p53 are part of the DNA damage response network. ‘The DNA 
Damage Model’ (Figure 70) predicts increased ATM-NBS1 signalling in the atmin∆B/∆B; 
p53∆B/∆B mutants is able to circumvent of p53 loss, and activate sufficient cell-cycle 
checkpoints after DNA damage to prevent accumulation of deleterious mutations. One 
would predict over-expression of an ATMIN protein unable to bind ATM would reduce 
the proliferation of p53∆B/∆B MEFs.  
 
It is important to establish the tissue-specificities of the mechanism. Ablation of 
ATMIN function in some tissues types, including B cells and brain, should protect 
against cancer development in p53-deficient cells. We currently do not know if ATMIN 
suppresses the initiation or maintenance of cancerous cells. ATMIN function could be 
acutely inactivated by tamoxifen injection of p53∆/∆; atminf/f; CD19-CreERT mice once 
they show symptoms of lymphoma. Defining whether loss of ATMIN from an 
established p53∆B/∆B cancer promotes tumour regression will establish the therapeutic 
potential of targeting ATMIN in p53∆/∆ driven cancers. 
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Figure 69: The Transcription Model for ATMIN/p53 cross-talk 
a) In wildtype cells p53 represses a ‘pro-growth gene’, and transcription does not occur. 
b) In p53∆/∆ cells the repression of the ‘pro-growth’ gene is lost. ATMIN represses 
transcription of a second repressor ‘X’, and the ‘pro-growth’ gene is activated. c) 
atmin∆/∆; p53∆/∆ cells have lost the ability to repress ‘X’, and thus ‘X’ is now able to 
repress transcription of the ‘pro-growth’ gene. Therefore, even though p53-mediated is 
repression is absent; the loss of ATMIN ensures the ‘pro-growth’ gene is not expressed.  
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Figure 70: The ‘DNA Damage’ Model for p53 and ATMIN signalling 
a) In wildtype cells, upon DNA damage ATM signals via either ATMIN or NBS1 to 
activate cell cycle checkpoints, promoting DNA repair or apoptosis. This prevents 
genomic instability and accumulation of cancer-promoting mutations. b) Loss of p53 
impairs checkpoint activation, leading to the continued proliferation of cells harbouring 
DNA damage. There is the increased likelihood of cancer development. c) In the 
absence of ATMIN and p53, increased NBS1-dependent ATM signalling increases the 
propensity of checkpoint activation by p53-independent mechanisms, for example 
BRCA1 phosphorylation. Thus, pre-malignant cells undergo DNA repair, senescence or 
apoptosis and probability of cancer development is reduced.  
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7.5 DMAP1 is a novel regulator of ATM function 
We have identified DMAP1 as a novel regulator of ATM function. DMAP1 deficient 
cells exhibit reduced ATM signalling after IR (Figure 52), hypotonic stress and 
oxidative stress (Figure 56). Abrogation of DMAP1 function renders cells 
radiosensitive and defective in DNA-damage induced G2/M cell cycle arrest (Figure 
55). 
 
7.5.1 DMAP1’s putative PI3-K interaction motif is dispensable for 
regulation of ATM signalling 
DMAP1 was identified in a screen for proteins containing PI3-K interaction motifs 
(Figure 51). Surprisingly, I was unable to demonstrate interaction between ATM and 
DMAP1 under a wide range of conditions (Figure 58). It is plausible that DMAP1 and 
ATM interact but I cannot detect such an interaction due to technical limitations; 
ATM’s large molecular weight makes it difficult immunoprecipitate with high 
efficiency. I therefore characterised the functional importance of DMAP1’s PI3-K 
interaction motif. Overexpression of both full-length DMAP1 and a truncation mutant 
lacking the ATM interaction domain augmented ATM signalling (Figure 59). This 
suggests interaction with ATM is not required for DMAP1 regulation of ATM 
signalling. DMAP1’s putative PI3-K interaction motif could be coincidental, or reflect 
DMAP1’s evolution from an ancestral PI3-K interacting protein. 
 
Moreover, I was unable to detect DMAP1 localisation to the double strand break site 
(Figure 60, Figure 61, Figure 62). This could be due to a number of technical limitations. 
For example, DMAP1 could transiently associate with the break site. Alternatively, only 
a fraction total cellular DMAP1 protein localises to the break site. Detection is masked 
by the strong IF signal from pan-nuclear, DNMT1-associated DMAP1 (Rountree et al., 
2000). However, considering DMAP1 does not detectably interact with ATM, its 
putative ATM interaction motif is not required for augmentation of ATM signalling, 
and DMAP1 is not detectably recruited to DNA damage foci it is probable that DMAP1 
does not regulate ATM pathway activation through direct interaction with ATM.  
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Figure 71: DMAP1-Tip60 H4K16 acetylation regulates ATM signalling 
Upon either IR-induced DSBs or hypotonic shock ATM autophosphorylates, 
monomerises and localises to the damage site. For full activation of ATM signalling, 
chromatin changes must also occurs. A Tip60-DMAP1 complex acetylates H4K16, 
facilitating ATM activation.  
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7.5.2 DMAP1 regulates ATM signalling by H4K16 acetylation 
It is known that ATM activation is regulated by changes in chromatin structure 
(Bakkenist and Kastan, 2003; Kim et al., 2009). For example, H4K16 is acetylated by 
the histone acetyltransferase Tip60 after DNA damage (Li et al., 2010; Wu et al., 2011). 
DMAP1 interacts with Tip60, and H4K16Ac is dramatically downregulated in DMAP1 
deficient cells. ATM substrate phosphorylation and 53BP1 foci formation is rescued in 
DMAP1 deficient cells pre-treated with histone deacetylase inhibitors. This suggests a 
model whereby DMAP1’s impact on ATM signalling occurs through its interaction 
with the histone acetyltransferase Tip60 and modulates chromatin acetylation, including 
H4K16Ac (Figure 71).  
 
It must be noted that whilst there is clear evidence DMAP1-Tip60 influences ATM 
signalling via H4K16Ac levels, one cannot rule out a model whereby DMAP1-Tip60 
also acetylates non-histone proteins. Crucially, it is postulated Tip60 acetylates ATM 
after DNA damage (Sun et al., 2009; Sun et al., 2007). However, I was unable to 
reliably detect ATM acetylation or interaction between Tip60 and ATM, probably due 
to technical limitations. Alternatively, perhaps Tip60 is capable of acetylating ATM in 
vitro, but this does not reflect Tip60’s in vivo substrates.   
 
7.5.3 DMAP1, histone acetylation, and oxidative stress 
The reduced H202 induced ATM signalling in dmap1 deficient cells suggests DMAP1-
Tip60 dependent H4K16 acetylation is required for ATM signalling after oxidative-
stress (Figure 56b). However, these results must be interpreted with caution.  
 
A recent paper by the Tanya Paull group demonstrated pS1987-ATM and pS15-p53, but 
neither pS824-KAP1 nor pH2AX, phosphorylation after 30 minutes 250µM H202 
treatment (Figure 1, Guo et al., 2010b). As pH2AX and pS824-KAP1 are considered to 
only be phosphorylated at DSB sites, this was interpreted as ATM activation by 
oxidative stress independently of DSB induction. In contrast to their results, I observe 
robust pS824-KAP1 after 30 minutes 250µM H202 treatment (Figure 56a). The 
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observation of pS824-KAP1 in my H202 treatment protocol does alter the interpretation 
of the experiments. Whilst it is evident DMAP1 is required for ATM pathway activation 
after oxidative stress, one cannot conclude DMAP1 is required for formation of ATM 
cysteine linked dimers; as the oxidative stress treatment appears to be inducing DSBs 
and thus presumably monomeric ATM is present. It is unclear why I observe pS824-
KAP1 whilst the Paull group do not. Perhaps differences in cellular sensitivity to 
oxidative stress, or an increased pS824-KAP1 detection threshold are responsible. 
 
7.5.4 DMAP1: Open Questions and Future Directions 
A key outstanding question is the mechanism by which DMAP1 regulates Tip60 
activity. Tip60 has a wide range of acetylation targets under basal conditions, so Tip60 
catalytic activity per se is unlikely to be regulated by DNA damage (Squatrito et al., 
2006).  
 
DMAP1 contains a SANT domain, also present in the yeast homolog Eaf2, which 
interacts with histone tails (Boyer et al., 2002). It is therefore tempting to conjecture 
DMAP1 provides Tip60 with positional information. It has been proposed that Tip60 
recruitment to DSBs occurs by binding H3K9me3, which is exposed after CK2 
phosphorylates HP1-β, prompting HP1-β dissociation from chromatin (Sun et al., 2009). 
However, several unanswered questions remain from this model. Firstly, the mechanism 
of CK2 regulation by DNA damage is unknown. Secondly, it is premature to conclude 
HP1-β dissociation is the only mechanism of Tip60 recruitment to DSBs. Thirdly, the 
model proposed by Sun and colleagues suggests Tip60 association with H3K9me3 
activates its acetyltransferase activity. Given the wide range of Tip60 substrates, this is 
unlikely to be the only mechanism of Tip60 activation (Squatrito et al., 2006). Thus it is 
conceivable DMAP1 provides Tip60 with positional information.  
 
To investigate DMAP1 regulation of Tip60, I would initially focus on DMAP1’s SANT 
domain. IP-Mass Spectrometry of DMAP1 could determine the histone modifications 
bound by the SANT domain. This would provide insight into how DMAP1 confers 
positional information to Tip60, especially through comparison of DMAP1 histone 
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binding in untreated and irradiated cells. If successful, mutation of the amino acids 
proposed to interact directly with histones would reveal if interaction between 
DMAP1’s SANT domain and chromatin regulates ATM signalling.  
 
7.5.5 DMAP1-Tip60 - A therapeutic potential? 
Unfortunately, the pre-implantation lethality of dmap1-/- mice precluded study of the 
consequence of dmap1 loss in murine tumour models (Figure 66). Conversely, Tip60 is 
an established haploinsufficient tumour suppressor; Eµ-Myc; tip60+/- B cells do not 
activate an oncogene-induced DDR and mice have accelerated lymphoma onset 
(Gorrini et al., 2007). Moreover, H4K16Ac is downregulated in a range of cancers 
(Fraga et al., 2005). Taken together, this suggests DMAP1-Tip60 offers an intriguing 
therapeutic potential. The HDAC inhibitors Vorinostat and Romidepsin are approved 
for treatment of T-cell lymphoma, with many more currently in clinical trials (Mann et 
al., 2007; Prince and Dickinson, 2012). Our study suggests treatment of cancers 
exhibiting abrogated ATM signalling with HDAC inhibitors would have therapeutic 
benefit.  
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7.6 Concluding Remarks 
In my PhD studies I have identified DMAP1 as a novel regulator of ATM function. 
DMAP1 interacts with the histone acetyltransferase Tip60. Acetylation of H4K16 by 
DMAP1-Tip60 facilitates ATM signalling, presumably by creating a permissive 
chromatin structure for recruitment and phosphorylation of DNA damage proteins.  
 
Furthermore, I have also investigated the in vivo functions of the ATM interacting 
protein ATMIN. Loss of ATMIN in MEFs leads to DNA damage accumulation, 
premature senescence and reduced recruitment of pS1987-ATM to sites of DNA 
damage. ATMIN is required for suppression of telomeric DNA damage; we propose 
ATMIN is required for efficient telomere maintenance. However, I observed that 
ATMIN is dispensable for OIS in KRasG21D induced colonic serrated hyperplasia. 
Investigation of ATM signalling in doubly-deficient nbs1∆/∆; atmin∆/∆ MEFs and 
intestines revealed increased ATMIN-dependent ATM signalling is partly responsible 
for the proliferation arrest of nbs1∆/∆ cells. Thus, competition between the ATM co-
factors ATMIN and NBS1 is a fundamental mechanism of ATM signalling, and 
disruption of this balance is deleterious to cells.  
 
Moreover, I have characterised the lymphoma-free survival of atmin∆B/∆B; p53∆B/∆B mice, 
compared to the B-cell lymphoma predisposition of p53∆B/∆B mutants. Due to p53’s 
frequent mutation in cancer, ATMIN is therefore an attractive therapeutic target.  
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